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RESUMO 
Nos últimos 30 anos foram-se acumulando evidências que têm vindo a apoiar a infecção 
viral como um factor responsável por 15-20% dos tumores malignos em humanos a nível 
mundial (W. S. Liang et al. 2014; McLaughlin-Drubin and Munger 2008). Estudos sobre os 
vírus oncogénicos demonstraram a sua importância no mau funcionamento celular ao longo do 
processo carcinogénico e demonstraram que a sua associação com o cancro varia entre 15% e 
100% (McLaughlin-Drubin and Munger 2008), dependendo do tipo de tumor. Com a grande 
quantidade de informação genómica e metagenómica acessível nos consórcios internacionais 
públicos, tais como a base de dados TCGA, hoje em dia é possível inferir indiretamente 
infecções virais a partir de estudos genómicos centrados em humanos, uma vez que parte das 
reads irá alinhar com vírus e bactérias. 
Tomando como ponto de partida a pesquisa feita por Tang et al. 2013, concentramo-nos nos 
cancros cervical (CESC), hepatocelular (LIHC) e da cabeça e pescoço (HNSC), que são 
conhecidos por apresentar uma alta proporção de casos virais-positivos (Tang et al. 2013). 
Fizemos download de dados RNA-Seq de 309, 424 e 566 amostras, respectivamente, e 
comparamos unmapped reads contra uma base de dados viral de referência (retirada da base 
de dados do NCBI) usando as ferramentas Batch, SAMTOOLS, bowtie e PRINTSEQ. A 
quantificação de cada vírus foi feita usando partes por milhão (ppm) e apenas vírus com ppm 
acima de 10 foram considerados como estando a infectar positivamente uma amostra. 
Confirmamos que cerca de 94% das amostras de CESC foram infectadas, principalmente por 
HPV (papilomavírus humano) e, especificamente, pela estirpe HPV16. Quase 32% das 
amostras LIHC foram infectadas por HBV (vírus da hepatite B). E por volta de 17% de 
amostras HNSC foram infectadas e o HPV16 foi o vírus mais comum. 
A avaliação de enriquecimento diferencial de vias metabólicas entre grupos infectados e não 
infectados, para cada tipo de cancro, foi realizada por GSEA. Os sinais de enriquecimento para 
infecção e vias relacionadas com sistema imune eram evidentes no grupo infectado CESC, 
enquanto nos grupos infectados de LIHC e HNSC o enriquecimento era principalmente 
relacionado com replicação e reparação de DNA. Este facto parece indicar que a infecção é 
especialmente ativa no CESC, contradizendo alegações anteriores de que a tumorigenese no 
colo do útero não estava diretamente ligada à infecção. Nos três tipos de cancro, os vírus 
integraram os seus genomas no genoma do hospedeiro, afetando a replicação, manutenção e 
reparação do DNA. No nosso estudo sobre a integração do genoma de HPV16 numa amostra 
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de tumor HNSC, foi confirmada a integração viral no gene humano RAD51B que codifica uma 
proteína implicada na reparação de DNA por recombinação homóloga. Desta forma, 
conseguimos confirmar que HPV16 pode atuar tanto como agente cancerígeno directo e 
indirecto. 
Provavelmente através da integração do genoma viral no genoma do hospedeiro, a infecção 
aumentou a quantidade de mutações somáticas no grupo de amostras infectadas em LIHC, mas 
não em HNSC onde o consumo de tabaco é também um importante agente cancerígeno. O 
reduzido número de amostras não-infectadas em CESC não permitiu uma comparação fiável 
da quantidade de mutações somáticas entre grupos de infectados e não-infectados. Ainda assim, 
nos grupos infectados de LIHC e HNSC, algumas mutações somáticas ocorreram no contexto 
de vias relacionadas com o sistema imunológico, mostrando que podem contribuir para tornar 
estes indivíduos susceptíveis à infecção. 
Além disso, ao verificar a expressão dos genes de HPV16 em cinco amostras de CESC e de 
HNSC, confirmou-se que os genes E6 e E7 estão entre os mais expressos em muitas das 
amostras, enquanto que o E2 não é expresso. Os genes E6 e E7 são conhecidos por serem 
preferencialmente integrados no genoma do hospedeiro, ao contrário do gene E2, o qual 
controla a expressão daqueles, que não é integrado ou é fragmentado. Acredita-se que é a sobre-
expressão de E6 e E7 que inicia a carcinogénese. 
As taxas de infecção viral inferidas neste trabalho por mining de bases de dados omicos são 
muito semelhantes aos obtidos pelos métodos tradicionais (Tang et al. 2013), mostrando que a 
informação disponível nos consórcios internacionais públicos pode elucidar, indiretamente, 
sobre o envolvimento da infecção viral na tumorigénese. O elevado número de amostras por 
tumor, a grande variedade de origem geográfica das amostras e a caracterização de alto 
rendimento para diferentes plataformas omicas permitem comparações e avaliações múltiplas, 
numa escala não acessível anteriormente. 
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ABSTRACT 
In the past 30 years, accumulated evidence has been supporting viral infection as one factor 
responsible for 15-20% of human malignancies worldwide (W. S. Liang et al. 2014; 
McLaughlin-Drubin and Munger 2008). Studies on oncogenic viruses have proved their im-
portance on cellular malfunction along the carcinogenic process, and showed that their associ-
ation with cancer can amount from 15% to 100% (McLaughlin-Drubin and Munger 2008), 
depending on the type of tumour. With the large amount of genomic and metagenomic infor-
mation available on public international consortia, such as TCGA database, it is nowadays 
possible to indirectly infer viral infections from the human centred omics studies, as a portion 
of the reads will align in viruses and bacteria.  
Taking as starting point the research made by Tang et al. 2013, we focused on cervical 
(CESC), hepatocellular (LIHC) and head and neck squamous cell (HNSC) carcinomas, which 
are known to show a high proportion of viral-positive cases (Tang et al. 2013). We downloaded 
RNAseq data from 309, 424 and 566 samples, respectively, and run the unmapped reads against 
a reference database of viruses (downloaded from NCBI) by using the tools Batch, 
SAMTOOLS, Bowtie and PRINTSEQ. Quantification of each virus was performed using parts 
per million reads (ppm) and only viruses with ppm above 10 were considered as positively 
infecting the sample. We confirmed that around 94% of CESC samples were infected, mostly 
by HPV (Human papillomavirus) and specifically by the HPV16 strain. Nearly 32% of LIHC 
were infected by HBV (hepatitis B virus). Almost 17% of HNSC samples were infected, and 
the HPV16 was the most common present virus. 
The evaluation of differential enrichment of metabolic pathways between infected and non-
infected groups, for each cancer type, was performed in GSEA. Signs of enrichment for infec-
tion and immune related pathways were evident in CESC infected group, while in LIHC and 
HNSC infected groups the enrichment was mostly related with DNA replication and repair. 
This seems to indicate that infection is especially active in CESC, contradicting previous claims 
that tumorigenesis in cervix was not directly linked with infection. For the three cancer types, 
the viruses integrate their genome in the host genome, affecting DNA replication, maintenance 
and repair. In our investigation of integration of HPV16 genome in one HNSC tumor sample, 
we confirmed integration in the human RAD51B gene that codes a protein involved in DNA 
repair by homologous recombination. We thus confirmed that HPV16 can act both as indirect 
and direct carcinogen. 
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The infection, most probably through the integration of the viral genome in the host genome, 
increased the amount of somatic mutations in the infected group in LIHC, but not in HNSC 
where tobacco consumption is also an important carcinogen. The low number of non-infected 
samples in CESC did not allow a reliable evaluation of changes in the amount of somatic mu-
tations. Even so, in both LIHC and HNSC infected groups, some somatic mutations occurred 
in the context of immune-related pathways, showing that they can contribute to render these 
individuals susceptible to infection.  
Also, when checking expression of HPV16 genes in five samples each from CESC and 
HNSC, we confirmed that E6 and E7 genes are amongst the ones more expressed in many 
samples, while E2 is not expressed. E6 and E7 have been said to be preferentially integrated in 
the host genome, while E2, which controls their expression, is not integrated or it is disrupted. 
It is believed that the overexpression of E6 and E7 initiates carcinogenesis.  
The viral infection rates inferred here from mining the omics databases are very similar to 
the ones evaluated by standard methods (Tang et al. 2013), showing that public international 
consortia can indirectly provide interesting insights into the involvement of viral infection in 
tumorigenesis. The high number of samples per tumor, the wide geographic origin of the sam-
ples, and the high-throughput characterisation for different omics platforms allows multilayer 
comparisons and evaluations, in a scale not affordable before. 
 
KEYWORDS 
Cancer, Viral Infection, RNAseq, Cervical carcinoma, Hepatocellular carcinoma, Head and 
neck squamous cell carcinoma. 
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1. INTRODUTION 
In the past, the occurrence of “house cancers” started the idea that cancer could be caused 
via some infectious agents. These “house cancers” were known to occur in people living in the 
same place, mostly between married couples and transmitted from mother to child. In the 19th 
century, these observations encouraged studies that could test the idea of development of can-
cer malignancies through bacteria, fungi or parasites. Initially, these studies were unsuccessful 
in finding such agents, leading to a step-back in the hypothesis for many years (McLaughlin-
Drubin and Munger 2008). 
Some significant researches revealed cancer formation with cell-free transmission in non-
malignant tumours in animals, but not in human models (McLaughlin-Drubin and Munger 
2008). This was the case of Francis Peyton Rous experiments in 1911 that showed that the 
sarcomatous chest tumour on chicken could be transmitted over cell-free tumour excerpts, con-
firming once more the hypothesis of the involvement of small infectious agents. Like many 
before him, these studies were treated like curiosities for many years. Only in the 1950s, after 
Ludwik Gross proved that murine retrovirus and polyomavirus induced murine cancers, Rous 
research was fully appreciated and awarded a Nobel Prize in 1966 (McLaughlin-Drubin and 
Munger 2008; Moore and Chang 2010).  
Following the success in proving viral infection in animal cancers, a crescent number of 
scientists started a demand to discover oncogenic viruses in humans. Yet, it would take more 
53 years since Rous’s famous research for the first human oncogenic virus to be observed. In 
1964, during a study in cell lines of Burkitt’s lymphoma from African pediatric patients, An-
thony Epstein, Bert Achong and Yvonne Barr identified small particles on the electron micro-
scope. These particles were then identified as a virus by virological studies and named Epstein 
Barr virus (EBV) in their honour (Morales-Sánchez and Fuentes-Pananá 2014; Moore and 
Chang 2010). Later on, in 1970, hepatitis B virus (HBV) was discovered by D. S. Dane in 
human cells by using hepatitis B surface antigen (McLaughlin-Drubin and Munger 2008). 
Thanks to these two studies and to the development of model systems, additional studies on 
viral infection in cancer led to the identification of seven more oncogenic viruses, suggesting 
that more viruses important in cancer development can still be discovered (McLaughlin-Drubin 
and Munger 2008; Morales-Sánchez and Fuentes-Pananá 2014).  
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1.1. Viral Infection in cancer 
Surprisingly, only a small portion of people infected with oncogenic viruses actually de-
velop cancer, and an even smaller part of that group of people transmits the infection. Cancers 
seem to be a final event of the viral infection, and eventually lead to host death and viruses 
destruction (Moore and Chang 2010; Morales-Sánchez and Fuentes-Pananá 2014). Tumour 
viruses usually maintain their persistence in the host by creating a chronic infection during a 
period of many years, with a very small production, or almost none, of viral particles (Morales-
Sánchez and Fuentes-Pananá 2014).  
Studies through the past century led to the conclusion that infectious agents (viruses, bacte-
ria and parasites) should be divided in two groups in relation to their involvement in cancer: 
direct and indirect carcinogens.  
Direct carcinogen agents can be found in the cancer cells in a monoclonal form, which in-
dicates that these agents are responsible for tumour cell transformations by keeping the carcin-
ogen phenotype through expressing at least one transcript. This oncogenic persistence is main-
tained by viral formation of episomes or incorporation into the host genome (Morales-Sánchez 
and Fuentes-Pananá 2014; Moore and Chang 2010). In summary, direct carcinogen viruses 
have three essential characteristics: the viral genome can be found in every tumour cell; once 
host cells have grown, the virus can immortalize; and the virus causes cell transformation, im-
mortalization and migration by disturbing the cell normal functioning (Chen et al. 2014). Hu-
man papillomavirus (HPV), EBV and molluscum contagiosum (MCV) are examples where 
this activity is easily seen (Figure 1A) (Morales-Sánchez and Fuentes-Pananá 2014; Moore and 
Chang 2010; Chen et al. 2014). 
On the other hand, indirect carcinogen agents lead to cancer through infection and inflam-
mation that eventually causes cell mutation, showing that these agents are not restricted to 
remain inside the host cells (Morales-Sánchez and Fuentes-Pananá 2014; Moore and Chang 
2010). Thus, these viruses work over two principal ways: starting chronic inflammation and 
immunosuppression. Chronic inflammation is initiated by chemokines produced by mutated 
cells that attack immune cells and injure local tissue. In this way, this kind of tumour activity 
resumes to a cycle between infections, inflammations and local tissue destruction (Figure 1B). 
In a similar manner, the immunosuppression process stars with an immune response failure. 
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The most common example of this process is displayed by HIV virus, which infection is re-
sponsible for lowering the host defences and consequently increasing the risk of new infections 
to occur in the host (Figure 1C) (Morales-Sánchez and Fuentes-Pananá 2014).  
A.  
B.  
C.  
Figure 1. Direct and indirect viral carcinogenesis processes (images taken from Morales-Sánchez et al. 2014). (A) Represen-
tation of direct viral carcinogenesis. Superior Section: Formation of episomes by viral genomes (e.g. herpesvirus). Lower 
Section: Viral integration into de host DNA (e.g. retroviruses). (B) Representation of chronic inflammation of indirect viral 
carcinogenesis. Production of chemokines from infected cells which attack immune cells and damage the local tissue. (C) 
Representation of immunosuppression of indirect viral carcinogenesis. Immunosuppression is caused by HIV and EBV infec-
tion, and is controlled by cytotoxic CD8 T cells. While HIV infection develops, immune system starts failing and the host 
becomes more venerable to EBV infection (Morales-Sánchez and Fuentes-Pananá 2014). 
 
Still, there are many viruses that cannot be classified only into direct and indirect mecha-
nisms, such as HBV and HCV (hepatitis C virus). HBV genome is integrated into the host cells 
in almost all HBV-related tumours, however it is still not clear if the virus requires cell prolif-
eration to maintain the genome transcription or not. Nevertheless, this type of classification is 
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still important, as it is a practical way to classify cancers that have a bigger chance of occurring 
via the action of oncogene viruses (Morales-Sánchez and Fuentes-Pananá 2014; Moore and 
Chang 2010).  
Some studies have recently showed new techniques for viral detection on high-throughput 
DNA and RNA sequencing. These new studies allow an efficient unbiased detection of viruses 
in extended collections of data from cancer samples, overcoming limitations of studies based 
on low-throughput methodologies. One such study was performed by Tang et al. (2013), whom 
mapped virus infection in 4,433 samples from 19 human cancers, by using human centred 
RNASeq data. The inference based on RNASeq guarantees that the viral genome is being tran-
scribed and that the infection is active. From the results obtained by Tang study it is possible 
to acknowledge that cervical (CESC), hepatocellular (LIHC) and head and neck squamous cell 
(HNSC) carcinomas are the top three cancers with higher viral infection rates (96.6%, 32.4% 
and 14.8%, respectively) (Tang et al. 2013). However, this work was based in a limited number 
of the samples now available in TCGA: 87 of 309 for CESC (28%); 34 of 424 for LIHC (8%); 
and 304 of 566 for HNSC (54%). 
1.1.1. Cervical carcinoma (CESC) 
Nowadays, the second principal cause of female death is cervical cancer. Thanks to large 
endorsements for vaccination and constant control through Papanicolaou test (Pap test), the 
frequency of this carcinoma dropped drastically in developed countries, but not yet in devel-
oping countries, where 80% of cases occur (Adams et al. 2014; Muñoz et al. 2003). HPV has 
been reported in closely 100% of cervical cancers, mainly the high risk HPV16 and HPV18 
strains. This infection can occur from sexual contact or via vertical transmission from mother 
to child during pregnancy or during birth (Adams et al. 2014).  
Even if many women are infected with HPV, in most cases the immune cells eliminate the 
infection agents, and only a small portion of infected woman will progress from infection to 
cervical cancer. These women normally manifest immunity deficiencies caused by inherent 
genomic instability or because of bad life style habits, like smoking (Adams et al. 2014; 
Canavan and Doshi 2000). 
1.1.2. Hepatocellular carcinoma (LIHC) 
Hepatocellular carcinoma is one of the most common cancers worldwide and one of the 
most rapid cause of death. This cancer is common in Asia and Africa, but recently it is also 
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rising in America and Europe (Siegel and Zhu 2009; Chen et al. 2006). The principal risk fac-
tors for LIHC are known to be abusive alcohol consumption and infection through HBV and 
HCV; however, it has been reported that 5-30% of the patients are cryptogenic (unknown dis-
ease cause). The majority of LIHC cases are associated to a metabolic syndrome manifested in 
the liver named non-alcoholic fatty liver disease (NAFLD), consisting in fat deposits in liver 
cells in absence of any history of excess alcohol consumption. NAFLD is also related with 
insulin resistance, obesity, diabetes, dyslipidemia, and other metabolic conditions (Siegel and 
Zhu 2009). 
The best treatment to this cancer is still the partial hepatectomy, though it is only applicable 
to about 9-27% patients. Percutaneous local ablative therapy (PLAT) and radiofrequency ab-
lation (RFA) are being applied and allowing a better cancer control (Chen et al. 2006). 
1.1.3. Head and neck squamous cell carcinoma (HNSC) 
This cancer occurs 90% of the times from squamous cell carcinomas in mucosal surfaces in 
the neck and head. The principal risk factors have been reported to be dangerous life style 
habits, like ultraviolet light exposure and tobacco and alcohol consumption. Recently it was 
proved that HPV infection is a major cause, mostly in oropharyngeal cancer (tonsillar and base 
of tongue cancer). Till recently, 66% to 95% of the cases occurred in men after 50 years of age, 
but with the increasing number of female smokers this number tends to vary (Adams et al. 
2014; Egloff et al. 2014). 
Patients diagnosed with this cancer and HPV positive showed improvement and higher sur-
vival rates when treated with chemotherapy, radiation and surgery, than the HPV negative 
counterparts. This led to the idea that HPV condition is a good biomarker of HNSC. As no 
diagnostic tools are available, HNSC patients must check for persistent symptoms such as ach-
ing throats, inflamed glands and oral wounds (Adams et al. 2014).  
1.2. Lipids influence in viral carcinogenesis infection 
Lipids are the most important components in cell membranes, playing important roles in 
many biological functions like cell growth and division, energy production, motioning, mainte-
nance of cell membrane integrity, activity of membrane enzymes, and DNA helix stabilization 
(Raju et al. 2014). Cholesterol is a lipid that executes some of those functions, and the lipopro-
tein receptors placed in the cell surface are responsible for its absorption and control within 
cells. This mechanism is very important during membrane fusion for entry of virions in the 
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cells and during particle maturation. Taking the example of non-enveloped viruses, its capsid 
interacts with the host membrane and usually controls some of the membrane constituents, like 
glycosphingolipids, to start the viral infection. Some viruses, like HCV, can even induce viral 
entrance with functional low-density lipoprotein receptor (LDL-R) (Heaton and Randall 2011). 
Likewise, lipids play an important role during the viral life cycle since this occurs in the 
membranous cell organelles (as endoplasmic reticulum), assisting the membrane curvature and 
drafting core proteins to enable the construction of virus particles (Heaton and Randall 2011; 
Konan and Sanchez-Felipe 2014). Other example of its importance is the recognition of lipids 
droplets (LDs) as sites for assembly of some viruses (e.g. HCV). LDs are organelles derived 
from endoplasmic reticulum which are abundant in cholesterol esters and triglycerides (Konan 
and Sanchez-Felipe 2014). Furthermore, there are some changes in lipid metabolism and in 
specific lipid species, which are expected to be important in viral replication, assembly and 
secretion events. Some of those changes are the increase of flux metabolic directed into fatty 
acid biosynthesis pathway (visible in metabolic analysis of cytomegalovirus infection), and the 
inhibition of cholesterol and sphingolipids biosynthesis, or knockdown of proteins involved in 
their transport (visible during HCV production) (Heaton and Randall 2011; Konan and 
Sanchez-Felipe 2014). 
In the other hand, oncogenic studies have showed that cholesterol is found in low concen-
tration and can indicate a continuous oncogenic process, in some growing tissues and blood 
partitions (Singh et al. 2013). So far, most claims of variations in lipid profiles among normal 
and tumour cells (like in CESC and HNSC) (Raju et al. 2014; Singh et al. 2013) have been 
associated with bad life habits like the use of tobacco, and not with infection. It has been re-
ported that tobacco carcinogens are responsible for greater amount of peroxidation of polysatu-
raded fatty acids through induction of free radicals and production of reactive oxygen species. 
This lipid peroxidation can heavily disturb fundamental membrane cell components and may 
lead to carcinogenesis since, because of it, great utilization of lipids like cholesterol, lipopro-
teins and triglycerides is needed for membrane syntheses of the new cells. In order to provide 
for these needs, lipids are taken from blood circulation, degraded from lipoproteins or metab-
olised. 
The elucidation of the involvement of lipids in cancer is very important, namely in terms of 
treatment. Some studies have shown that antioxidant vitamins have a great defensive influence 
against lipid peroxidation (Patel et al. 2004). It was also suggested that cancer cells or several 
minor malfunctions during the lipid or antioxidant vitamin metabolism can be responsible for 
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the drop of lipid concentration that occurs during hypolipidemia (Raju et al. 2014; Singh et al. 
2013; Patel et al. 2004). Yet, these associations are controversial since many studies have re-
ported a different relation between cancer and lipid profile parameters (Raju et al. 2014; Patel 
et al. 2004). It is also not yet guaranteed that cancer diagnosis through lipid parameters is viable 
(Raju et al. 2014). 
1.3. Database and bioinformatic tools  
Following the publication of the human genome sequence, an increase in large-scale ge-
nome studies has taken place, namely in the cancer research field. Soon after, the idea of a 
unified record of cancer genomes emerged in order to deal with the following issues: independ-
ent tumour genome studies could lead to investment of resources in the same type of cancer 
instead of broadening the spectre of types of cancer studied; the absence of normalisation be-
tween the different studies could produce noise and biases in the analyses and comparisons; 
the existence of many cancers that differ through the world should lead to a coordinated strat-
egy between local consortia; and the fact that only one organisation could coordinate and, con-
sequently, accelerate the distribution of data and a more efficient analysis (Hudson et al. 2010). 
Researchers and funding agency councils from 22 countries, encouraged from that initial 
idea, gathered in late 2007 in Toronto, Canada, to decide the best way to proceed. The Interna-
tional Cancer Genome Consortium (ICGC) was launched, aiming to perform a comprehensive 
and high-throughput analysis of tumours in an organized way (Zhang et al. 2011). Given the 
dimension of this challenge, operational groups were formed in order to create policies and 
plans that would form the base requirements to participate in the ICGC (Hudson et al. 2010).  
In order to hasten cancer research, the consortium has as main goals: (1) the creation of 
complete sets of genomic anomalies in tumours of 50 distinct cancer types and subtypes, in 
high resolution, fullness, high quality and controlled data; (2) form complementary lists of 
transcriptomic and epigenomic datasets from the correspondent tumours; and (3) allow the 
whole investigation community to have access to the data obtained promptly with the least 
limitations. Thus, ICGC also organized the research community so that no repeated researches 
occur, and promoted the proliferation of new technologies, software and techniques (Hudson 
et al. 2010; Zhang et al. 2011).  
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The large amount of genetic information available in these databases raises bioethical issues, 
particularly concerning the patient anonymity. Since the genomic data allow individual identi-
fication, data access policies were developed in order to protect that information. Those access 
policies consist in dividing the dataset into two different sets (Table 1). The first set will contain 
accessible information and will not have data capable of identifying the individual identity. 
The second set will be the most restricted group, and although it will not contain direct identi-
fication of the individual, it will have complex genomic and clinical data that belong to a unique 
human being. The permission of access to the second set can only be given by the Data Access 
Compliance Office to researchers that submit their project (Hudson et al. 2010; Zhang et al. 
2011). 
 
Table 1. List of sets of information from each group of access (Zhang et al. 2011). 
ICGC Open Access Datasets ICGC Controlled Access Datasets 
 Cancer Pathology 
 Histologic type or subtype 
 Histologic nuclear grade 
 Patient/Person 
 Gender 
 Age range 
 Gene Expression (normalized) 
 DNA methylation 
 Genotype frequencies 
 Computed Copy Number and Loss of 
Heterozygosity 
 Newly discovered somatic variants 
 Detailed Phenotype and Outcome Data 
 Patient demography 
 Risk factors 
 Examination 
 Surgery 
 Drugs 
 Radiation 
 Sample 
 Slide 
 Specific histological features 
 Protocol 
 Analyte 
 Aliquot 
 Gene Expression (probe-level data) 
 Raw genotype calls 
 Gene-sample identifier links 
 Genome sequence files 
 
Initially, the consortium started by including two European consortia and 10 participating 
countries, but currently the number increased to 15 (Hudson et al. 2010). Another important 
project that contributed to ICGC development was The Cancer Genome Atlas (TCGA). This 
project is older than ICGC, and it was initiated by the US National Institutes of Health (NIH). 
These two related projects were the main factors of the great growth of complete comprehen-
sion of cancer genomes (Hudson et al. 2010). 
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1.3.1. TCGA 
The Cancer Genome Atlas is a public funded project by the US National Institutes of Health 
and was created as a Pilot Project from the Nacional Institute of Health (NIH) in 2006, with 
similar aims to ICGC but at a local scale in the US. It is currently using large-scale genome 
sequencing and multi-dimensional analyses in order to characterise above 30 human cancers 
(Hudson et al. 2010; Tomczak et al. 2015).  
 
Figure 2. TCGA structure and relation between partners. TSSs (Tissue Source Sites) is responsible for clinical metadata and 
biospecimen assemble from authorised cancer patients. BCR (Biospecimen Core Resource) then approves these data collected 
from TSSs. After approbal, processing and validation of the quality and quantity of sample, BCR registers and submits 
metadata to DCCs (Data Coordinated Centers). At the same time, molecular analysis are provided to GCCs (Genome Charac-
terization Centers) and GSCs (Genome Sequencing Centers) for additional genomic characterization and high-throughput se-
quencing. Sequence-related data is stored in DCC. GSCs submits trace files, sequences, and alignment mappings to CGHub 
(NCI’s Cancer Genomics Hub secure repository). Then genomic data submitted to DCC and CGHub are made accessible to 
the research community and to GDACs (Genome Data Analysis Centers). GDACs supply new information-processing analysis 
and visualisation tools to the research community (Tomczak et al. 2015).  
 
TCGA is well structured and divided in many partners who are responsible for different 
tasks, from the sample gathering and manipulation, to high performance methods based on 
microarrays and next-generation sequencing, and respective bioinformatic data analysis (Tis-
sue Source Sites, Genome Characterization Centers, Genome Data Analysis Centers, etc.). For 
a better understanding of the cancer omics, different approaches have been applied: RNA se-
quencing (RNAseq), MicroRNA sequencing (miRNAseq), DNA sequencing (DNAseq), SNP-
based platforms, Array-based DNA methylation sequencing, and Reverse-phase protein array 
(RPPA) (Tomczak et al. 2015).  
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NIH, the National Cancer Institute (NCI) and the National Human Genome Research Insti-
tute (NHGRI) established partnerships with other North American and European institutes, and 
in 2010 TCGA data was largely incorporated the ICGC Data Portal (Tomczak et al. 2015). Yet, 
TCGA is not allowed to officially become ICGC’s member for legal and technical manners, 
once it belongs to the US’s NIH (Figure 2) (Hudson et al. 2010). 
1.3.2. Bioinformatic tools 
With the growing number of available genomic data, the demand on fast and efficient anal-
yses led to the need of developing new bioinformatics tools. Many of the recently implemented 
tools were used by Tang et al in 2013 that, in fact, proved their applicability. Some of the 
studies performed in this thesis are based on the pipeline implemented by Tang and his col-
leagues. 
1.3.2.1. SAMtools  
The first step on the processing of data is the alignment for a competent read mapping 
against a reference sequence. Diverse alignment tools were available but generated different 
formats that made complex the downstream processing, and rendering it urgent to develop an 
universal format. This led to the genesis of the Sequence Alignment/Map (SAM) format (Fig-
ure 3) (Li et al. 2009).  
The SAM format is simple and flexible, once it can retain information from numerous se-
quencing platforms and read aligners, and supports single and paired-ended reads and blending 
reads of various types. This format is prepared to support alignment sets over 1011 base pairs 
which is approximately the size needed for a human genome. A similar format is the Binary 
Alignment/Map (BAM) format, which consists in a binary representation of the SAM format. 
Basically it has the same information of a SAM file but is represented in a more compacted 
way that can process information from a particular location in the genome without loading the 
entire file data, in order to improve performance (Li et al. 2009). Nowadays, almost all genomic 
studies use SAM/BAM files as the base files for diverse types of analyses. But many of the 
current informatic methods take too much RAM memory and require several CPUs, so it is 
very important to use the correct and more appropriate tools for each research (Langmead et 
al. 2009).  
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Figure 3. Representation of a SAM file. 1- Header Line. VN indicates the format version and SO the sorting order alignment. 
2- Sequence dictionary. SN represents de sequence name and LN the sequence length. 3- QNAME, Query template NAME. 
4- FLAG, bitwise FLAG. 5- RNAME, Reference sequence NAME. 6- POS, 1-based left end mapping POSition. 7- MAPQ, 
MAPping Quality. 8- CIGAR, CIGAR string. 9- RNEXT, Reference name of the mate/NEXT read. 10- PNEXT, Position of 
the mate/NEXT read. 11- TLEN, observed Template LENgth. 12- SEQ, segment SEQuence. 13- QUAL, ASCII of phred-
scaled base QUALity+33 (Li et al. 2009). 
 
SAMtools consists in a collection of software packages which par and manipulate the exist-
ent alignments in the SAM/BAM files and have the capability to: (1) sort and combine align-
ments; (2) exchange other alignment formats to SAM or BAM format; (3) eliminate PCR rep-
licas; (4) call SNPs and short indel variants; (5) create an output with information listed per-
position; and (6) show this output in a text-based format (FASTA) (Li et al. 2009).  
The only disadvantage of this software is the fact that it takes a little too long for alignment 
and indexing of data. For example, to use a MAQ file with 112GB it takes about 10h to convert 
it and 40 min to index it with less than 30 MB of memory. This tool has implementations using 
two different languages, Java and C, which grant different functionalities. Since SAMtools is 
such an efficient tool, for the past six years it has become a crucial instrument for next gener-
ation sequencing (NGS) alignment studies (Li et al. 2009). 
1.3.2.2. PRINSEQ 
PRINSEQ is a bioinformatic tool that is used to filter, reformat and trim NGS data, and that 
is used to create a pre-processing statistic synopsis of data and of its quality, permitting an 
efficient control before any downstream study being made (Schmieder and Edwards 2011). 
This tool supports FASTA, FASTQ and QUAL files of genomic and metagenomic datasets, 
and it was implemented in two different ways: (1) in a web interface, which is very easy to use; 
and (2) a standalone lite version (Schmieder and Edwards 2011). The principal difference be-
tween these two versions is that the standalone version does not create any statistic synopsis in 
graphical form. 
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1.3.2.3. Bowtie 
Bowtie was developed to create an ultrafast, memory-efficient short read aligner optimized 
for mammalian re-sequencing. Bowtie can align short DNA sequence reads to long sequences 
in a fast way and using an acceptable amount of RAM memory. By being based in full-text 
minute-space index, it applies Burrows-Wheeler indexing which results in a memory occupa-
tion of 1.3GB for a human genome. With this low RAM memory occupation, it allows an 
ordinary computer, with 2GB RAM, to use this software.  
Bowtie was especially optimized to achieve the highest performance. Because of that if 
more than a match exists for the same read, it is assured that one will be reported, but not 
necessarily the best alignment. In other words, Bowtie may fail valid alignments if there are 
many mismatched reads. To avoid this, Bowtie has an option that increases the precision but it 
will reduce its performance (Langmead et al. 2009). This tool is very practical, and supports 
FASTA and FASTQ files, and Bowtie2 supports also insertions, deletions or paired-end align-
ments (Langmead et al. 2009; Langmead and Salzberg 2012).  
1.3.2.4. Picard Tools 
Set of bioinformatics tools for high-throughput sequencing data manipulation compatible 
with SAM, BAM, CRAM and VCF files. All Picard Tools only work through command line 
and are provided as a single executable jar file (Java file) (Broad Institute 2016).  
Even though there are around 80 tools available for a high variety of tasks, in this thesis we 
only used two of those tools – SamToFastq and MarkDuplicates. SamToFastq has as primary 
objective to convert SAM or BAM files into FASTQ. Furthermore, it also has options which 
allow to extract read sequences and base quality scores from the input files. In this thesis this 
tool will be mostly used to split whole genome files into forward and reverse sequences that 
will serve as input files in the bioinformatic tool VirusSeq (which will be explained below) in 
order to detect viral integration in human genomes (Broad Institute 2016). 
MarkDuplicates locates and tags duplicated reads in BAM and SAM files. Then, these du-
plicate reads are defined as originated from the same DNA fragment and acknowledged as read 
pairs which have identical 5’ positions for both reads in mate pair. As an output, a new SAM 
or BAM file is created with all duplicated sequences removed, identified in the SAM flag field, 
or even marked with a duplicate type in the “DT” optional attribute. Additionally, it also out-
puts a second file with the number of read pairs examined, unmapped reads, unpaired reads, 
duplicated unpaired reads, duplicated read pairs and optical duplicated read pairs (duplicates 
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that appear clustered together during sequencing and can emerge from optical/image-pro-
cessing artifacts or from bio-chemical processes during clonal amplification and sequencing) 
(Broad Institute 2016). 
1.3.2.5. VirusSeq (with Mosaik) 
As it was said before in this report, many viruses are related to human tumours and with the 
improvement of bioinformatic technologies it became possible to detect viral presence/infec-
tion in human cells through the analyses of paired-end reads by VirusSeq. This algorithm uses 
NGS data and detects known viruses and its integration sites in the human genome.  
This tool uses FASTQ format files with paired-end reads as input, and those reads can be 
whole-transcriptomic or whole-genomic data. The first step is the alignment to the reference 
genome, by using the program Mosaik (provided when VirusSeq is downloaded). This program 
is an aligner tool that, contrary to what happens with Bowtie, can compare at the same time the 
viral genome against the tumour genome in study so that the viral integration can be deter-
mined. VirusSeq starts the identification of human and non-human sequences by aligning the 
input file with the human genome reference. Then, the non-human sequences are compared 
against the viral database in order to find any virus present in those sequences. The genome 
sequences of well-known viruses are all put together into one single chromosome named 
chrVirus, which will serve as a viral database. This viral database was combined with the hu-
man reference genome hg19 making this reference genome named hg19Vrus where the 
chrVirus was designed as chr25 (Chen et al. 2013). With this strategy ViruSeq can, then, iden-
tify if any of the viruses is infecting the inputted sample and describe its precise location when 
inserted in the human genome. 
VirusSeq is a very effective tool, yet, it also has some crucial limitations: (1) the virus data-
base must be updated frequently by the user (Chen et al. 2013); (2) it takes too much memory 
RAM, and an ordinary computer cannot run it; (3) and it takes a long time to run. 
1.3.2.6. PCA 
The big datasets being produced and analysed currently have a high amount of variables and 
variance contributing to it. This is the case of the expression profiles for the around 20,000 
human genes that is inferred from RNAseq data. Several parameters can contribute with vari-
ability to the human gene profile, besides the cancer and infection status, such as the date when 
the lab analysis was perform, the lab that performed it, the geographical origin of the sample, 
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etc. Some theoretical techniques allow to investigate the partitioned effect of the multifactorial 
variables, as the older and commonly used principal component analysis (PCA) (Jolliffe and 
Cadima 2016). PCA is a classical method which reduces de data dimension by transforming a 
new set of variables called principal components (PC) which are unrelated and orthogonal. PCs 
are ordered so that the kth PC have the kth higher variances of all PCs. As PCA can detect 
artefacts and biases, it is usually used as pre-processing phase (Y. Liang et al. 2005; Yao et al. 
2012). 
However, this technique is not perfect. It may fail when it comes to reproduce biology rela-
tions. Recent studies have showed that microarray gene expression may have a super-Gaussian 
distribution, and the PCA method considers that gene expression follow a multivariate distri-
bution. Also, PCA reduces the data based on the maximization of its variance, and sometimes 
biological problems do not relay on the data highest variance (Yao et al. 2012). 
1.3.2.7. Gene Set Enrichment Analysis 
Gene Set Enrichment Analysis (GSEA) is a computational process that evaluates differences 
among two biological states of a set of genes and determines if they are statistically significant 
(Subramanian et al. 2007). Its principal goal is to determine if a defined set of genes S are 
randomly distributed through a list L of mRNA expression profiles of genes ordered according 
to their differences. The GSEA method works on three principal steps: (1) calculation of an 
Enrichment Score (ES) that, shows the degree of representation of set S in the extremes of the 
entire ranked list L (top or bottom); (2) estimation of Significance Level of ES by using an 
empirical phenotype-based permutation test that conserves the correlation arrangement of the 
gene expression data; and (3) adjustment of estimated significance level to consider for multi-
ple hypothesis testing (Subramanian et al. 2005). GSEA also offers the possibility to perform 
preranked analysis, where the gene set enrichment analysis is run against the ranked list of 
genes created during the default GSEA run. This allows to perform a correction of results from 
the default GSEA run, and to obtain more accurate values.  
Two indicators are important in GSEA results, the False Discovery Rate (FDR) and the 
Normalized Enrichment Score (NES). FDR is the probability of a gene set represents a false 
positive; it is a ratio of the actual ES vs. the ES of all gene sets against all permutations of the 
dataset and the actual ES vs. ES of all gene sets against the actual dataset. On the other hand, 
the NES value represents, as its name indicates, the normalization of the ES value and can be 
used to compare analysis results all over the gene set.  
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There are many tools that execute similar functions as GSEA, but it is beyond doubt that 
GSEA continues to be the most used. Many have reported lack sensitivity of this method, how-
ever many improvements have been made do correct that limitation. The fact that GSEA was 
conceived to find general dissimilarities in a cumulative distribution probably gave advantage 
of GSEA over other methods like z-test, which only could identify sets of genes with mean 
shifts (Irizarry et al. 2009). 
1.3.2.8. G:Cocoa (G:Profiler) 
It is known that most of the somatic mutations in cancer are usually unique events occurring 
independently in different patients, with the exception of the ones affecting oncogenes and 
proto-oncogenes (Lawrence et al. 2015). But these independent somatic mutations can affect 
the same metabolic pathways, and in our specific case, make infected individuals more suscep-
tible to the viral infection. To test this we used G:Cocoa from G:Profiler webtool (Reimand et 
al. 2016). 
G:Profiler is a public web server developed and maintained by the Institute of Computer 
Science of University of Tartu with the objective of characterising and manipulating gene lists 
of high-throughput genomics. This web server is currently available for over 80 species and 
has six available tools, as G:Cocoa tool used in this work (Reimand et al. 2016). 
G:Cocoa is a enrichment tool which performs functional analysis of dozens of gene lists 
allowing a simple and minimal view of functional enrichments of those lists and providing a 
means to rank and compare gene lists through their functional annotations. Because of the mul-
tiple functional enrichment analysis and its comparison against many reference lists, this tool 
performs a multiple testing correction which methodically reduces the significance of each p-
value, discarding the number of false positive values. By default it is used the tailor-made al-
gorithm g:SCS, otherwise the user may choose to use Bonferroni correction (BC) or Benaja-
mini-Hochberg False Discovery Rate (Reimand et al. 2016). 
1.3.2.9. HTSeq 
HTSeq is a Python package which allows the fast processing and analysis of high-through-
put sequencing (HTS) data. This tool receives as input the most common file formats for ref-
erence sequences, short reads, short read alignments, genomic feature, annotation and score 
data (FASTA, FASTQ, SAM/BAM, GFF, VCF, etc.). The principal component of this tool is 
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a container class which allows working with genomic coordinates (genomic positions or ge-
nomic intervals) more simply. This tool contains two different applications: HTSeq-qa, for 
quality assessment; and HTSeq-count, for processing RNA-seq alignments for expression anal-
ysis (Anders et al. 2015). 
HTSeq-count receives as input SAM/BAM files from RNAseq data and GTF/GFF files with 
gene models. The number of times each gene had its exons overlapped in the aligned reads is 
counted. It is important to notice that ambiguous reads (reads which overlap with more than 
one gene or that align to various positions) are not considered. Even if this tool is written in 
Python, it can be run with simple shell commands without any Python knowledge. Also, this 
tool requires very little RAM memory, being able to process over 1.2 million reads per minute 
using around 250 to 450MB RAM, approximately (Anders et al. 2015). 
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2. AIMS 
In order to better understand the impact and effect of viral infection in cancer, this study has 
six principal aims:  
1) to estimate infection rates in CESC, LIHC and HNSC from inference on the TCGA avail-
able RNASeq data. The work of Tang et al. 2013 quantified in 425 samples belonging to these 
cancer types, but we enlarged to the full amount of 1299 samples currently available at TCGA. 
The lower quantity of cases checked in Tang et al. work will be used as quality control in our 
analysis; 
2) to fully characterize the virus strains that are present in each infected individual, by using 
an updated human viral reference database, according to information deposited in NCBI;  
3) to check if specific human pathways are associated with the infection, by performing 
gene enrichment analysis (using GSEA tool) between infected and non-infected groups in the 
three types of cancer;  
4) to determine if infection is responsible for an increasing of somatic mutations, or if these 
are related with immune-related pathways; 
5) to identify which viral genes are expressed during infection of the most prevalent viruses;  
6) to detect viral insertion within a human genome. 
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3. METHODS 
3.1. Viral database 
For the construction of the reference viral database, a list of accession numbers of all known 
human viruses was downloaded through the NCBI complete viral genome website. Then, all 
bacteriophages and endogenous viruses were removed from the list, making a final total of 
5003 viruses. A Python script was created, to receive that list as input. Then, by using the Bio 
package provided freely by NCBI that contained the module Entrez and their efetch function, 
the genomes of all viruses in that list were downloaded into a single fastq file. This final fastq 
file was then used as reference database to investigate viral presence in the cancer samples. 
3.2.  Human raw RNAseq database 
Since our intention was to investigate active viral infection, implying transcription of viral 
genes, we downloaded the dataset of raw RNAseq samples for each cancer. This dataset aimed 
to address the human transcriptome, but other non-human transcripts are also indirectly 
screened, namely viral transcripts. 
The RNAseq data was downloaded from the CGHUB database, provided by TCGA, filter-
ing the data only for RNAseq with HG19 assembly, accounting to 309 samples from CESC 
cancer, 424 from LIHC and 566 samples from HNSC. All RNAseq samples were downloaded 
as BAM files and each sample had an average size of 7GB which corresponded to a total size 
of 8.62TB of downloaded information (2.14TB for CESC, 2.49TB for LIHC and 3.99TB for 
HNSC). In mean, around one week was needed for the download for each cancer type. Most 
of these RNAseq samples were from the solid tumor, but a few were from the solid normal 
tissue. We extracted both in order to do some comparisons. 
3.3.  Viral presence detection  
Once all samples had been downloaded, the viral presence procedure could be implemented. 
Initially all BAM files were indexed through SAMTOOLS which allows to analyse directly 
specific parts of the BAM file without reading through all the sequence. In this case, 
SAMTOOLS allowed us to focus on the unmapped regions against the known human tran-
scriptome, information previously processed by TCGA team. These unmapped regions were 
extracted from the BAM files and converted to fastq files. A quality control was then applied 
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to the fastq files, by using PRINTSEQ program, which removes reads with less than 45 nucle-
otides.  
Thereafter, Bowtie tool was used to align each sample (the cleaned fastq files of unmapped 
reads) against the viral database previously created, and limiting the data to 2 mismatches and 
a maximum of 25 valid alignments for each read, outputting the alignment in a SAM file for-
mat.  
Finally, we used SAMTOOLS and Picard Tools to remove duplicated reads from the SAM 
file and count how many times each virus was aligned within each sample. The final output is 
a text file with a list of viruses found in each sample and the number of times each virus aligned 
with that sample. This whole process took around 4 to 5 days to be completed for each cancer 
type analysed here in a dual-core computer with 4GB RAM memory.  
3.4.  Infection state determination in a cancer sample 
Following others (Tang et al. 2013), we calculated the parts per million (ppm) value for each 
virus in each sample. In order to do that the number of each virus reads on that sample was 
divided by the total number of reads in the same sample and multiplied by one million, accord-
ing to the following formula:  
    =  
           
      ′             
×  10  
 
The total number of reads in the sample is the sum of all human and non-human reads which 
were previously determined using SAMTOOLS. We report all viruses present in a sample, 
even with low ppm, but we established a threshold for a sample to be considered as infected: 
when the most prevalent virus is >10 ppm. 
3.5. Human transcriptomic profile and matrix construction 
In order to investigate human gene expression differences between infected and non-in-
fected groups, we used the gene expression values inferred by TCGA team and deposited in 
their database. Single files for each sample, with the complete list of normalized expression 
counts for all known human genes (20,531 genes), were downloaded (average of 400MB each) 
and merged into one matrix per cancer type. That matrix had in the first column the list of all 
genes and in the successive columns the normalized counts for each sample. A matrix with this 
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distribution was used in the GSEA software that we will discuss bellow, while a reverse one 
was used in the PCA analyses. 
3.6.  PCA 
Gene expression is influenced by several factors that can lead to spurious or false results in 
statistical analyses of differential expression. In order to have an idea on the variance among 
the samples we performed principal component analyses (PCA) (Mardia et al. 1979) by using 
an R script. We controlled for variance between tumour and normal tissue samples, and be-
tween infected and non-infected samples.  
3.7. Gene Expression Analysis 
For a gene expression enrichment evaluation between infected and non-infected groups, we 
performed a GSEA analysis (Subramanian et al. 2007). Both groups were constructed in order 
to have an equivalent number of individuals, controlled by the group with the lower number of 
samples and the other made of the same size by picking up samples at random controlling for 
the population group and geographical origin to which the individuals belonged. In the end, 
size of groups amounted to 18 in CESC, 118 in LIHC and 86 in HNSC.  
This tool analyses if significantly differentially expressed genes are organised within known 
metabolic pathways, so it incorporates reference lists of metabolic pathways from diverse da-
tasets as KEGG (Ogata et al. 1999) and Gene Ontology (Consortium 2001). We performed the 
analyses against KEGG and the three main Gene Ontology lists (Biological Process, Molecular 
Function and Cellular Component). 
When running GSEA we used most of the default parameters, except for a small number of 
exceptions. First we started by changing the option “Collapse dataset to gene symbols” from 
True to False, since our matrix already had gene names there is no need to associate to any chip 
annotation file, and by setting the gene “Max size” and “Min size” parameters to 1000 and 5, 
respectively. This option allowed us to exclude from the analyses metabolic pathways having 
a too limited number of genes. 
Once each GSEA run had finished we used the same data to do a Preranked run. We left 
almost all parameters as default only changing the “Collapse dataset to gene symbols”, the gene 
“Max size” and “Min size” parameters like we did previously on the normal GSEA run.  
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In the results, pathways with false discovery rate (FDR) lower than 0.25 are considered as 
significantly differentially expressed between the two groups, and they are ranked based on the 
Normalized Enrichment Score (NES). We present the top of the metabolic pathways in each 
cancer type in a graphical form by using R. 
3.8. Somatic mutations in infected and non-infected groups 
In order to test the hypothesis if viral infection leads to increased somatic mutation, we 
downloaded the curated somatic mutation profiles reported by TCGA team in their website. 
Each file presented all mutations, their functional implications and respective genes and sam-
ples. We counted number of mutations per class of type of mutation in infected and non-in-
fected groups, and calculated the ratios of these mutations (by dividing number of mutations 
per number of samples). The results are shown through bar plots performed through R. 
To test if independent somatic mutations affect the same metabolic pathways we used G:Co-
coa from G:Profiler webtool (Reimand et al. 2016) The curated files of somatic mutations were 
used to count the number of times each gene was hit in infected and non-infected groups from 
each cancer. Then, those genes wore sorted in descending order through those counts, divided 
by infected or non-infected groups and used as input in G:Cocoa tool. 
In this tool the inputted information is then compared with information available in the same 
four references list of metabolic pathways used in GSEA (KEGG, the Gene Ontology Biolog-
ical Process, Molecular Function and Cellular Component reference lists). Then, the results are 
presented in a list of metabolic pathways significantly mutated in each or in both groups. Bar 
plots (representing –log(p-value)) for each infected and non-infected groups were built in R for 
the most significant pathways. 
3.9. Viral integration on the host genome  
With viral presence confirmed in the cancer samples we could now investigate its integra-
tion into the host genome, the most direct proof of an active infection and potentially providing 
additional information of contribution to cancer development (depending on the integration 
location in the human genome). We began by using a HNSC sample known to have viral inte-
gration (Tang et al. 2013), in order to check if we were able to correctly detect it. For this we 
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used VirusSeq tool, which uses Hg19 as reference to human genome and has an extra chromo-
some which corresponds to the reference viral database from which each tested sample would 
have to be compared. 
We started by downloading the whole genome bam file from the TCGA database (total size 
of 200GB). Then, by using the Picard Tool SamToFasq, we divided the sample into two, cor-
responding to the forward and reverse sequences, and converted it into fastq files. These two 
fastq files will serve, then, as input files for VirusSeq, which was run with all default options. 
Unfortunately, because this tool uses a large amount of RAM memory and takes a very long 
time to finish the whole process (approximately two weeks), it must be run in a powerful server. 
Since we had limited access to a server we could only perform the investigation of viral inte-
gration in one sample.  
3.10. Expressed Viral genes 
We also identified the most expressed viral genes for the most frequent viruses in each can-
cer type, by using HTSeq toll (ref). We downloaded a GFF file with information of all coding 
sequences (CDS) for HPV16 and HBV from NCBI database and then five samples per cancer 
where those viruses hade a higher infection rate. GFF and SAM files from each sample that 
were a result output after aligning each sample with the viral database were used as input in 
HTSeq. Each run took around 2 hours in the same computer used for viral presence detection, 
since the most time consuming part was already performed during the previous viral infection 
detection. 
As output it is then presented the number of times each gene was expressed in every sample 
as well as information about ambiguous reads, not aligned reads or even low quality reads. 
Samples from different cancers that were infected by the same virus, CESC and HNSC, were 
compared.  
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4. RESULTS AND DISCUSSION  
4.1. Cervical carcinoma (CESC) 
In the total 309 samples from the CESC cancer downloaded from TCGA, 304 samples were 
from tumour tissue (TP) with 286 infected and 18 not infected (94.1% infection), 3 samples 
from normal tissue (NT) with 1 infected and 2 not infected, and 2 metastic samples, one in-
fected and another not infected (Figure 4; Table 1 in annexes).  
 
Figure 4. RNAseq samples distribution through tissue type and infection results in samples from CESC cancer.  
 
We were limited to three patients for which we had both normal and cancer tissue samples, 
and only one had infection in both tissues, while two had only infection in the tumor (at least 
according to our classification as infected, with ppm>10).  
The results of the rate of infection in CESC (Figure 5) meet the expected outcome of nearly 
100% infected cases for this type of tumour (Tang et al. 2013). The predominant virus in the 
94.1% infected CESC samples is HPV (Figure 6), and diverse strains are observed. However, 
the more frequent one across samples is HPV16 and this is also the one that reaches extremely 
high ppm values (above 300ppm). High values of ppm are also relatively common in HPV18 
and HPV45 that infect a similar number of patients (approximately 22% each) (Figure 6). It is 
also important to mention that HPV31 is a very common virus among the infected samples too. 
This virus infects only a few samples (6%) with ppm above 300, however, it infects a very 
large number of samples (51%) with ppm between 10 and 300 ppm. Likewise, even though not 
as common as the previous viruses, HPV26 is present in a considerable number of samples. 
Some of those samples have a considerable high value of ppm (between 50 and 300; 13%) yet, 
the big majority have ppm from 10 to 50 (16%). In the same line of thought, HPV33, HPV58 
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and HPV68b are present in a very small number of samples where these viruses have a very 
high ppm, like 100 to 300 or above 300, there are a considerable number of samples where they 
are present with ppm between 10 and 50 (Figure 6). HHV are very rare (mostly present in ppm 
between 2 and 10) and present in a small number of samples (in total, 41 samples). 
 
 
Figure 5. Percentage distribution of viral infection in CESC samples. Each sample was represented by the virus with the 
higher ppm and only tumour tissue samples were considered in this graphic. Virus with ppm lower than 10 were not consid-
ered as infecting a sample. 
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Figure 6. Viral presence distribution in CESC cancer samples by ppm. Each column represents one sample. Viruses with ppm smaller than 2 were not considered. 
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We checked the effect of variance in the gene expression profiles through two PCAs. In the 
first one (Figure 7A), we checked the effect of TP versus NT samples. The NT samples, even 
though in a very small number, are distanced from most TP samples, showing that there are 
significant differences in gene expression between the normal and tumor tissues. But even more 
interesting, the TP samples are organised in two clusters, which deserves further investigation. 
In the second PCA (Figure 7B), only the TP samples were considered, to check the variability 
between infected and non-infected groups. As we can see, the split is not perfect, being 12 non-
infected samples dispersed in the cluster of the left, and the remaining six in the other cluster. 
The low number of non-infected samples precludes the application of a statistical test.  
 
 
A 
 
B 
Figure 7. PCA of CESC samples. (A) Comparing samples between tumour and normal tissues. (B) Comparing infected and 
not infected TP samples. 
 
We then identified all tumor infected samples present in the two clusters, concluding that 
there were 61 and 225 samples on the left and right cluster, respectively. After, we checked 
their associated clinical information in order to detect any relevant factor, and could not see 
any significant difference which could explain the two clusters. We then evaluated if the clus-
tering could be due to a different profile of virus infecting the samples (Table 2). When con-
sidering only strains with ppm>10, there is a bigger percentage of HPV18 and HPV45, a con-
siderable higher percentage of HPV33, HPV39 and HPV53 and a smaller percentage of HPV31 
infection on the left cluster in comparison with the right cluster. While HPV16 and HPV52 are 
more frequent in the right than the left cluster. So, it seems that differences in proportions of 
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the HPV strains that infect the patients can contribute to differential expression profiles of the 
human genome. 
 
Table 2. Count of samples bearing infection in each cluster of the PCA of Figure 7B. The percentage was calculated using the 
number of samples infected by each virus with ppm>10 and the total of infected samples in each cluster (61 samples in the left 
cluster and 225 in the right cluster). 
Virus 
Left Cluster Right Cluster 
Nº of samples % Nº of samples % 
HPV16 36 59.02 154 69.68 
HPV18 31 50.82 36 16.29 
HPV26 20 32.79 69 31.22 
HPV31 29 47.54 147 66.52 
HPV33 22 36.07 46 20.81 
HPV39 13 21.31 16 7.24 
HPV45 32 52.46 36 16.29 
HPV52 4 6.56 21 9.50 
HPV53 10 16.39 6 2.71 
HPV56 1 1.64 4 1.81 
HPV58 8 13.11 32 14.48 
HPV59 12 19.67 17 7.69 
HPV68b 17 27.87 34 15.38 
HPV34 0 0 5 2.26 
HPV70 0 0 11 4.98 
HPV4 0 0 1 0.45 
HPV5 0 0 1 0.45 
HPV69 0 0 2 0.90 
HHV4 0 0 1 0.45 
HBV 0 0 1 0.45 
 
The main genes responsible for the variability in PC1, in decreasing order, were: KRT14, 
DSG3, CLCA2, DSC3, SERPINB13, CALML3, SPRR1B, TMPRSS11D, KRT6C, BNC1, 
KRT6A, RHCG, IVL, MUC5B, PKP1, SPRR1A, KRT5, PROM1, SPRR2A, LASS3, TP63, SBSN, 
GBP6, SPRR2D and KRT6B. 
GSEA was used to evaluate differences in expression profiles between the infected and non-
infected groups (Figure 8; genes involved in some pathways are displayed in Table 2 in an-
nexes). In the bar plot for GO_BP, it is immediately visible a few obvious pathways related to 
viral infection in top of the graphic (e.g.: cellular defence response, defence response, immune 
response, response to virus, inflammatory response, immune system process, endosome 
transport, JAK-STAT cascade, response to other organism, T-cell activation), and even the 
pathways related to cell death are also important in the defence to viral infection. 
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Figure 8. GSEA results for CESC when comparing infected and non-infected samples and using the Gene Ontology Biological 
Process (GO_BP), Molecular Function (GO_MF) and Cellular Component (GO_CC), and the KEGG references lists. For 
each graphic 19 metabolic pathways with FDR smaller than 0.25 were picked and then sorted by NES value. The positive NES 
values mean that these are more expressed in the infected than in the non-infected. 
 
Considering the GO_MF bar plot, all pathways involving interleukins, cytokines and chem-
okines are related with the immune system. In fact, interleukins and chemokines are types of 
cytokines, a group of small proteins that are important in cell signalling and being produced by 
diverse types of cells, including immune cells like macrophages, B lymphocytes, T lympho-
cytes and mast cells. Besides these, pathways related to DNA repair were also overexpressed 
in the infected group. 
When analysing the GSEA GO_CC, pathways related with chromosomes are at the top of 
differentiation, concordant with an active viral infection and integration of viral in the host 
genome. But also pathways related to membrane movement and lipid rafts are highlighted, 
being more related with entrance and replication of the virus in the cell. 
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Finally, in the results using the KEGG reference list, a mix of the metabolic events seen in 
the previous GO lists is observed: some relevant pathways directly related to infection like 
proteosome regulation, natural killer cell mediated cytotoxicity, primary immunodeficiency, 
antigen processing and preservation; other pathways related to DNA replication, mismatch re-
pair, cytosolic DNA sensing pathway; and diseases related with infection or inflammation, as 
graph versus host disease, type I diabetes, asthma and leishmanial infection. 
We also downloaded the curated file of somatic mutations in CESC, but given that this only 
contained 194 samples of which only 10 were from non-infected patients, we decided to not 
follow with analyses on the possible influence of infection in the total number of somatic mu-
tations. 
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4.2. Hepatocellular carcinoma (LIHC) 
From the 424 RNAseq samples available in TCGA for LIHC (Figure 9; Table 3 in annexes), 
371 were from TP with 253 non-infected and 118 infected (infection rate of 31.8%), 50 from 
NT with 40 non-infected and 10 infected, and 3 samples from recurrent tumour tissue all in-
fected. 
 
Figure 9. RNAseq samples distribution through tissue type and infection results in samples from LIHC cancer. 
 
There were 50 NT samples to compare with the TP, and of these, two non-infected in NT 
were infected in TP, while three infected in NT were non-infected in TP. All recurrent tumor 
tissue samples were infected. The results obtained here for the viral infection in LIHC (Figure 
10) meet the expected rates presented by Tang et al. in 2013, when analyzing a smaller subset 
of samples. Still, a low proportion of 8.89% of the samples, although considered as non-in-
fected, have viruses detected in ppm between 2 and 10. 
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Figure 10. Percentage distribution of viral infection in LIHC samples. Each sample was represented by the virus with the 
higher ppm and only tumour tissue samples were considered in this graphic. Virus with ppm lower than 10 were not consid-
ered as infecting a sample. 
 
In Figure 11 it is possible to see in more detail the distribution of the main viruses and their 
ppm in patients that have at least one virus attaining a ppm>2. Almost all of the 31.8% infected 
samples are infected by HBV (usually with high ppm), and less than 10% of those have HCV 
or HHV as the main infecting viruses (see also Table 3 in annexes). Adeno-associated virus 
(HAdV) was also observed in six samples, and in two of them, strain HAdV-2 attains a fre-
quency between 100-300 ppm. Seven strains of HHV were observed in this sample, most with 
ppm inferior to 10, so we could not consider these viruses as infecting the samples, and only 
one had HHV5 strain Merlin with ppm between 10 and 50, and two other had HHV4 with ppm 
between 100 and 300. HHV1 strain 17 was the most frequent across patients, although always 
in small ppm. Three strains of HCV were observed, which genotype 1 attained infection rates 
in four samples (three with ppm between 50 and 100, and one between 100 and 300). 
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Figure 11. Viral presence distribution in LIHC cancer samples by ppm. Each column represents one sample. Viruses with ppm smaller than 2 were not considered. 
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The PCA test to evaluate clustering between TP and NT (Figure 12A) indicate a clear sep-
aration between the two groups, supporting a big difference in expression pattern in tumorigen-
esis. The PCA test between infected or non-infected groups (Figure 12B) does not show any 
differentiating clustering between the two categories, with only a slight tendency for the in-
fected samples to spread in the upper side of the PCA. 
 
 
A 
 
B 
Figure 12. PCA of LIHC samples. (A) Comparing Samples from tumor and normal tissue. (B) Comparing Samples from 
infected and not infected samples from TP samples only.  
 
Despite the not clear distinction in expression profiles between infected and non-infected 
groups in the PCA, we performed a GSEA analysis, as integrating expression of genes in met-
abolic pathways can be more informative: in PCA analysis, significant differences in a low 
number of genes may not be enough in the total of 20,000 genes, but if these alterations are in 
the few genes that make a metabolic pathway, they can reach statistical significance. The re-
sults presented in Figure 13 show that the enriched pathways in the infected group are related 
with cell division, DNA and RNA replication and repair, in all the reference lists of metabolic 
pathways. No pathway directly related to immune response is enriched in the infected group in 
LIHC. It seems that the common feature in cancer cells of constant replication and constant 
need of energy is significantly increased in the infected group when compared with the non-
infected one. 
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Figure 13. GSEA results for LIHC when comparing infected and non-infected samples and using the Gene Ontology Biological 
Process (GO_BP), Molecular Function (GO_MF) and Cellular Component (GO_CC), and the KEGG references lists. For 
each graphic 26 metabolic pathways with FDR smaller than 0.25 were picked and then sorted by NES value. The positive NES 
values mean that these are more expressed in the infected than in the non-infected. 
 
For LIHC, the more even number of samples in the infected and non-infected groups al-
lowed us to evaluate the effect of infection in the amount of somatic mutations. The curated 
file downloaded from TCGA database contained information for 193 samples where 45 of them 
were infected and the others 148 samples were non-infected. The number of somatic mutations 
per sample varied extensively, from 40 to 1800 mutations per sample, corresponding to a total 
of 53,000 somatic mutations found in 193 LIHC samples. The total count and the ratios of 
different classes of somatic mutations in the two groups are displayed in Figure 14 and Table 
4 in annexes. 
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A B 
Figure 14. LIHC Somatic Mutations. (A) Global count of somatic mutations in 193 LIHC samples. (B) Each somatic muta-
tion type ratio (number of mutations found and divided by the number of sample) per infected and non-infected samples. 
 
In the 193 samples, 11 types of somatic mutations were found, with silent, RNA and mis-
sense being the most common ones. In opposition, in frame insertion, translation start site and 
nonstop mutations where rare. Globally, all mutations have similar ratio values in both groups, 
indicating that they are equally common in both infected and non-infected samples, although 
the tendency is for a slightly higher value in infected patients. The big exceptions are RNA and 
frame shift deletions mutations, which have a double ratio in infected compared with non-
infected samples (statistically significant for the RNA class; two-tailed Fisher exact test 
p=0.017).  
Then we performed a G:Cocoa analysis in the mutations occurring in coding genes, com-
paring the lists of ranked hit genes between the infected and non-infected groups. G:Cocoa 
results for LIHC (Figure 15) show that infected samples had a bigger number of significantly 
somatic mutated-hit pathways than non-infected samples. Most of these pathways are related 
with cancer and cell signalling, structural proteins on membranes, cell junction, DNA and RNA 
replication, transcriptional and energy mechanisms. These processes are known to be affected 
in cancer cells, which have a high rate of cell division. But more interesting, a few of the sig-
nificant pathways in the infected group are related with immune response: phosphatidylinositol 
phospholipase C activity; inflammatory mediator regulation of TRP channels; leukocyte ag-
gregation; somatic diversification of immune receptors. Maybe somatic mutations in the genes 
involved in these pathways render these patients more susceptible to the infection. The hit-
mutated genes in the immune-related pathways are represented in Table 5 in annexes. 
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Figure 15. Pathways having a significant amount of genes hit by somatic mutations in infected and non-infected LIHC groups 
obtained through G:Cocoa when running against Gene Ontology Biological Process (BP), Molecular Function (MF) and 
Cellular Component (CC), and the KEGG references lists.  
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4.3. Head and neck squamous cell carcinoma (HNSC) 
For the 566 HNSC RNAseq samples available at TCGA database, 520 were TP being 86 
infected and 434 non-infected (16.5% infection rate), 44 NT with 3 infected and 41 non-in-
fected, and 2 metastic tissue samples one infected and the other non-infected (Figure 16; Table 
6 in annexes). Most of the samples having both tumor and normal tissue had concordant infec-
tion status except for four samples (two infected and two non-infected TP samples had its anal-
ogous NT samples with opposite viral infection presence). 
 
Figure 16. RNAseq samples distribution through tissue type and infection results in samples from HNSC cancer. 
 
Figure 17. Percentage distribution of viral infection in HNSC samples. Each sample was represented by the virus with the 
higher ppm and only tumour tissue samples were considered in this graphic. Virus with ppm lower than 10 were not considered 
as infecting a sample. 
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The 16.5% infection rate in HNSC, the smallest in the three types of cancer studied in this 
work, is concordant with values estimated previously in a very limited subset of this cohort 
(Tang et al. 2013). 
From all viruses found, HPV16 is the most frequent (80% of infected samples) and where 
the highest values of ppm are attained, with a big proportion of patients having ppm values 
above 300 and between 100 and 300. The HPV16+ cases were mainly observed in tonsil 
(48.5%) and base of tongue (19.1%), corresponding to 73.3% and 48.1% of the cases in these 
tissues. Another HPV strain infected some patients, HPV26, but ppm values were in general 
lower, around 10 to 50 and 50 to 100. Two other HPV, HPV53 and HPV32, were observed 
only in one sample each (Table 6 in annexes). 
A total of seven HHV strains were observed, with low ppm values that would not be con-
sidered as infecting the patient, in most of the cases. HHV1 strain 17 was the most common 
among all samples, but there are only three samples where this virus had ppm above 10. 
Apart from HHV and HPV viruses, there were also other two viruses present (HBV and 
HAdV-C). The HBV virus was only present in two samples and even if it was considered as 
infecting those samples, its ppm were not much higher than 10. In the other hand, HAdV-C 
virus were present in more samples but none where this virus had ppm above 10. 
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Figure 18. Viral presence distribution in HNSC cancer samples by ppm. Each column represents one sample. Viruses with ppm smaller than 2 were not considered. 
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The PCA on the comparison between TP and NT samples (Figure 19A), did not reveal clear 
clustering, with TP samples being dispersed and NT samples spreading among them and 
slightly displacing to the left side of the plot. This seems to indicate slight differences in gene 
expression profile between TP and NT samples. The same is true for the PCA comparison 
between infected and non-infected samples (Figure 19B), with samples spreading all over the 
plot, and just a slight higher frequency of infected samples in the lower left corner of the PCA. 
Again, this seems to indicate the existence of a few differences in gene expression profile be-
tween infected and non-infected samples 
 
 
A 
 
B 
Figure 19. PCA of HNSC samples. (A) Comparing Samples from tumor and normal tissue. (B) Comparing Samples from 
infected and not infected samples from TP samples only. 
The main genes responsible for the variability in PC1, in decreasing order, were: KRT19, 
KLK5, KRTDAP, KRT1, DEFB103B, NTS, CDSN, SPRR2G, DSG1, WNK2, WFDC12, 
FAM25A, LCE3D, MYO3A, LCE3E, PNLIPRP3, S100A7, SPINK6, PCDH19, KRT14, 
FAM3B, CRCT1, NTRK2, SPRR2B and S100A7A. 
The GSEA results (Figure 20; genes in main pathways are listed in Table 7 in annexes), for 
the GO_BP reference list, indicated that pathways differentially more expressed in infected 
than in non-infected groups are related to DNA replication and organization, and cell division, 
with none related to viral infection or to lipid metabolisms. Similar results were found when 
using GO_MF, but it included lipid kinases activity pathway. When using GO_CC, the nucleus 
and chromosome are the main cellular components identified, but also an immunological syn-
apse is significant. Regarding the results for KEGG reference list, in concordance with the 
previous lists, some pathways related to cell division and DNA repair are observed, but the 
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signal for differential expression in immune-related pathways is stronger (T- and B-cell recep-
tor signalling, primary immunodeficiency, intestinal immune network for IGA production).  
 
 
Figure 20. GSEA results for HNSC when comparing g infected and non-infected samples and using the Gene Ontology Bio-
logical Process (GO_BP), Molecular Function (GO_MF) and Cellular Component (GO_CC), and the KEGG references lists. 
For each graphic 29 metabolic pathways with FDR smaller than 0.25 were picked and then sorted by NES value. The positive 
NES values mean that these are more expressed in the infected than in the non-infected. 
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A B 
Figure 21. HNSC Somatic Mutations. (A) Global count of somatic mutations in 279 HNSC samples. (B) Each somatic mutation 
Ratio (number of mutations found and divide them by the number of sample) per infected and non-infected samples. 
 
For HNSC, TCGA website provides information for somatic mutations in less than half of 
the initial samples, amounting to 279 samples where 39 were infected and 240 were non-in-
fected samples. It was possible to identify (Figure 21 and table 9 in annexes) that silent and 
missense mutations were the most frequent mutations in HNSC cancer appearing over 12900 
and 33200 times, respectively, in all 279 samples. On the other hand, in frame insertions and 
nonstop mutations were very rare in these samples appearing only around 40 times each. Re-
garding the ratio of those mutations among infected and non-infected samples, they are identi-
cal. The G:Cocoa analysis of the somatic mutations occurring in coding genes (Figure 22) in-
dicated that in both infected and non-infected groups many similar pathways directly related to 
cell maintenance and division mechanisms were found, in accordance with higher rate of cell 
replication in tumor tissues. Regarding the results in the infected group, some pathways are 
related to viral infection, as lymphocyte activation and Fc gamma R-mediated phagocytosis. 
Lymphocytes act as principal response to viral infection in an organism and phagocytosis plays 
an essential role in host-defense mechanisms through the uptake and destruction of infectious 
pathogens. The hit-mutated genes in the immune-related pathways are represented in Table 8 
in annexes. 
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Figure 22. Pathways affected by somatic mutations in infected and non-infected HNSC samples obtained through G:Cocoa when running against Gene Ontology Biological Process (BP), 
Molecular Function (MF) and Cellular Component (CC), and the KEGG references lists. 
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Furthermore, a single whole genome sample was downloaded in order to confirm and detect 
viral insertion in the host genome, by using the VirusSeq tool. The sample was from a patient 
where the HPV16 virus was highly expressed, and which Tang et al. (2013) confirmed has 
having the virus inserted in the host genome. The whole genome had approximately 200 GB, 
and this this tool used around 50GB RAM memory, which with the server we had available 
took around two weeks to finish. 
 
Table 3. VirusSeq results of HNSC sample TCGA-BA-4077-01B. Confirmation of HPV16 insertion on an infected sample 
and its correspondent expressed genes and location on the host genome. 
Viral 
Transcript 
Host Gene 
Discordant Read 
Pairs 
Virus Chr. ID 
Virus Integration 
Location 
Gene Chr. 
ID 
Gene Integration Lo-
cation 
HpV16gp2_E7 RAD51B//intron7 331 25 581007 14 68699686 
HpV16gp4_E2 RAD51B//intron7 46 25 583997 14 68683564 
HpV16gp4_E2 RAD51B//intron7 103 25 584022 14 68741478 
HpV16gp5_E4 RAD51B//intron7 440 25 583794 14 68741301 
HpV16gp6_E5 RAD51B//intron7 10 25 584257 14 68683629 
 
We confirmed that the HPV16 virus was inserted in the genome of the patient. That the viral 
genes inserted were E2, E4, E5 and E7, which were inserted on the chromosome 14, in the 
intron 7 of RAD51B gene of the human genome (Table 3). These results replicated the ones 
obtained by Tang et al. (2013), but due to limitations of server, we could not pursue in checking 
viral insertion in all the infected samples we characterised here for the three tumor types.  
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4.4. Direct comparison between all cancer results 
The observation that, in CESC and HNSC, a big portion of samples are infected by HPV 
enables to test if the same type of virus can influence significantly on the host gene expression 
profile, independently on the infected tissue. We thus performed a PCA analysis for CESC and 
HNSC infected samples and identifying the presence or absence of HPV (Figure 23). 
 
Figure 23. Comparison between CESC and HNSC cancer expression profiles. Only infected samples from each cancer were 
used and were identified by the presence or absence of any HPV virus.  
 
The two cancers tend to form clusters, but there is still a considerable overlap between CESC 
and HNSC infected HPV samples along the right side of the PCA. Joining these results with 
the ones observed in Figure 7B this side of the plot is mainly formed by CESC samples infected 
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by HPV16, which is the dominant HPV strain observed in HNSC infected samples. It seems 
thus that this strain of HPV determines a response of the host that involves a distinct host gene 
profile that prevails across cervix and head and neck tissues.  
The main genes responsible for the variability in PC1, in decreasing order, were: KRT14, 
DSG3, SPRR1B, SPRR2A, IVL, SPRR1A, DSC3, CLCA2, SBSN, SPRR2D, TMPRSS11D, 
CALML3, SPRR2E, KRT6C, RHCG, SERPINB13, KRT6A, LASS3, PKP1, SPRR3, KRT6B, 
BNC1, GBP6, MUC5B and TP63. 
In these cancers, we selected five samples from each type which were HPV16+, in order to 
check which viral genes are more expressed by using HTSeq tool. 
 
 
Figure 24. Distribution of HPV16 expressed genes when infecting CESC and HNSC samples.  
 
The HPV16 genome contains 10 protein coding genes (CDS), whose functions are presented 
in Table 10 in annexes. From the results obtained through HTSeq (Figure 24; Table 11 in an-
nexes) it is possible to say that the two genes coding the transforming proteins E6 and E7 are 
highly expressed in almost all samples, in both tissues. E1 and E2, which play an important 
role in viral DNA replication are differentially expressed, with E1 being expressed in all sam-
ples and E2 non-expressed. The transforming protein E5, which contributes to cell transfor-
mation and polyploidy cells through endoreplication, is more expressed in CESC than in 
HNSC. While the genes for the minor capsid protein L2 and major capsid protein L1, playing 
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an essential role in virus assembly by recruiting viral components, have usually low expression 
except in two samples, L1 being dominantly expressed in one CESC sample and L2 dominating 
in one HNSC sample. 
 
 
Figure 25. Distribution of HBV expressed genes when infecting LIHC samples. 
 
We also performed a similar analysis in five LIHC samples HBV+. HBV only has seven 
CDS (Table 12 in annexes). In this cancer the variability of expressed CDS is far smaller (Fig-
ure 25; Table 13 in annexes). All samples have a big percentage of CDS3 and CDS4 expression, 
which code the small envelope protein and the X protein, respectively. Both are very important 
for viral infection especially the X protein, since it promotes cell cycle progression and inhibits 
tumour suppressor protein. Other CDS like CDS0, which codes polymerase protein, and CDS5, 
responsible for assembly of pre-capsid proteins, are expressed in very small percentages. Fi-
nally, the remaining CDS (CDS1, CDS2 and CDS6) coding envelope protein assembles were 
completely undetectable. 
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5. CONCLUSION 
The availability of extensive RNAseq datasets in TCGA for CESC, LIHC and HNSC al-
lowed us to investigate the infection rates in these tumors, in sample sizes between 309 and 
566. The infection rates we obtained accorded with values described previously in more limited 
datasets (Tang et al. 2013): 94% for CESC; 32% for LIHC; and 17% for HNSC. At the same 
time, we were able to characterise in great detail the viral diversity observed in each human 
sample, even for low present viruses. Most infected CESC samples bear several HPV strains, 
although HPV16 is by far the most common in each sample and overall in the dataset. LIHC 
infected samples are homogeneously infected by HBV, while most HNSC infected samples are 
mainly infected by HPV16. HHV1 strain 17 is common in all three tissues, especially so in 
HNSC, but usually does not attain infection levels. 
When investigating the impact of infection upon the host gene expression, a clear sign of 
enrichment in immune-related pathways was observed in the infection group in CESC, less so 
in HNSC, and not at all in LIHC. The signal in CESC seems to indicate an active immune 
response against the virus, as the pathways detected as enhanced were: cellular defence re-
sponse, defence response, immune response, response to virus, inflammatory response, im-
mune system process, endosome transport, JAK-STAT cascade, response to other organism, 
T-cell activation, pathways involving interleukins, cytokines and chemokines, proteasome reg-
ulation, natural killer cell mediated cytotoxicity, primary immunodeficiency and antigen pro-
cessing and preservation. These results contradict claims that cervical cancer arises rarely as a 
result of infection, with most infections being cleared by the host without clinical symptoms, 
as in general, HPV infections evade both adaptive and innate immune responses, with the life 
cycle being totally intra-epithelial, without viraemia, cell lysis or inflammation (Egawa et al. 
2015). Till this work, no proper GSEA test had been applied to the comparison between in-
fected and non-infected groups, given the extremely high infection rate not enabling enough 
number of non-infected patients for proper statistical evaluation (Adams et al. 2014). The larger 
dataset analysed here, allowed us to overcome this limitation, and to provide evidence on the 
contrary. We observed that those immune-related pathways incorporate genes such as MICB, 
HLA-B/G, CCL5, CCR5/6/7, KLRC2/3/4, IL1RL2/IL10RB/IL12B (Table 2 in annexes) These 
genes play a leading role in the immune response to viral infection. In HNSC, the few immune 
related enriched pathways in the infected group were limited to: immunological synapse, T- 
and B-cell receptor signalling, primary immunodeficiency and intestinal immune network for 
IGA production. These pathways involved mostly major histocompatibility complex (HLA-
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DMA/DMB/DOA/DOB/DPB1/DQA2/DRA/DPA1/DQA1), tumor necrosis factor receptor su-
perfamily (TNFRSF13B/13C/17), PIK3 (PIK3R1/R3/R5/CA/CB/CG) and mitogen-activated 
protein kinase (MAPK13/MAP2K7/3K8/3K14) genes, which also play a role in signalling con-
trol of cell cycle (Table 7 in annexes). Recently, Yan et al. (2016) by analysing HNSC TCGA 
mRNA and miRNA datasets, and performing differential analyses between tumor and normal 
tissues, observed several immune-related pathways as overexpressed in the tumor tissue (as 
defense response, response to virus, and primary immunodeficiency) (Yan et al. 2016). These 
results of a clear signal of immune-response involvement in CESC need to be confirmed in an 
independent work. 
Another category of pathways enriched in CESC infected group was more compatible with 
integration of viral genome in the host genome: pathways related with chromosomes, DNA 
replication, mismatch repair, cytosolic DNA sensing pathway. Genes of the family minichro-
mosome maintenance complex, as MCM2/4/5/6, which are highly conserved proteins involved 
in the initiation of eukaryotic genome replication, polymerase DNA catalytic subunits 
(POLA1/2, POLD1/2/3/4, POLE2/3/4) also involved in the initiation of DNA replication, are 
amongst the significantly enriched expressed genes. These pathways are also the dominantly 
enriched in the infected group in LIHC and HNSC, through the same genes and also other 
families as the cyclin-dependent kinase inhibitors (CDKN2D), that act as negative regulators 
of proliferation of normal cells and, in the case of CDKN2A, a well-known biomarker for 
HNSC infection (Zhang et al. 2016). This seems to indicate that integration in the host genome 
is very important in the three cancer types. Tang et al. (2013) showed that the integration of 
the viral genome in the host genome is very high for HPV18 (100%), HPV16 (59%) and HBV 
(77%), which are the dominant viruses in infected CESC, LIHC and HNSC samples. It is 
known that for HPV16, the main trigger for the transformation of the epithelial cells is the over-
expression of the viral genes E6 and E7, usually integrated in the host genome, which lose 
control from the viral E2 protein that is mostly not integrated or disrupted (Adams et al. 2014; 
Egawa et al. 2015). E6 and E7 proteins bind, respectively, to and inactivate the tumor suppres-
sor proteins TP53 and RB1, and thus host cells avoid apoptosis and grow in an uncontrolled 
manner (Zhang et al. 2016). Our analyses of the expression of HPV genes confirmed the over-
expression of E6 and E7 genes and almost no-expression of E2, both in the samples from CESC 
and HNSC. However, in the only integration confirmation we performed, we saw that E2 was 
also integrated in the host genome in this case. We also detected samples were instead of E6 
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and E7 overexpression, there was overexpression of L1 or L2 genes, which may indicate that 
these samples have a more active infection, with need of production of capsid for new virions. 
Still in CESC, one top enriched pathway in the infected group was keratinocyte differentia-
tion, which perfectly matches the fact that HPV infection and replication occurs, respectively, 
in the proliferating and differentiated keratinocytes of the epithelium (Adams et al. 2014). 
Genes for small proline rich proteins (SPRR1A/B) and involucrin (IVL), which are cross-linked 
envelope proteins of keratinocytes, as well as transglutaminase (coded by TGM1) which cross-
links those proteins to membrane proteins, are overexpressed in that pathway. Interestingly, 
these genes are amongst the ones responsible for splitting the two clusters in PCA comparing 
infected and non-infected groups in CESC, which we confirmed that is also associated with a 
separation (although not perfect) between HPV16- and HPV16+ samples. In fact, the main 
genes responsible for PC1 in that figure (Figure 7B) are the ones coding for the already men-
tioned small proline rich proteins (SPRR1A/B and SPRR2A/D) and involucrin (IVL), as well as 
keratins (KRT5/6A/6B/6C/14), SERPINB13 (that may play a role in the proliferation or differ-
entiation of keratinocytes), and other proteins related with cell-adhesion. These genes are iden-
tical to the ones governing PC1 in HNSC (Figure 19B) and CESC together with HNSC (Figure 
23), showing how the tropism of HPV16 to keratinocytes (Egawa et al. 2015) is fundamental 
in driving the host gene expression in the two tissues. However, the signal of keratinocyte-
related pathway is not detected in the GSEA analyses conducted in HNSC.  
Given the viral integration in the host genome, which mostly occurs in known cancer genes 
such as MYC, ERBB2, RAD51B (as in the sample we analysed here), MLL4 and the 13q22.1 
region (Tang et al. 2013). This integration leads to increase in somatic mutations in the infected 
group, except for HNSC, given that tobacco is an important carcinogen in this tumor type and 
that TP53 mutations occur in HPV- cases (Adams et al. 2014; Zhang et al. 2016). As there were 
few non-infected samples for comparison purposes in CESC, we did not conduct these tests in 
this tumor type. But we confirmed the higher amount of somatic mutations in the infected 
group, especially RNA and frame shift deletions, in LIHC, and the slight lower amount of 
mutations in HNSC infected group. In concordance, when performing enrichment pathway 
analyses, the LIHC infected samples had a bigger number of significantly somatic mutated-hit 
pathways than non-infected samples, while in HNSC, the number was similar in both groups. 
In LIHC, the pathways were mostly related with cancer and cell signalling but a few related 
with immune response, such as phosphatidylinositol phospholipase C activity (mostly phos-
pholipase C genes mutated), inflammatory mediator regulation of TRP channels (many MAPK 
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genes), leukocyte aggregation (including TNFSF genes) and somatic diversification of immune 
receptors. In HNSC, in both infected and non-infected groups there were many similar path-
ways directly related to cell maintenance and division mechanisms, while in the infected group, 
some pathways are related to viral infection, as lymphocyte activation (including MAPK and 
PIK3 genes) and Fc gamma R-mediated phagocytosis (PIK3 genes). In accordance with our 
results, the comprehensive analyses performed by TCGA of the HNSC (Lawrence et al. 2015) 
showed that one dominant feature of the HPV+ associated HNSC tumors is the presence of 
helical domain mutations of the oncogene PIK3CA. It seems that some somatic mutations in 
the infected LIHC and HNSC groups may render these patients more susceptible to the infec-
tion. 
 
  
Genomic and transcriptomic analyses in cancers related with viral infection 
 
52 
 
REFERENCES 
Adams, Allie; Wise-Draper, Trisha; Wells, Susanne. 2014. “Human Papillomavirus Induced 
Transformation in Cervical and Head and Neck Cancers.” Cancers 6 (3): 1793–820. 
Anders, Simon; Pyl, Paul Theodor; Huber, Wolfgang. 2015. “HTSeq-a Python Framework to Work 
with High-Throughput Sequencing Data.” Bioinformatics 31 (2): 166–69. 
Broad Institute. 2016. “Picard Tools.” Http://broadinstitute.github.io/picard/ [Accessed 20 July 2016]. 
Canavan, Timothy P.; Doshi, Nipa R. 2000. “Cervical Cancer.” American Family Physician 61 (5): 
1369–76. 
Chen, Chien-Jen; Hsu, Wan-Lun; Yang, Hwai-I; Lee, Mei-Hsuan; Chen, Hui-Chi; Chien, Yin-Chu; 
You, San-Lin. 2014. “Epidemiology of Virus Infection and Human Cancer.” In Viruses and 
Human Cancer, edited by Mei Hwei Chang and Kuan-Teh Jeang, 193:11–32. Recent Results in 
Cancer Research. Berlin, Heidelberg: Springer Berlin Heidelberg. 
Chen, Min-Shan; Li, Jin-Qing; Zheng, Yun; Guo, Rong-Ping; Liang, Hui-Hong; Zhang, Ya-Qi; Lin, 
Xiao-Jun; Lau, Wan Y. 2006. “A Prospective Randomized Trial Comparing Percutaneous Local 
Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma.” Annals of 
Surgery 243 (3): 321–28. 
Chen, Yunxin; Yao, Hui; Thompson, Erika J.; Tannir, Nizar M.; Weinstein, John N.; Su, Xiaoping. 
2013. “VirusSeq: Software to Identify Viruses and Their Integration Sites Using next-Generation 
Sequencing of Human Cancer Tissue.” Bioinformatics 29 (2): 266–67. 
Consortium, T. G. O. 2001. “Creating the Gene Ontology Resource: Design and Implementation.” 
Genome Research 11 (8): 1425–33. 
Egawa, Nagayasu; Egawa, Kiyofumi; Griffin, Heather; Doorbar, John. 2015. “Human 
Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia.” Viruses 7 (7): 3863–
90. 
Egloff, Ann Marie; Lee, Ju-Whei; Langer, Corey J; Quon, Harry; Vaezi, Alec; Grandis, Jennifer R; 
Seethala, Raja R; et al. 2014. “Phase II Study of Cetuximab in Combination with Cisplatin and 
Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern 
Cooperative Oncology Group Trial E3303.” Clinical Cancer Research : An Official Journal of the 
American Association for Cancer Research 20 (19): 5041–51. 
Heaton, Nicholas S.; Randall, Glenn. 2011. “Multifaceted Roles for Lipids in Viral Infection.” Trends 
in Microbiology 19 (7): 368–75. 
Hudson, Thomas J.; Anderson, Warwick; Aretz, Axel; Barker, Anna D; Bell, Cindy; Bernabé, Rosa R; 
Bhan, M K; et al. 2010. “International Network of Cancer Genome Projects.” Nature 464 (7291): 
993–98. 
Irizarry, R. A.; Wang, Chi; Zhou, Yun; Speed, T. P. 2009. “Gene Set Enrichment Analysis Made 
Simple.” Statistical Methods in Medical Research 18 (6): 565–75. 
Jolliffe, Ian T.; Cadima, Jorge. 2016. “Principal Component Analysis: A Review and Recent 
Developments.” Philosophical Transactions of the Royal Society A: Mathematical, Physical and 
Engineering Sciences 374 (2065): 20150202. 
Konan, Kouacou V; Sanchez-Felipe, Lorena. 2014. “Lipids and RNA Virus Replication.” Current 
Opinion in Virology 9 (4): 45–52. 
Langmead, Ben; Salzberg, Steven L. 2012. “Fast Gapped-Read Alignment with Bowtie 2.” Nature 
Methods 9 (4): 357–59. 
Langmead, Ben; Trapnell, Cole; Pop, Mihai; Salzberg, Steven L. 2009. “Ultrafast and Memory-
Efficient Alignment of Short DNA Sequences to the Human Genome.” Genome Biology 10 (3): 
Genomic and transcriptomic analyses in cancers related with viral infection 
 
53 
 
R25.1-R25.10. 
Lawrence, Michael S.; Sougnez, Carrie; Lichtenstein, Lee; Cibulskis, Kristian; Lander, Eric; Gabriel, 
Stacey B.; Getz, Gad; et al. 2015. “Comprehensive Genomic Characterization of Head and Neck 
Squamous Cell Carcinomas.” Nature 517 (7536): 576–82. 
Li, Heng; Handsaker, Bob; Wysoker, Alec; Fennell, Tim; Ruan, Jue; Homer, Nils; Marth, Gabor; 
Abecasis, Goncalo; Durbin, Richard. 2009. “The Sequence Alignment/Map Format and 
SAMtools.” Bioinformatics 25 (16): 2078–79. 
Liang, Winnie S; Aldrich, Jessica; Nasser, Sara; Kurdoglu, Ahmet; Phillips, Lori; Reiman, Rebecca; 
McDonald, Jacquelyn; et al. 2014. “Simultaneous Characterization of Somatic Events and HPV-
18 Integration in a Metastatic Cervical Carcinoma Patient Using DNA and RNA Sequencing.” 
International Journal of Gynecological Cancer 24 (2): 329–38. 
Liang, Y.; Tayo, B.; Cai, X.; Kelemen, A. 2005. “Differential and Trajectory Methods for Time Course 
Gene Expression Data.” Bioinformatics 21 (13): 3009–16. 
Mardia, K. V.; Kent, J. T.; Bibby, J. M. 1979. Multivariate Analysis. London: Academic Press. 
McLaughlin-Drubin, Margaret E.; Munger, Karl. 2008. “Viruses Associated with Human Cancer.” 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1782 (3): 127–50. 
Moore, Patrick S; Chang, Yuan. 2010. “Why Do Viruses Cause Cancer? Highlights of the First Century 
of Human Tumour Virology.” Nature Reviews Cancer 10 (12): 878–89. 
Morales-Sánchez, Abigail; Fuentes-Pananá, Ezequiel M. 2014. “Human Viruses and Cancer.” Viruses 
6 (10): 4047–79. 
Muñoz, Nubia; Bosch, F. Xavier; de Sanjosé, Silvia; Herrero, Rolando; Castellsagué, Xavier; Shah, 
Keerti V.; Snijders, Peter J.F.; Meijer, Chris J.L.M. 2003. “Epidemiologic Classification of 
Human Papillomavirus Types Associated with Cervical Cancer.” New England Journal of 
Medicine 348 (6): 518–27. 
Ogata, H; Goto, S; Sato, K; Fujibuchi, W; Bono, H; Kanehisa, M. 1999. “KEGG: Kyoto Encyclopedia 
of Genes and Genomes.” Nucleic Acids Research 27 (1): 29–34. 
Patel, P S; Shah, M H; Jha, F P; Raval, G N; Rawal, R M; Patel, M M; Patel, J B; Patel, D D. 2004. 
“Alterations in Plasma Lipid Profile Patterns in Head and Neck Cancer and Oral Precancerous 
Conditions.” Indian Journal of Cancer 41 (1): 25–31. 
Raju, Kalyani; Punnayanapalya, Shruthi Suresh; Mariyappa, Narayanaswamy; Eshwarappa, Sumathi 
Mayagondanahalli; Anjaneya, Chandramouli; Jun, Lee. 2014. “Significance of the Plasma Lipid 
Profile in Cases of Carcinoma of Cervix : A Tertiary Hospital Based Study” 15: 3779–84. 
Reimand, Jüri; Arak, Tambet; Adler, Priit; Kolberg, Liis; Reisberg, Sulev; Peterson, Hedi; Vilo, Jaak. 
2016. “g:Profiler—a Web Server for Functional Interpretation of Gene Lists (2016 Update).” 
Nucleic Acids Research 44 (April): W83–W89. 
Schmieder, Robert; Edwards, Robert. 2011. “Quality Control and Preprocessing of Metagenomic 
Datasets.” Bioinformatics 27 (6): 863–64. 
Siegel, Abby B.; Zhu, Andrew X. 2009. “Metabolic Syndrome and Hepatocellular Carcinoma.” Cancer 
115 (24): 5651–61. 
Singh, Simranjit; Ramesh, Venkatapathy; Premalatha, Balakrishnan; Prashad, KarthikshreeVishnu; 
Ramadoss, Koliyan. 2013. “Alterations in Serum Lipid Profile Patterns in Oral Cancer.” Journal 
of Natural Science, Biology and Medicine 4 (2): 374–78. 
Subramanian, Aravind; Kuehn, Heidi; Gould, Joshua; Tamayo, Pablo; Mesirov, Jill P. 2007. “GSEA-
P: A Desktop Application for Gene Set Enrichment Analysis.” Bioinformatics 23 (23): 3251–53. 
Subramanian, Aravind; Tamayo, Pablo; Mootha, Vamsi K; Mukherjee, Sayan; Ebert, Benjamin L; 
Gillette, Michael a; Paulovich, Amanda; et al. 2005. “Gene Set Enrichment Analysis: A 
Genomic and transcriptomic analyses in cancers related with viral infection 
 
54 
 
Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles.” Proceedings of 
the National Academy of Sciences of the United States of America 102 (43): 15545–50. 
Tang, Ka-Wei; Alaei-Mahabadi, Babak; Samuelsson, Tore; Lindh, Magnus; Larsson, Erik. 2013. “The 
Landscape of Viral Expression and Host Gene Fusion and Adaptation in Human Cancer.” Nature 
Communications 4 (October). Nature Publishing Group: 2513. 
Tomczak, Katarzyna; Czerwińska, Patrycja; Wiznerowicz, Maciej. 2015. “Review The Cancer Genome 
Atlas (TCGA): An Immeasurable Source of Knowledge.” Współczesna Onkologia 1A: 68–77. 
Yan, Li; Zhan, Cheng; Wu, Jihong; Wang, Shengzi. 2016. “Expression Profile Analysis of Head and 
Neck Squamous Cell Carcinomas Using Data from The Cancer Genome Atlas.” Molecular 
Medicine Reports 13 (5): 4259–65. 
Yao, Fangzhou; Coquery, Jeff; Lê Cao, Kim-Anh. 2012. “Independent Principal Component Analysis 
for Biologically Meaningful Dimension Reduction of Large Biological Data Sets.” BMC 
Bioinformatics 13 (February). BioMed Central: 24. 
Zhang, Junjun; Baran, Joachim; Cros, A; Guberman, Jonathan M; Haider, Syed; Hsu, Jack; Liang, 
Yong; et al. 2011. “International Cancer Genome Consortium Data Portal—a One-Stop Shop for 
Cancer Genomics Data.” Database: The Journal of Biological Databases and Curation 2011 
(September). Oxford University Press: bar026. 
Zhang, Wensheng; Edwards, Andrea; Fang, Zhide; Flemington, Erik K; Zhang, Kun. 2016. “Integrative 
Genomics and Transcriptomics Analysis Reveals Potential Mechanisms for Favorable Prognosis 
of Patients with HPV-Positive Head and Neck Carcinomas.” Scientific Reports 6 (April). Nature 
Publishing Group: 24927. 
 
 
 
 
Genomic and transcriptomic analyses in cancers related with viral infection 
 
I 
 
ANNEXES 
Table 1. CESC resume table of viral infection. 
CESC Samples Nº Reads 
Human 
Reads 
Non-Hu-
man Reads 
Viral In-
fection 
Virus 
Found 
Total Hu-
man Viral 
Reads 
Total ppm of 
Human Viral 
Reads 
Human 
Virus 
with 
ppm>10 
Sum of all 
Reads with 
ppm>10 
Sum of all 
ppm bigger 
than 10 
Bigger ppm 
found 
Virus with bigger ppm 
TCGA-4J-AA1J-01A-21R-A38B-07 118091872 3351580 121443452 Yes 7 29215 8716.784324 5 29209 8714.994123 6150.830355 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-Q1-A73P-01A-11R-A32P-07 129566280 4144362 133710642 Yes 17 31573 7618.301685 9 31534 7608.89131 3867.66407 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-VS-A9UP-01A-11R-A42T-07 115495726 2593965 118089691 Yes 19 13543 5220.964815 8 13475 5194.750123 3247.923546 NC_001357 » Human papillomavirus - 18 
TCGA-VS-A9V5-01A-11R-A42T-07 120683236 2656068 123339304 Yes 10 10807 4068.796432 5 10772 4055.619059 2896.010193 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A957-01A-11R-A42T-07 53034359 1359417 54393776 Yes 12 5013 3687.610201 6 4998 3676.576061 2721.754988 
M12732 » Human papillomavirus type 33 
complete genome 
TCGA-ZJ-AAXD-01A-21R-A42T-07 61842201 1609661 63451862 Yes 9 4303 2673.233682 5 4280 2658.944959 2359.503026 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A3HD-01B-11R-A213-07 166691923 4492768 171184691 Yes 12 13158 2928.706757 5 13100 2915.797121 2201.983276 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UL-01A-11R-A42T-07 103948945 2167696 106116641 Yes 16 7747 3573.840612 7 7685 3545.238816 2189.421395 NC_001357 » Human papillomavirus - 18 
TCGA-VS-A9V3-01A-11R-A42T-07 83914920 2046142 85961062 Yes 9 6169 3014.942266 5 6132 2996.859455 2150.388389 
D90400 » Human papillomavirus type 58 
complete genome 
TCGA-VS-A9UD-01A-11R-A42T-07 65306360 2004117 67310477 Yes 12 4739 2364.632405 5 4682 2336.190951 2111.154189 
NC_001526 » Human papillomavirus 
type 16 
TCGA-Q1-A6DT-01A-11R-A32P-07 122568863 3693586 126262449 Yes 16 11063 2995.192207 5 10995 2976.781912 2102.022262 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A439-01A-11R-A24H-07 237540117 7233358 244773475 Yes 18 25534 3530.034044 8 25363 3506.393573 1883.495881 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-IR-A3LB-01A-11R-A24H-07 227676657 6606611 234283268 Yes 12 20520 3105.979754 5 20465 3097.654758 1879.935113 NC_001357 » Human papillomavirus - 18 
TCGA-Q1-A73O-01A-11R-A32P-07 160629916 4531268 165161184 Yes 16 15447 3408.979562 7 15356 3388.896882 1865.923622 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-EA-A1QS-01A-61R-A22U-07 176704793 6633869 183338662 Yes 10 21716 3273.504497 4 21593 3254.96328 1862.110934 
FR751039 » Human papillomavirus type 
68b complete genome 
TCGA-EK-A2H0-01A-11R-A180-07 178994152 7175668 186169820 Yes 13 21796 3037.487243 5 21693 3023.133177 1827.704403 
M62849 » Human papillomavirus ORFs 
(HPV-39) 
TCGA-VS-A9UI-01A-11R-A42T-07 82890073 2573902 85463975 Yes 9 5147 1999.687634 4 5125 1991.1403 1704.416097 
X74481 » Human papillomavirus type 52 
genomic DNA 
TCGA-VS-AA62-01A-11R-A42T-07 116243429 2910235 119153664 Yes 13 8837 3036.524542 4 8746 3005.25559 1621.862152 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-C5-A3HF-01A-11R-A213-07 169111651 6391918 175503569 Yes 18 20429 3196.067284 10 20373 3187.30622 1604.056873 NC_001357 » Human papillomavirus - 18 
TCGA-VS-A9UZ-01A-11R-A42T-07 90519136 2419872 92939008 Yes 11 4455 1841.006467 3 4390 1814.145542 1601.737613 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A97N-01A-11R-A38B-07 111480979 2857908 114338887 Yes 8 5355 1873.748209 4 5307 1856.952708 1566.530483 
NC_001526 » Human papillomavirus 
type 16 
TCGA-WL-A834-01A-11R-A352-07 112613702 4992324 117606026 Yes 13 8415 1685.587718 4 8330 1668.561576 1540.765383 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UV-01A-11R-A42T-07 95961856 1895259 97857115 Yes 11 3107 1639.353777 4 3072 1620.886645 1505.335155 
X74481 » Human papillomavirus type 52 
genomic DNA 
TCGA-LP-A4AX-01A-12R-A24H-07 105651053 3353918 109004971 Yes 9 5394 1608.268301 4 5327 1588.291663 1407.011143 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A953-01A-11R-A38B-07 177720560 6174986 183895546 Yes 16 10920 1768.425062 5 10773 1744.619339 1362.108351 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A8EB-01A-11R-A36F-07 142428353 4006316 146434669 Yes 12 7577 1891.263696 4 7487 1868.799166 1362.848063 
NC_001526 » Human papillomavirus 
type 16 
Genomic and transcriptomic analyses in cancers related with viral infection 
 
II 
 
TCGA-VS-A9UB-01A-22R-A42T-07 84908691 1999318 86908009 Yes 10 3936 1968.671319 3 3921 1961.168759 1354.962042 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-EK-A2RM-01A-21R-A18M-07 144276484 4099513 148375997 Yes 15 10585 2582.014009 4 10471 2554.205829 1348.452853 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-FU-A3TX-01A-11R-A22U-07 197613889 4560827 202174716 Yes 15 14619 3205.339733 5 14441 3166.311724 1335.284149 NC_001357 » Human papillomavirus - 18 
TCGA-EA-A5FO-01A-21R-A28H-07 113840288 3518377 117358665 Yes 10 6720 1909.971558 6 6692 1902.013343 1332.432539 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MY-A913-01A-11R-A37O-07 150316371 5655598 155971969 Yes 14 13231 2339.45199 5 13213 2336.269302 1303.840902 NC_001357 » Human papillomavirus - 18 
TCGA-ZJ-AAX8-01A-11R-A42T-07 138013957 3406767 141420724 Yes 9 8403 2466.561405 4 8382 2460.397204 1291.547088 
M62849 » Human papillomavirus ORFs 
(HPV-39) 
TCGA-JW-AAVH-01A-11R-A38B-07 118290407 2883947 121174354 Yes 7 4170 1445.935033 3 4134 1433.452141 1275.682251 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MA-AA3Y-01A-11R-A38B-07 147969259 6909483 154878742 Yes 12 21870 3165.215111 6 21775 3151.465891 1250.74481 
FR751039 » Human papillomavirus type 
68b complete genome 
TCGA-JW-A5VL-01A-11R-A28H-07 149414711 5222922 154637633 Yes 10 12200 2335.857208 7 12191 2334.134034 1247.768969 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1M9-01A-11R-A13Y-07 216879099 8679070 225558169 Yes 18 15948 1837.524067 6 15862 1827.61517 1245.064275 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MA-AA41-01A-11R-A38B-07 143550983 5066468 148617451 Yes 11 8616 1700.592994 5 8523 1682.237013 1236.166892 
NC_001526 » Human papillomavirus 
type 16 
TCGA-FU-A40J-01A-11R-A24H-07 195416145 6482615 201898760 Yes 15 10947 1688.670389 7 10880 1678.335054 1234.069893 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A8EC-01A-11R-A36F-07 145345989 4502129 149848118 Yes 11 6784 1506.842651 5 6724 1493.515623 1228.974114 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UC-01A-11R-A42T-07 127093012 3600515 130693527 Yes 11 6250 1735.862786 5 6200 1721.975884 1227.324424 
M12732 » Human papillomavirus type 33 
complete genome 
TCGA-IR-A3LF-01A-21R-A22U-07 164084856 5502722 169587578 Yes 13 8732 1586.851016 5 8643 1570.677204 1215.035032 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A2M2-01A-21R-A18M-07 140221573 4746740 144968313 Yes 11 6976 1469.640217 5 6878 1448.994468 1198.506765 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A94X-01A-11R-A38B-07 128812958 3336341 132149299 Yes 16 4948 1483.061836 4 4792 1436.304024 1195.621191 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-C5-A7CH-01A-11R-A33Z-07 122764021 4977330 127741351 Yes 11 7233 1453.188757 4 7123 1431.088555 1147.402322 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7X8-01A-11R-A36F-07 119803218 7359797 127163015 Yes 16 17402 2364.467389 6 17279 2347.754972 1144.73266 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-VS-A9UQ-01A-21R-A42T-07 114021267 2987841 117009108 Yes 9 3818 1277.845777 2 3758 1257.764386 1134.263838 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A959-01A-11R-A42T-07 88133059 2873312 91006371 Yes 12 3594 1250.82135 2 3555 1237.248165 1134.231159 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-Q1-A5R1-01A-11R-A28H-07 113568275 5393780 118962055 Yes 12 8103 1502.285966 5 8014 1485.785479 1101.639296 
NC_001526 » Human papillomavirus 
type 16 
TCGA-Q1-A73R-01A-11R-A33Z-07 188229981 8578467 196808448 Yes 18 11706 1364.579478 5 11489 1339.283582 1058.114463 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A2LZ-01A-11R-A213-07 173570183 5738326 179308509 Yes 10 7866 1370.783047 3 7699 1341.680483 1055.882848 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EX-A69L-01A-11R-A32P-07 131369701 5000928 136370629 Yes 11 5994 1198.577545 5 5965 1192.778621 1025.009758 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A3HL-01A-11R-A213-07 178906142 5548288 184454430 Yes 15 7526 1356.45446 4 7393 1332.483101 1025.361337 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9U7-01A-11R-A42T-07 207451337 4164346 211615683 Yes 12 5514 1324.097469 4 5437 1305.607171 1022.969753 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EX-A449-01A-11R-A32Y-07 133858274 6361710 140219984 Yes 15 8786 1381.07521 6 8745 1374.630405 1020.794723 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7CJ-01A-11R-A32P-07 129823759 4172220 133995979 Yes 12 4944 1184.980658 3 4846 1161.491963 1016.724909 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A907-01A-11R-A37O-07 116969582 4949388 121918970 Yes 12 8155 1647.67846 2 7995 1615.351231 1014.87295 NC_001357 » Human papillomavirus - 18 
TCGA-ZJ-AAXN-01A-11R-A42T-07 247314173 9387967 256702140 Yes 33 18650 1986.58559 6 18449 1965.175207 1007.459869 NC_001357 » Human papillomavirus - 18 
TCGA-ZJ-A8QR-01A-11R-A37O-07 113212977 5039842 118252819 Yes 11 5975 1185.553039 3 5878 1166.306404 993.880364 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A1OC-01A-11R-A14Y-07 126179430 5083017 131262447 Yes 13 5461 1074.361941 3 5384 1059.213456 969.896422 
NC_001526 » Human papillomavirus 
type 16 
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TCGA-C5-A1MJ-01A-11R-A14Y-07 201716763 9304831 211021594 Yes 20 19955 2144.584894 6 19772 2124.917692 964.767657 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-JX-A3Q0-01A-11R-A32Y-07 146493850 4919521 151413371 Yes 16 5949 1209.264072 4 5754 1169.626067 957.410284 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-ZJ-AAXI-01A-11R-A42T-07 112611559 4506206 117117765 Yes 11 5021 1114.241115 3 4915 1090.718001 950.245062 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A3GN-01A-11R-A213-07 198451487 8044708 206496195 Yes 17 11031 1371.211979 5 10869 1351.07452 945.839178 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1ML-01A-11R-A14Y-07 107424587 5327311 112751898 Yes 7 5708 1071.45988 3 5617 1054.378091 945.505153 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A0VK-01A-21R-A10U-07 239743463 5491184 245234647 Yes 13 6434 1171.696304 3 6313 1149.660984 943.876585 
NC_001526 » Human papillomavirus 
type 16 
TCGA-LP-A5U2-01A-11R-A28H-07 141366205 4080020 145446225 Yes 11 4319 1058.573241 4 4236 1038.230204 925.975853 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9U5-01A-11R-A42T-07 76738412 2350578 79088990 Yes 7 2327 989.969275 2 2299 978.057312 913.817793 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A3HS-01A-11R-A213-07 202725170 6151663 208876833 Yes 8 6835 1111.081669 3 6700 1089.136385 900.894604 
NC_001526 » Human papillomavirus 
type 16 
TCGA-ZJ-A8QO-01A-11R-A37O-07 148839160 6155499 154994659 Yes 18 9454 1535.862483 5 9352 1519.291936 897.246511 
M12732 » Human papillomavirus type 33 
complete genome 
TCGA-VS-A94W-01A-12R-A37O-07 143424338 6468055 149892393 Yes 13 7478 1156.14354 3 7273 1124.449313 896.405488 
NC_001526 » Human papillomavirus 
type 16 
TCGA-ZJ-A8QQ-01A-11R-A37O-07 139944411 9235197 149179608 Yes 14 14183 1535.755004 3 13929 1508.251529 892.780089 
M62849 » Human papillomavirus ORFs 
(HPV-39) 
TCGA-C5-A7UH-01A-11R-A352-07 140147683 5956000 146103683 Yes 12 6819 1144.895904 3 6666 1119.207522 892.377435 
NC_001526 » Human papillomavirus 
type 16 
TCGA-JX-A5QV-01A-22R-A28H-07 134797908 5574000 140371908 Yes 10 5718 1025.834229 4 5637 1011.302476 891.998565 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A8XJ-01A-11R-A37O-07 132756585 4849741 137606326 Yes 17 6198 1278.006394 4 6108 1259.4487 889.325842 
M12732 » Human papillomavirus type 33 
complete genome 
TCGA-MA-AA3W-01A-11R-A38B-07 112777715 3670756 116448471 Yes 7 3664 998.159507 4 3651 994.618002 874.206839 
NC_001526 » Human papillomavirus 
type 16 
TCGA-HM-A4S6-01A-11R-A26T-07 129184613 4479509 133664122 Yes 11 4431 989.170914 3 4365 974.437154 860.58539 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A411-01A-11R-A24H-07 231960683 7132378 239093061 Yes 15 7912 1109.307444 4 7802 1093.884816 838.990867 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7CK-01A-11R-A32P-07 174197658 4344085 178541743 Yes 12 4577 1053.616583 3 4527 1042.106681 837.460593 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A8EL-01A-11R-A37O-07 146339443 6092782 152432225 Yes 13 6244 1024.819204 3 6094 1000.199908 828.028969 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-DS-A7WF-01A-11R-A352-07 143071789 6932643 150004432 Yes 11 6582 949.421454 3 6542 943.651649 822.918474 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7CG-01A-11R-A32P-07 144031929 4319414 148351343 Yes 10 4444 1028.843265 4 4433 1026.296623 821.870745 
X74481 » Human papillomavirus type 52 
genomic DNA 
TCGA-JX-A3Q8-01A-11R-A21T-07 157739769 5717823 163457592 Yes 12 6309 1103.391972 4 6248 1092.723577 815.170389 
NC_001526 » Human papillomavirus 
type 16 
TCGA-Q1-A6DV-01A-11R-A32P-07 134257054 5919744 140176798 Yes 11 5869 991.428008 3 5791 978.251762 812.872989 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1MK-01A-11R-A14Y-07 151353537 7239505 158593042 Yes 13 9916 1369.706908 4 9793 1352.716795 801.021617 
D90400 » Human papillomavirus type 58 
complete genome 
TCGA-EX-A1H5-01A-31R-A13Y-07 176326973 5544618 181871591 Yes 10 5530 997.363569 3 5424 978.245931 794.464109 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UO-01A-11R-A42T-07 204733331 5135786 209869117 Yes 15 5738 1117.258388 4 5642 1098.566022 784.690016 NC_001357 » Human papillomavirus - 18 
TCGA-C5-A2LS-01A-22R-A22U-07 136158371 5431129 141589500 Yes 9 4942 909.939721 3 4896 901.470026 780.86895 
NC_001526 » Human papillomavirus 
type 16 
TCGA-Q1-A73Q-01A-21R-A32P-07 127836430 11688173 139524603 Yes 26 12560 1074.590531 6 12303 1052.602489 759.485678 
M12732 » Human papillomavirus type 33 
complete genome 
TCGA-ZJ-AB0H-01A-11R-A42T-07 95544488 3309924 98854412 Yes 11 4462 1348.067204 4 4374 1321.480493 750.772525 NC_001357 » Human papillomavirus - 18 
TCGA-EA-A3QD-01A-32R-A22U-07 158959506 8457937 167417443 Yes 9 8232 973.286985 5 8135 961.818467 749.473542 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A8XH-01A-11R-A37O-07 169848532 5834920 175683452 Yes 12 5129 879.01805 3 5047 864.964729 742.426631 
NC_001526 » Human papillomavirus 
type 16 
TCGA-Q1-A6DW-01A-11R-A32P-07 139944972 3883024 143827996 Yes 8 5177 1333.239247 2 5140 1323.710592 733.706513 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
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TCGA-EK-A2R8-01A-21R-A18M-07 136482168 7475828 143957996 Yes 19 10726 1434.757458 3 10494 1403.724109 724.468246 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-ZJ-AAXA-01A-11R-A42T-07 272523092 6193407 278716499 Yes 13 5673 915.974036 4 5598 903.864384 721.573764 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MA-AA3X-01A-22R-A42S-07 124599784 8329922 132929706 Yes 11 8522 1023.058799 4 8385 1006.612066 721.375302 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DG-A2KL-01A-11R-A180-07 178951244 6826226 185777470 Yes 13 6100 893.612372 3 5934 869.294395 721.628613 
NC_001526 » Human papillomavirus 
type 16 
TCGA-JX-A3PZ-01A-11R-A32Y-07 145232552 5228089 150460641 Yes 17 6083 1163.522653 3 5986 1144.969032 713.262532 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-VS-A9V2-01A-11R-A42T-07 101349477 2563397 103912874 Yes 6 2035 793.86845 3 2026 790.357483 711.945906 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A8QF-01A-21R-A37O-07 138574255 6238983 144813238 Yes 12 6368 1020.679174 3 6238 999.842443 707.166537 
NC_001526 » Human papillomavirus 
type 16 
TCGA-FU-A2QG-01A-11R-A18M-07 201951071 8084747 210035818 Yes 15 7587 938.433821 3 7430 919.014535 706.639305 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A43B-01A-81R-A32Y-07 101403793 3976917 105380710 Yes 8 3196 803.63759 3 3146 791.065038 703.81152 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A3HQ-01A-11R-A213-07 229193607 9788167 238981774 Yes 12 10248 1046.978459 5 10141 1036.046893 703.196012 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9V1-01A-11R-A42T-07 78251056 2151137 80402193 Yes 5 2226 1034.801595 3 2222 1032.942113 697.305657 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-LP-A5U3-01A-11R-A28H-07 128040465 5523660 133564125 Yes 7 4320 782.090136 2 4279 774.667521 693.923956 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UY-01A-11R-A42T-07 116596054 2535098 119131152 Yes 9 2221 876.100253 3 2181 860.321771 692.28093 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A1QT-01A-11R-A14Y-07 244524044 9711902 254235946 Yes 15 9064 933.287834 3 8823 908.472923 692.34636 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A5RQ-01A-11R-A28H-07 122779875 4125668 126905543 Yes 11 3267 791.871765 3 3217 779.752515 688.373374 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7CO-01A-11R-A352-07 145507646 6231500 151739146 Yes 13 4487 720.051352 2 4426 710.262377 681.858301 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-ZJ-AAXB-01A-11R-A42T-07 61516995 1612059 63129054 Yes 3 1282 795.256253 2 1281 794.635928 678.635211 NC_001357 » Human papillomavirus - 18 
TCGA-MY-A5BF-01A-11R-A26T-07 124490541 5413223 129903764 Yes 9 4365 806.3588 3 4304 795.090097 674.090094 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1MP-01A-11R-A14Y-07 131469235 5966041 137435276 Yes 11 4597 770.527724 2 4444 744.882578 674.65175 
NC_001526 » Human papillomavirus 
type 16 
TCGA-JW-A5VG-01A-11R-A28H-07 141858852 5521838 147380690 Yes 13 3948 714.979323 3 3860 699.042602 673.869824 
X77858 » Human papilloma virus type 59 
complete viral genome 
TCGA-EA-A3HU-01A-11R-A213-07 197792377 7491877 205284254 Yes 13 6426 857.728979 3 6302 841.177718 668.323839 
NC_001526 » Human papillomavirus 
type 16 
TCGA-JW-A69B-01A-11R-A32P-07 178359672 6159869 184519541 Yes 10 4846 786.705041 3 4794 778.263304 667.871346 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A5O9-01A-11R-A28H-07 140000706 4285092 144285798 Yes 7 3346 780.846711 4 3343 780.14661 666.496775 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A0VM-01A-11R-A10U-07 200911285 9632137 210543422 Yes 15 7827 812.592261 3 7635 792.658991 659.147601 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UR-01A-11R-A42T-07 103100263 2786810 105887073 Yes 6 2106 755.702756 3 2091 750.320258 655.947122 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A902-01A-11R-A37O-07 140473634 8012075 148485709 Yes 13 6539 816.143133 3 6380 796.298088 650.268501 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2PI-01A-11R-A18M-07 189539351 5925127 195464478 Yes 11 4692 791.881761 2 4533 765.046893 642.855419 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A3HT-01A-61R-A21T-07 199406770 8506245 207913015 Yes 14 6831 803.05705 3 6654 782.248807 631.065764 
NC_001526 » Human papillomavirus 
type 16 
TCGA-FU-A3NI-01A-11R-A21T-07 216359088 7928957 224288045 Yes 11 6045 762.395358 3 5906 744.864678 629.843244 
NC_001526 » Human papillomavirus 
type 16 
TCGA-FU-A770-01A-11R-A33Z-07 110252004 8154653 118406657 Yes 13 8573 1051.301631 4 8493 1041.491282 621.117784 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A3GK-01A-11R-A213-07 189910737 8096855 198007592 Yes 10 5990 739.793413 3 5876 725.713873 613.571566 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DG-A2KH-01A-21R-A22U-07 203504157 7329666 210833823 Yes 13 10947 1493.519624 3 10852 1480.558596 613.806959 NC_001357 » Human papillomavirus - 18 
TCGA-IR-A3LI-01A-11R-A32Y-07 126451347 4588136 131039483 Yes 10 3064 667.809322 3 3024 659.091187 611.577338 
NC_001526 » Human papillomavirus 
type 16 
Genomic and transcriptomic analyses in cancers related with viral infection 
 
V 
 
TCGA-VS-A952-01A-11R-A38B-07 123681770 7268306 130950076 Yes 12 5194 714.609429 2 5063 696.585972 606.331104 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A8QA-01A-11R-A37O-07 127394786 5373674 132768460 Yes 14 3858 717.944555 3 3806 708.267751 600.706332 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DG-A2KK-01A-11R-A180-07 173549755 7375098 180924853 Yes 6 6109 828.327975 4 6045 819.650124 595.110736 
NC_001526 » Human papillomavirus 
type 16 
TCGA-ZJ-AB0I-01A-11R-A42T-07 103149568 3273050 106422618 Yes 8 2285 698.125601 2 2256 689.265364 592.108278 
NC_001526 » Human papillomavirus 
type 16 
TCGA-ZJ-AAXJ-01A-11R-A42T-07 103915425 3255116 107170541 Yes 8 2060 632.849951 2 2005 615.953471 591.683983 
NC_001526 » Human papillomavirus 
type 16 
TCGA-LP-A7HU-01A-11R-A33Z-07 130799586 9723303 140522889 Yes 13 6638 682.689823 4 6527 671.273949 591.671369 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UM-01A-11R-A42T-07 101668127 2309241 103977368 Yes 6 1437 622.282387 2 1428 618.385002 585.473755 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BI-A20A-01A-11R-A14Y-07 164775983 9189583 173965566 Yes 14 6410 697.528931 3 6244 679.464999 577.828178 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MA-AA42-01A-12R-A38B-07 111198721 4840178 116038899 Yes 7 3173 655.554404 2 3135 647.703452 572.499606 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A8XK-01A-11R-A37O-07 128487978 7941438 136429416 Yes 11 5587 703.52498 3 5464 688.0366 567.781301 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A2M1-01A-11R-A18M-07 257073020 9478631 266551651 Yes 15 6908 728.797227 3 6731 710.123646 561.578988 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A3LQ-01A-21R-A21T-07 199898973 6311125 206210098 Yes 8 5966 945.31482 2 5915 937.233853 558.379053 
NC_001583 » Human papillomavirus 
type 26 
TCGA-EA-A6QX-01A-12R-A33Z-07 128494146 7283625 135777771 Yes 16 6947 953.783317 4 6821 936.484238 551.785684 
D90400 » Human papillomavirus type 58 
complete genome 
TCGA-C5-A2LX-01A-11R-A18M-07 188562235 15620784 204183019 Yes 16 10024 641.709147 3 9663 618.598913 525.517797 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A905-01A-11R-A37O-07 145144616 7592161 152736777 Yes 11 4809 633.416495 2 4685 617.083858 516.980607 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A901-01A-11R-A37O-07 149847526 5850883 155698409 Yes 9 3686 629.990378 3 3641 622.299232 510.521232 
NC_001526 » Human papillomavirus 
type 16 
TCGA-IR-A3LL-01A-11R-A213-07 186899012 7669114 194568126 Yes 10 4507 587.681966 3 4446 579.727985 502.926414 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7X3-01A-11R-A352-07 117566394 8184756 125751150 Yes 10 6756 825.436946 5 6745 824.092985 501.419957 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-C5-A1MN-01A-11R-A14Y-07 140085948 9583208 149669156 Yes 11 5655 590.094673 3 5575 581.746739 499.10218 
NC_001526 » Human papillomavirus 
type 16 
TCGA-XS-A8TJ-01A-11R-A36F-07 147186898 5531608 152718506 Yes 10 3033 548.303495 2 2948 532.937258 493.708159 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A94Z-01A-11R-A38B-07 133732493 3192282 136924775 Yes 8 2444 765.596524 3 2423 759.018157 487.738865 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2R9-01A-11R-A18M-07 166223238 9197301 175420539 Yes 12 8386 911.789232 3 8222 893.957913 484.489961 
M12732 » Human papillomavirus type 33 
complete genome 
TCGA-C5-A1MI-01A-11R-A14Y-07 220557148 8700193 229257341 Yes 16 7604 874.0036 3 7290 837.912447 480.793932 NC_001357 » Human papillomavirus - 18 
TCGA-MA-AA3Z-01A-11R-A38B-07 104187538 3213917 107401455 Yes 9 1812 563.798008 2 1764 548.862961 475.743462 
NC_001526 » Human papillomavirus 
type 16 
TCGA-FU-A23K-01A-11R-A16R-07 182868672 8597004 191465676 Yes 17 5436 632.313306 4 5391 627.078923 474.816576 NC_001357 » Human papillomavirus - 18 
TCGA-FU-A3TQ-01A-11R-A22U-07 207605213 10152439 217757652 Yes 13 5820 573.261259 3 5701 561.539942 471.413815 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1BQ-01C-11R-A213-07 200148840 10987374 211136214 Yes 17 6097 554.909666 2 5973 543.623982 470.085027 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-MY-A5BD-01A-11R-A26T-07 120065637 4537862 124603499 Yes 9 2354 518.746492 3 2336 514.779867 466.959991 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UU-01A-11R-A42T-07 75284823 2171334 77456157 Yes 7 1146 527.786143 2 1127 519.035763 461.928013 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A1OD-01A-11R-A14Y-07 246343358 12105033 258448391 Yes 15 5961 492.439798 3 5863 484.343992 452.125988 
NC_001526 » Human papillomavirus 
type 16 
TCGA-JW-A5VK-01A-11R-A28H-07 141447515 4625224 146072739 Yes 8 3373 729.261977 3 3364 727.316126 446.032452 
AB027020 » Human papillomavirus type 
69 DNA complete genome 
TCGA-EK-A2H1-01A-11R-A180-07 147079197 4917541 151996738 Yes 8 2432 494.556121 2 2386 485.201852 445.344533 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9U6-01A-11R-A42T-07 157350502 3821938 161172440 Yes 11 2469 646.00734 4 2389 625.075551 439.305923 
M12732 » Human papillomavirus type 33 
complete genome 
Genomic and transcriptomic analyses in cancers related with viral infection 
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TCGA-VS-A8QM-01A-11R-A37O-07 139117902 9461304 148579206 Yes 12 4739 500.882333 3 4687 495.386259 430.278955 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A8XI-01A-11R-A37O-07 149193925 10720112 159914037 Yes 8 5387 502.513408 4 5365 500.46119 429.939538 
X74481 » Human papillomavirus type 52 
genomic DNA 
TCGA-IR-A3L7-01A-21R-A213-07 176435501 5919332 182354833 Yes 13 4215 712.073592 2 4108 693.997228 424.034334 NC_001357 » Human papillomavirus - 18 
TCGA-R2-A69V-01A-11R-A32P-07 100015722 3750580 103766302 Yes 10 3348 892.661934 5 3319 884.929797 421.801428 
M62849 » Human papillomavirus ORFs 
(HPV-39) 
TCGA-DS-A1OA-01A-11R-A14Y-07 158677679 11770495 170448174 Yes 12 8118 689.690617 4 8024 681.704549 419.268688 
D90400 » Human papillomavirus type 58 
complete genome 
TCGA-EA-A5ZF-01A-11R-A28H-07 128333241 3914623 132247864 Yes 5 2364 603.889569 2 2348 599.802331 411.022977 NC_001357 » Human papillomavirus - 18 
TCGA-FU-A3HY-01A-11R-A21T-07 183231438 6334289 189565727 Yes 7 4974 785.249931 3 4962 783.35548 408.096315 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-C5-A2LT-01A-11R-A18M-07 169736075 5970895 175706970 Yes 7 4535 759.517627 3 4489 751.813589 407.979038 
U21941 » Human papillomavirus type 70 
complete genome 
TCGA-Q1-A5R2-01A-11R-A28H-07 141525574 4993423 146518997 Yes 7 3227 646.250078 3 3165 633.833745 404.732385 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A3HE-01A-21R-A22U-07 173786860 8984740 182771600 Yes 21 4584 510.198403 2 4332 482.150847 401.569773 NC_001357 » Human papillomavirus - 18 
TCGA-EK-A2IP-01A-11R-A180-07 174581621 9326879 183908500 Yes 11 5150 552.167557 4 5053 541.767508 400.777152 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A3QE-01A-21R-A21T-07 225645335 12201886 237847221 Yes 10 5839 478.532583 2 5731 469.681491 398.299083 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MA-AA43-01A-11R-A42T-07 128954678 2779136 131733814 Yes 7 1287 463.093565 2 1272 457.696205 394.36717 NC_001357 » Human papillomavirus - 18 
TCGA-C5-A7CL-01A-11R-A32P-07 136972015 6500033 143472048 Yes 11 3361 517.074296 2 3295 506.920503 390.921092 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7XC-01A-11R-A38B-07 112880915 3502446 116383361 Yes 7 1513 431.983821 2 1499 427.986613 378.021531 
NC_001526 » Human papillomavirus 
type 16 
TCGA-LP-A4AU-01A-32R-A32Y-07 151113995 5936720 157050715 Yes 9 3687 621.050007 2 3659 616.333598 375.796736 NC_001357 » Human papillomavirus - 18 
TCGA-UC-A7PI-01A-11R-A42S-07 136347452 10296605 146644057 Yes 14 5787 562.02991 2 5744 557.853778 371.09319 NC_001357 » Human papillomavirus - 18 
TCGA-ZJ-AAX4-01A-11R-A42T-07 91180487 2390679 93571166 Yes 4 924 386.501073 2 921 385.2462 364.33164 
NC_001526 » Human papillomavirus 
type 16 
TCGA-PN-A8MA-01A-11R-A36F-07 123323113 5627038 128950151 Yes 6 2259 401.454547 2 2184 388.126044 360.758182 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1M7-01A-11R-A13Y-07 206481328 7196021 213677349 Yes 17 3461 480.960242 2 3326 462.199874 360.338026 NC_001357 » Human papillomavirus - 18 
TCGA-ZJ-AAXF-01A-31R-A42T-07 91244898 2611781 93856679 Yes 4 1035 396.28131 2 1033 395.51555 359.524784 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2RA-01A-11R-A18M-07 188202959 9195352 197398311 Yes 12 3823 415.753526 3 3697 402.05095 357.136954 
X74481 » Human papillomavirus type 52 
genomic DNA 
TCGA-C5-A1M5-01A-11R-A13Y-07 181362670 19774658 201137328 Yes 19 14113 713.691234 3 13662 690.884262 356.82033 
D90400 » Human papillomavirus type 58 
complete genome 
TCGA-VS-A8EI-01A-11R-A37O-07 126431967 11064593 137496560 Yes 10 4094 370.009091 2 4020 363.321091 352.74682 
NC_001526 » Human papillomavirus 
type 16 
TCGA-FU-A23L-01A-11R-A16R-07 218138631 9242271 227380902 Yes 11 6072 656.981387 2 6015 650.81407 342.664698 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-UC-A7PF-01A-11R-A352-07 118149410 8562019 126711429 Yes 11 3541 413.570677 2 3450 402.942343 338.705158 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A94Y-01A-11R-A38B-07 93585260 3396874 96982134 Yes 5 1365 401.840045 2 1335 393.008395 337.957781 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-VS-A958-01A-11R-A42T-07 95205558 2655211 97860769 Yes 6 1809 681.301787 3 1782 671.133103 334.06008 
M62849 » Human papillomavirus ORFs 
(HPV-39) 
TCGA-C5-A7UC-01A-11R-A352-07 130629762 5770563 136400325 Yes 11 2461 426.474852 2 2411 417.810186 325.444848 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-C5-A0TN-01A-21R-A14Y-07 118406550 8400390 126806940 Yes 9 3087 367.482936 2 2971 353.674055 320.818438 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MU-A8JM-01A-11R-A36F-07 147839793 5490279 153330072 Yes 5 3368 613.447877 2 3364 612.719317 314.555963 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-C5-A8YR-01A-12R-A37O-07 112474734 7039936 119514670 Yes 9 4077 579.124582 2 4052 575.573414 314.491495 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-C5-A1BL-01A-11R-A13Y-07 130738978 13498688 144237666 Yes 13 4608 341.366509 2 4536 336.032657 313.808275 
NC_001526 » Human papillomavirus 
type 16 
Genomic and transcriptomic analyses in cancers related with viral infection 
 
VII 
 
TCGA-EX-A3L1-01A-11R-A32Y-07 154269265 6001122 160270387 Yes 9 2721 453.415214 2 2685 447.416333 308.608957 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-DS-A7WH-01A-22R-A352-07 128826930 7559150 136386080 Yes 7 3393 448.859991 3 3378 446.875641 299.372284 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A8ZZ-01A-11R-A37O-07 152104547 4640856 156745403 Yes 7 1507 324.724575 2 1472 317.182864 298.6518 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1MQ-01A-11R-A14Y-07 128008947 9928543 137937490 Yes 8 4103 413.252983 3 4054 408.317716 294.403721 NC_001357 » Human papillomavirus - 18 
TCGA-Q1-A73S-01A-11R-A33Z-07 100147387 9649617 109797004 Yes 10 4063 421.05298 3 4023 416.907738 288.923384 NC_001357 » Human papillomavirus - 18 
TCGA-EA-A5ZD-01A-11R-A28H-07 126246100 4184548 130430648 Yes 11 1502 358.939603 3 1458 348.424728 288.681119 
D90400 » Human papillomavirus type 58 
complete genome 
TCGA-GH-A9DA-01A-21R-A37O-07 142835825 5284945 148120770 Yes 13 2123 401.707113 2 2072 392.05706 286.474126 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-FU-A3YQ-01A-11R-A22U-07 192293156 8858082 201151238 Yes 7 3666 413.859344 2 3617 408.327672 281.212118 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2RB-01A-11R-A18M-07 183938926 10810339 194749265 Yes 12 5389 498.504255 2 5202 481.206001 280.379736 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2GZ-01A-11R-A180-07 213815192 9209927 223025119 Yes 13 2695 292.619038 1 2569 278.93815 278.93815 
X74481 » Human papillomavirus type 52 
genomic DNA 
TCGA-LP-A4AV-01A-11R-A32Y-07 100684338 6377521 107061859 Yes 10 1891 296.510197 2 1838 288.199757 277.850908 
X74483 » Human papillomavirus type 56 
genomic DNA 
TCGA-FU-A3WB-01A-11R-A22U-07 195738966 7817589 203556555 Yes 7 3253 416.112947 2 3200 409.333363 275.14877 
NC_001526 » Human papillomavirus 
type 16 
TCGA-IR-A3LK-01A-12R-A213-07 167911447 10437538 178348985 Yes 10 4238 406.034448 2 4073 390.226124 273.819362 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-ZJ-AAXT-01A-11R-A42T-07 137800019 3531925 141331944 Yes 5 1091 308.896707 2 1062 300.685887 267.842607 NC_001357 » Human papillomavirus - 18 
TCGA-LP-A4AW-01A-11R-A24H-07 126893348 3522974 130416322 Yes 5 994 282.147981 2 990 281.012577 265.684618 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MU-A5YI-01A-11R-A32P-07 131405697 3894952 135300649 Yes 6 1129 289.862367 2 1123 288.32191 264.188108 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2RL-01A-11R-A18M-07 211682677 13387460 225070137 Yes 13 5139 383.866697 3 4987 372.512785 263.679593 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EX-A69M-01A-11R-A32P-07 131647198 7196629 138843827 Yes 7 2039 283.327097 2 1975 274.434044 262.345051 
X74481 » Human papillomavirus type 52 
genomic DNA 
TCGA-FU-A5XV-01A-11R-A28H-07 129798235 4411181 134209416 Yes 3 1306 296.065839 2 1305 295.839142 252.313383 NC_001357 » Human papillomavirus - 18 
TCGA-EK-A2RK-01A-11R-A18M-07 189028099 7777456 196805555 Yes 13 2305 296.369402 2 2180 280.29731 252.396156 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A3GM-01A-11R-A213-07 193731898 8395027 202126925 Yes 11 3537 421.320859 3 3519 419.176734 250.148094 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-EK-A2RJ-01A-11R-A18M-07 178181216 8111669 186292885 Yes 15 2144 264.310586 1 2033 250.626597 250.626597 
X77858 » Human papilloma virus type 59 
complete viral genome 
TCGA-HG-A2PA-01A-11R-A213-07 201003658 6878271 207881929 Yes 6 2055 298.766941 2 2008 291.93383 248.754374 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A8EH-01A-11R-A36F-07 152616659 7336929 159953588 Yes 9 2125 289.630717 2 2100 286.223296 245.334254 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2IR-01A-11R-A180-07 232294515 14179130 246473645 Yes 14 6004 423.439236 4 5891 415.469778 240.141673 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MU-A51Y-01A-11R-A26T-07 132992611 5101955 138094566 Yes 6 1586 310.86123 2 1578 309.293202 233.439926 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A8QC-01A-11R-A37O-07 146963815 6444844 153408659 Yes 7 1760 273.086516 2 1746 270.914237 232.899353 
NC_001526 » Human papillomavirus 
type 16 
TCGA-HM-A3JJ-01A-21R-A21T-07 195752623 6840736 202593359 Yes 10 1859 271.754383 2 1845 269.707821 232.577313 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A2LV-01A-11R-A18M-07 190662605 8378690 199041295 Yes 13 3046 363.541315 2 2970 354.470687 228.914067 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2R7-01A-11R-A18M-07 188760664 10214792 198975456 Yes 10 2976 291.3422 2 2931 286.936826 226.142637 NC_001357 » Human papillomavirus - 18 
TCGA-EK-A2RN-01A-12R-A213-07 172241768 12469940 184711708 Yes 10 3097 248.357249 3 3060 245.390114 218.445317 
NC_001526 » Human papillomavirus 
type 16 
TCGA-JW-A5VJ-01A-11R-A28H-07 156471940 5187985 161659925 Yes 8 1325 255.397808 2 1317 253.855784 215.690678 NC_001357 » Human papillomavirus - 18 
TCGA-EK-A2PK-01A-11R-A18M-07 148826873 14823054 163649927 Yes 11 4736 319.502309 2 4510 304.25579 213.856065 NC_001357 » Human papillomavirus - 18 
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TCGA-EK-A2RC-01A-11R-A18M-07 155398617 5833697 161232314 Yes 5 1442 247.18459 2 1402 240.327874 211.015416 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1BE-01B-11R-A13Y-07 192138983 6264610 198403593 Yes 8 1616 257.957001 2 1600 255.40297 207.993794 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1BI-01B-11R-A13Y-07 210804654 35274409 246079063 Yes 19 10791 305.915827 3 10329 292.818514 205.531438 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1BN-01B-11R-A14Y-07 155657974 13983396 169641370 Yes 14 4180 298.925953 2 3988 285.195384 204.814338 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-DS-A1OB-01A-11R-A14Y-07 189816694 9419457 199236151 Yes 9 1979 210.097035 1 1915 203.30259 203.30259 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-EK-A2PG-01A-11R-A18M-07 165959900 26843603 192803503 Yes 17 12300 458.209726 4 12062 449.343555 199.675133 
D90400 » Human papillomavirus type 58 
complete genome 
TCGA-C5-A1MH-01A-11R-A14Y-07 181002911 10135396 191138307 Yes 11 2546 251.198869 2 2507 247.350967 198.709552 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A7WI-01A-12R-A352-07 121348063 8872561 130220624 Yes 6 2207 248.744416 2 2178 245.475912 194.419627 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A0VN-01A-21R-A10U-07 206453363 28629328 235082691 Yes 14 7543 263.471079 2 6910 241.360887 192.250408 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A5ZE-01A-11R-A28H-07 124926194 4340803 129266997 Yes 5 846 194.894815 1 827 190.517745 190.517745 
X77858 » Human papilloma virus type 59 
complete viral genome 
TCGA-MY-A5BE-01A-21R-A26T-07 132342657 9685094 142027751 Yes 8 1997 206.193146 1 1834 189.36316 189.36316 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A2LY-01A-31R-A18M-07 115403904 8238399 123642303 Yes 6 2125 257.938467 2 2105 255.51081 189.235797 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9UH-01A-11R-A42T-07 108073460 4100497 112173957 Yes 5 860 209.730673 2 823 200.707377 187.294369 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-DR-A0ZL-01A-11R-A10U-07 162367597 24866508 187234105 Yes 14 5471 220.014808 3 5340 214.746678 185.711641 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7CM-01A-11R-A33Z-07 127053759 8437368 135491127 Yes 8 1811 214.640395 2 1786 211.677386 176.476835 NC_001357 » Human papillomavirus - 18 
TCGA-EA-A3Y4-01A-51R-A24H-07 196503717 6003638 202507355 Yes 9 1278 212.87093 2 1219 203.043555 173.394865 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-VS-A8EG-01A-11R-A36F-07 180384862 7805303 188190165 Yes 10 1897 243.039893 4 1890 242.143067 167.706494 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A3GJ-01A-21R-A213-07 175318540 11730585 187049125 Yes 12 2558 218.062439 2 2427 206.895052 162.055004 
D90400 » Human papillomavirus type 58 
complete genome 
TCGA-C5-A1M8-01A-21R-A13Y-07 221446458 7756963 229203421 Yes 8 1539 198.402389 3 1518 195.695145 157.020215 
NC_001526 » Human papillomavirus 
type 16 
TCGA-ZJ-AAXU-01A-11R-A42T-07 214779103 5671490 220450593 Yes 5 1016 179.141637 2 1007 177.554752 155.691009 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A7UE-01A-11R-A33Z-07 118300424 10138082 128438506 Yes 6 1778 175.378341 2 1745 172.123287 152.494328 
NC_001526 » Human papillomavirus 
type 16 
TCGA-IR-A3LH-01A-21R-A213-07 190835879 9585111 200420990 Yes 9 1987 207.300676 2 1967 205.214108 150.650316 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-EK-A2PL-01A-11R-A18M-07 106338339 6791432 113129771 Yes 8 1974 290.660349 3 1962 288.893417 150.189238 
M62849 » Human papillomavirus ORFs 
(HPV-39) 
TCGA-EK-A2RO-01A-11R-A18M-07 129357098 5760956 135118054 Yes 9 925 160.563628 1 858 148.933614 148.933614 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EX-A8YF-01A-11R-A37O-07 135341397 9864621 145206018 Yes 10 1857 188.248489 2 1809 183.382616 141.921317 NC_001357 » Human papillomavirus - 18 
TCGA-BI-A0VR-01A-11R-A10U-07 175984156 28930625 204914781 Yes 14 4737 163.736522 2 4452 153.885372 140.439413 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DG-A2KM-01A-11R-A180-07 210643129 9112359 219755488 Yes 8 1419 155.722573 2 1399 153.527752 134.76203 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BI-A0VS-01A-11R-A10U-07 221754124 30977248 252731372 Yes 21 4936 159.342759 2 4792 154.694181 134.29211 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1ME-01A-11R-A13Y-07 122154298 11703576 133857874 Yes 14 1891 161.574549 2 1822 155.678914 133.20715 NC_001357 » Human papillomavirus - 18 
TCGA-C5-A1BF-01B-11R-A13Y-07 177553931 7491679 185045610 Yes 6 1153 153.904085 3 1145 152.836234 127.341281 NC_001357 » Human papillomavirus - 18 
TCGA-RA-A741-01A-11R-A33Z-07 104903999 13724681 118628680 Yes 9 1995 145.358569 2 1963 143.027004 125.321674 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EK-A2RE-01A-11R-A18M-07 187611121 10821906 198433027 Yes 9 1502 138.792555 2 1489 137.591289 109.777335 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EX-A1H6-01B-11R-A22U-07 182628042 11790202 194418244 Yes 11 1322 112.127001 1 1211 102.712405 102.712405 
NC_001526 » Human papillomavirus 
type 16 
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TCGA-UC-A7PG-01A-11R-A42S-07 140198530 9063363 149261893 Yes 9 990 109.230976 2 948 104.596936 93.563504 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A3HR-01A-11R-A213-07 214074455 8346111 222420566 Yes 10 851 101.963657 1 775 92.85762 92.85762 
NC_001587 » Human papillomavirus 
type 34 
TCGA-UC-A7PD-01A-11R-A352-07 135115385 16236662 151352047 Yes 9 1691 104.147022 2 1657 102.052996 87.086866 
NC_001526 » Human papillomavirus 
type 16 
TCGA-IR-A3LC-01A-11R-A213-07 180551447 18192817 198744264 Yes 8 2917 160.338005 2 2873 157.919469 86.792496 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A0VL-01A-21R-A10U-07 165667301 19874272 185541573 Yes 11 3189 160.458706 2 3146 158.295106 86.795632 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1BK-01B-11R-A13Y-07 164923670 18616060 183539730 Yes 10 1948 104.640832 2 1900 102.062413 84.980388 
NC_001526 » Human papillomavirus 
type 16 
TCGA-UC-A7PG-06A-11R-A42S-07 150356407 14561775 164918182 Yes 7 1389 95.386723 2 1371 94.15061 83.918341 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A78R-01A-11R-A32P-07 112819875 7771944 120591819 Yes 9 636 81.832809 1 609 78.358774 78.358774 
X74481 » Human papillomavirus type 52 
genomic DNA 
TCGA-C5-A1M6-01A-11R-A13Y-07 119282731 18406755 137689486 Yes 13 1934 105.070123 2 1800 97.790186 77.199919 NC_001357 » Human papillomavirus - 18 
TCGA-FU-A3EO-01A-11R-A213-07 123736857 15949975 139686832 Yes 7 1269 79.561252 1 1227 76.92802 76.92802 
NC_001526 » Human papillomavirus 
type 16 
TCGA-EA-A50E-01A-21R-A26T-07 120493206 11757449 132250655 Yes 8 961 81.735415 1 829 70.508492 70.508492 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1MF-01A-11R-A13Y-07 154359388 17982449 172341837 Yes 13 1340 74.517103 1 1214 67.510271 67.510271 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-C5-A1BJ-01A-11R-A13Y-07 273528255 27074313 300602568 Yes 10 3028 111.840327 2 2999 110.7692 60.093861 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A1BM-01A-11R-A13Y-07 185889680 20159843 206049523 Yes 14 1619 80.308167 2 1419 70.387453 59.722687 NC_001357 » Human papillomavirus - 18 
TCGA-C5-A7X5-01A-11R-A36F-07 154346700 5258163 159604863 Yes 15 645 122.66641 3 557 105.930531 54.391619 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-JW-A5VI-01A-11R-A28H-07 138202281 4435004 142637285 Yes 7 334 75.309967 2 324 73.055177 53.663988 
NC_001593 » Human papillomavirus 
type 53 
TCGA-VS-A8Q8-01A-11R-A37O-07 113586085 8598163 122184248 Yes 5 449 52.220457 1 433 50.359594 50.359594 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DG-A2KJ-01A-11R-A32Y-07 72792235 5812677 78604912 Yes 6 347 59.697108 1 294 50.579105 50.579105 NC_001357 » Human papillomavirus - 18 
TCGA-VS-A950-01A-11R-A42T-07 109262513 3120238 112382751 Yes 13 396 126.913396 3 319 102.235791 49.996186 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-EA-A44S-01A-12R-A26T-07 138101110 13070336 151171446 Yes 8 718 54.933552 1 632 48.353768 48.353768 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DS-A1O9-01A-11R-A14Y-07 237218614 11660398 248879012 Yes 14 476 40.821932 1 432 37.048478 37.048478 
NC_001587 » Human papillomavirus 
type 34 
TCGA-C5-A7UI-01A-11R-A36F-07 101625249 31200653 132825902 Yes 14 1213 38.877393 1 1007 32.274966 32.274966 
M12732 » Human papillomavirus type 33 
complete genome 
TCGA-ZX-AA5X-01A-11R-A42T-07 74267128 3106134 77373262 Yes 9 224 72.11537 2 141 45.394049 28.009094 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-Q1-A5R3-01A-11R-A28H-07 201863457 16316652 218180109 Yes 7 747 45.78145 2 668 40.939771 23.53424 NC_001357 » Human papillomavirus - 18 
TCGA-JW-A852-01A-11R-A352-07 102227106 18576449 120803555 Yes 7 423 22.770768 1 400 21.532641 21.532641 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A9V0-01A-11R-A42T-07 52655226 1192819 53848045 Yes 3 44 36.887407 2 43 36.049057 20.958754 
M12732 » Human papillomavirus type 33 
complete genome 
TCGA-IR-A3LA-01A-11R-A22U-07 170083246 6283647 176366893 Yes 9 108 17.187469 1 96 15.277752 15.277752 
NC_001526 » Human papillomavirus 
type 16 
TCGA-VS-A8EK-01A-12R-A37O-07 138990889 6164069 145154958 Yes 9 192 31.148259 1 89 14.438515 14.438515 
J04353 » Human papillomavirus type 31 
(HPV-31) complete genome 
TCGA-FU-A3EO-11A-13R-A213-07 166691399 4740854 171432253 Yes 3 66 13.921541 1 64 13.499677 13.499677 
NC_001526 » Human papillomavirus 
type 16 
TCGA-C5-A8YT-01A-11R-A37O-07 138369094 5714932 144084026 Yes 3 84 14.698337 1 77 13.473476 13.473476 
X74479 » Human papillomavirus type 45 
genomic DNA 
TCGA-VS-A8QH-01A-11R-A37O-07 121332119 8833464 130165583 Yes 5 98 11.094176 1 90 10.188529 10.188529 
NC_001526 » Human papillomavirus 
type 16 
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Table 2. List of genes involved in significant pathways related to immune response and viral integration in CESC samples obtained through GSEA. 
CESC 
GO_BP Pathways Genes 
Cellular defence re-
sponse 
FOSL1, FAIM3, IL1RL2, NCF2, HLA-G, GNLY, LYST, C5AR1, ADORA2B, MICB, KLRC2, CCL5, CLEC5A, 
GAGE8, TCIRG1, KLRC3, KLRC4, PRF1, LBP, CD5L, CD160, TRAT1, KIR2DL4, MNDA, CD19, NCR1, TYROBP, 
CCR6, ITK, GAGE1, LSP1, CCR5, LGALS3BP, BECN1, KIR3DL2, CXCL9, CX3CR1, CD300C, MICA, KLRG1, 
UMOD, LILRB2, ADORA2A, VEZF1, ZNF148, NCF1, LY96, SPN, NCR2, CCR3, CCR2, CXCR2, IL4, CCR9, ITGB1, 
PAGE1, DCDC2 
Defence response 
FOSL1, CCR7, HCP5, CCL22, ALOX5AP, NFKB1, NMI, HLA-B, FAIM3, GPR68, BCL10, MX1, TPSAB1, PYDC1, 
LTB4R, ANXA1, IL10RB, F11R, LY75, FOXN1, IL12B, IL1RL2, SELE, NCF2, HLA-G, HRH1, GNLY, S100A9, 
IL1RAP, FOS, IL1A, RNASE6, IRAK2, APOBEC3G, IL32, LYST, BLNK, PTAFR, MX2, IFNK, IL20, C5AR1, 
CHRNA7, ADORA2B, CXCL11, TLR3, MICB, RSAD2, KLRC2, CCL13, CXCL1, CCL5, CD40, CXCL10, PSG8, 
PTPRCAP, IL18RAP, APOBEC3F, CLEC5A, MST1R, GAGE8, NLRP3, CCR4, S100A12, CCL26, AIF1, NOS2, IL13, 
NFX1, CXCL6, CD97, INHBA, CX3CL1, IL29, RAC1, TCIRG1, CD48, WFDC12, SFTPD, KLRC3, KLRC4, CRTAM, 
PSG3, CFHR1, APOL3, PRF1, LBP, ALOX15, CD5L, CD160, LILRA2, CEBPB, KCNN4, TRAT1, CCL23, CCL21, 
TNIP1, KIR2DL4, MNDA, S100A7, SP140, BNIP3L, CD19, NCR1, CYSLTR1, NFATC3, TYROBP, CEBPG, 
TNFRSF1A, PTPRC, TPST1, ANKRD1, MEFV, ADORA3, CCR6, ITK, IL12A, GAGE1, C5, LSP1, CCR5, CCL11, 
PARP4, HDAC5, CCL4, CD40LG, LILRA3, CCL3, LGALS3BP, GATA3, ELF3, WAS, CLEC1A, C3AR1, CD1D, 
BECN1, IL8, NFE2L1, NOD2, PGLYRP2, CAMP, KIR3DL2, CXCL9, S100A8, NLRC4, CX3CR1, STAB1, CD300C, 
TGFB1, MICA, VPS45, PRDX5, TLR7, AIMP1, KLRG1, CFP, UMOD, LYZ, LILRB2, CXCL2, PGLYRP3, 
ADORA2A, MBL2, FPR2, IL5, CCL3L3, CYBB, VEZF1, MGLL, ADORA1, CCL20, CCR1, IL9, PLA2G2E, IFNA2, 
DEFB127, DEFB118, LILRB3, AFAP1L2, ZNF148, NCF1, IL28RA, AZU1, GHRL, OR2H2, LALBA, CD84, LY96, 
BCL2, AOX1, SPN, AOAH, NCR2, CD83, DEFB1, TLR6, TNFAIP6, LILRA1, CCR3, CCR2, CYP4F11, TLR8, SOCS6, 
C2, NOD1, AHSG, CXCR2, IL4, NOX4, LILRB5, HP, CCR9, MLF2, MPO, XCR1, GHSR, PLA2G2D, IL17RB, 
HDAC7, PTX3, CLEC1B, ABCF1, P2RY11, STAB2, PLA2G7, CXCR4, EREG, SPACA3, PGLYRP4, KRT1, RELA, 
ORM1, DMBT1, CSF3R, SIGIRR, NFRKB, ITGB1, CCL24, PAGE1, TFF3, IL17C, PGLYRP1, COLEC12, TIAL1, 
APCS, TARBP2, CDO1, BNIP3, TACR1, APOA4, NFATC4, HDAC9, INHBB, CRP, S1PR3, CAMLG, AGER, KNG1, 
ORM2, RIPK2, AOC3, CHST2, DCDC2, CD81, SCG2, HDAC4, CADM1 
Immune response 
MR1, IL4R, MS4A2, CCL22, GPR183, IFI6, BCL10, PYDC1, LTB4R, CCR8, IL10RB, MS4A1, LY75, TRAF2, IL12B, 
BST2, TNFAIP1, IL7R, S1PR4, APOBEC3G, IL32, CNR2, BLNK, IK, PTAFR, CTLA4, TRIM22, IL15, IFNK, C5AR1, 
RSAD2, IKBKG, MBP, LAT2, CCL5, CIITA, CCRL1, RGS1, APOBEC3F, CD7, IL16, CCR4, FOXP3, SPINK5, 
TREM1, GZMA, TNFRSF14, SLA2, CCL2, DEFB4A, TREM2, CCL26, PAX5, NFIL3, CD96, PSMB10, CD86, CD97, 
CRHR1, CX3CL1, IL29, GBP2, SFTPD, LAT, CRTAM, CFHR1, CST7, IL6, FYB, CTSW, NCF4, DPP8, CD28, CE-
BPB, TRAT1, CCL23, SEMA7A, CCL21, IL6R, BNIP3L, NCR1, GPR65, CEBPG, PTPRC, SKAP1, TAPBP, TNFRSF4, 
IFITM3, CCR6, KIR2DL1, IL12A, FCGR2B, AIM2, GTPBP1, IKBKAP, IL6ST, CCR5, ARHGDIB, LY86, KIR2DL3, 
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CCL4, VIPR1, CD40LG, IL2RA, EBI3, IRF8, CTSG, IL18BP, CD74, WAS, ZAP70, CD22, FCGR3B, CD1D, LCP2, 
IL10, POU2AF1, IL7, PTGER4, FCN1, ST6GAL1, CD274, CD79B, APLN, POU2F2, IL18, CD79A, FCGR3A, 
ANXA11, TGFB1, BCAR1, ETS1, IL2RG, GPI, TLR7, SECTM1, CD164, HAMP, LILRB2, CCBP2, MBL2, CCL27, 
HRH2, SP2, CTSS, IL27, IL2, FCGR1A, CXCL13, CCL19, CCL20, CCR1, DEFB127, DEFB118, FCN2, PRELID1, 
TRAF6, CCL18, IL28RA, IGSF6, CHST4, DPP4, CTSC, BST1, BCL2, IFITM2, CD83, FTH1, DEFB1, IL1R2, LAX1, 
TGFB2, MADCAM1, LTF, IL17B, UBE2N, CCR2, TLR8, C2, IL4, AQP9, NFAM1, CEACAM8, IL27RA, ZEB1, 
MALT1, FCGRT, MNX1, CXCL12, GEM, CCR9, OPRD1, FCAR, PDCD1, CMKLR1, CXCR4, XBP1, EREG, RFX1, 
IL17A, MAP3K7, CNIH, SEMA4D, KRT1, DMBT1, CCL25, CCL24, GPR44, ODZ1, COLEC12, VTN, APOA2, 
SEMA3C, TARBP2, RAG1, CHUK, TCF12, BNIP3, APOA4, SOCS5, APOA1, THY1, TCF7, C1QBP, OPRK1, 
YTHDF2, TNFSF13, FYN, MAP4K2, PRKRA, ATP6V0A2, CADM1 
Response to virus 
FOSL1, POLA1, CCL22, ISG20, BCL3, IFNGR1, APOBEC3G, IFI44, TRIM22, IFNK, IRF7, RSAD2, CCL5, APO-
BEC3F, TNF, IL29, CCL8, BNIP3L, PTPRC, CCL11, CCL4, FGR, IFNAR2, HNRNPUL1, IFNA4, IFNAR1, TLR7, 
BANF1, IFNGR2, CREBZF, HBXIP, CCL19, IFNA17, IFNA7, IL28RA, LILRB1, BCL2, DUOX2, IVNS1ABP, IFNW1, 
TLR8, CCDC130, CXCL12, CXCR4, SPACA3, ABCE1, TARBP2, BNIP3, C19orf2, PRKRA 
Inflammatory re-
sponse 
CCR7, CCL22, ALOX5AP, NFKB1, NMI, GPR68, LTB4R, ANXA1, IL10RB, F11R, LY75, SELE, HRH1, S100A9, 
IL1RAP, FOS, IL1A, IRAK2, BLNK, PTAFR, IL20, CHRNA7, CXCL11, CCL13, CXCL1, CCL5, CD40, CXCL10, 
IL18RAP, NLRP3, CCR4, S100A12, CCL26, AIF1, IL13, NFX1, CXCL6, CD97, CX3CL1, RAC1, CFHR1, APOL3, 
LBP, ALOX15, CEBPB, CCL23, CCL21, NFATC3, TNFRSF1A, TPST1, MEFV, ADORA3, C5, CCR5, CCL11, 
PARP4, HDAC5, CCL4, CD40LG, CCL3, ELF3, C3AR1, IL8, NFE2L1, CXCL9, S100A8, TGFB1, VPS45, PRDX5, 
AIMP1, KLRG1, LYZ, CXCL2, ADORA2A, MBL2, FPR2, IL5, CCL3L3, CYBB, MGLL, ADORA1, CCL20, CCR1, 
IL9, PLA2G2E, IFNA2, AFAP1L2, GHRL, AOX1, AOAH, TNFAIP6, CCR3, CCR2, CYP4F11, C2, NOD1, AHSG, 
CXCR2, NOX4, XCR1, GHSR, PLA2G2D, HDAC7, PTX3, ABCF1, PLA2G7, CXCR4, KRT1, RELA, ORM1, SIGIRR, 
NFRKB, CCL24, IL17C, APCS, CDO1, TACR1, NFATC4, HDAC9, CRP, S1PR3, AGER, KNG1, ORM2, RIPK2, 
AOC3, CHST2, SCG2, HDAC4 
Immune system 
process 
MR1, IL4R, MS4A2, CCL22, CD47, CKLF, GPR183, LIG1, IFI6, BCL10, SAA1, PYDC1, LTB4R, CCR8, IL10RB, 
MS4A1, LY75, TRAF2, IL12B, ELF4, CDC42, BST2, ERAP2, TNFAIP1, IL7R, S1PR4, CTSE, APOBEC3G, IL32, 
CNR2, BLNK, IK, CD3D, PTAFR, CTLA4, TRIM22, IFI16, IL15, IFNK, C5AR1, RSAD2, IKBKG, MBP, LAT2, CCL5, 
CIITA, CCRL1, CD3E, MAFB, RGS1, APOBEC3F, CD7, IL16, CCR4, FOXP3, CLEC7A, SPINK5, TREM1, GZMA, 
TNFRSF14, SLA2, NOTCH2, CCL2, DEFB4A, TREM2, CCL26, CD2, PAX5, NFIL3, CD96, PSMB10, CD86, CD97, 
CRHR1, INHBA, JAG2, CX3CL1, IL29, GBP2, SFTPD, LRMP, LAT, CRTAM, LST1, CFHR1, CST7, IL6, FYB, 
CTSW, NCF4, DPP8, CD28, CEBPB, TRAT1, CCL23, SEMA7A, CCL21, IL6R, HELLS, NCK1, BNIP3L, NCR1, 
GPR65, CEBPG, LCK, SIRPG, PTPRC, NLRC3, SKAP1, TAPBP, TNFRSF4, IFITM3, MMP9, TAZ, CCR6, KIR2DL1, 
IL12A, LYN, FCGR2B, AIM2, GTPBP1, IKBKAP, IL6ST, CCR5, ARHGDIB, LY86, KIR2DL3, ITGB2, HDAC5, 
CCL4, VIPR1, CD40LG, IL2RA, EBI3, IRF8, CTSG, IL18BP, HCLS1, RPS19, CD74, WAS, ZAP70, CD22, FCGR3B, 
CD1D, LCP2, SOD1, IL10, POU2AF1, IL7, IL8, PTGER4, FCN1, ST6GAL1, TBX1, CD274, CD79B, APLN, POU2F2, 
MAP4K1, IL18, CD79A, FCGR3A, ANXA11, DOCK2, CSF1, TGFB1, BCAR1, ETS1, MLF1, IL2RG, GPI, SPI1, 
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RASGRP4, DYRK3, TLR7, MAL, AIMP1, RUNX1, SECTM1, CD164, IL31RA, HAMP, LILRB2, CCBP2, MBL2, 
CCL27, HRH2, SP2, SCIN, CTSS, NCOA6, IL27, IL2, FCGR1A, CD4, CXCL13, MYH9, CCL19, CCL20, CCR1, PRG3, 
DEFB127, DEFB118, FCN2, PRELID1, FOXO3, TRAF6, CCL18, TM7SF4, SART1, IL28RA, AZU1, IGSF6, CHST4, 
DPP4, CTSC, BST1, MLL, BCL2, ICOSLG, CD276, ZBTB16, IFITM2, CD83, FTH1, SIT1, DEFB1, IL1R2, LAX1, 
TGFB2, MADCAM1, LTF, GLMN, IL17B, UBE2N, CCR2, TLR8, C2, CXCR2, IL4, AQP9, NFAM1, CEACAM8, 
IL27RA, ZEB1, MALT1, FCGRT, CD34, SNRK, MNX1, IL21, CXCL12, GEM, CCR9, ACVR1B, OPRD1, FCAR, 
TPD52, PDCD1, CD24, HDAC7, PREX1, INHA, CMKLR1, CXCR4, SYK, XBP1, EREG, RFX1, IL17A, RAB3D, 
SPACA3, ACVR2A, MAP3K7, ALAS2, CNIH, SEMA4D, KRT1, DMBT1, CCL25, NOTCH4, CCL24, NCK2, GPR44, 
PF4, PRL, ODZ1, ZNF675, COLEC12, VTN, APOA2, ACIN1, INS, SEMA3C, TARBP2, RAG1, CHUK, TCF12, AKT1, 
CARTPT, BNIP3, APOA4, HDAC9, NHEJ1, SOCS5, APOA1, LDB1, THY1, TCF7, C1QBP, CDK6, LIG3, OPRK1, 
YTHDF2, TNFSF13, KIRREL3, CALCA, FYN, TLR4, MAP4K2, PRKRA, MIA3, SCG2, HDAC4, ATP6V0A2, 
CADM1 
Endosome transport 
ADRB2, EEA1, RAB14, VPS4B, TINAGL1, LYST, MON2, DOPEY2, RAB35, ABCA1, M6PR, STX5, TOM1, 
DOPEY1, ANKRD27, VTI1A, ZFYVE16, SQSTM1, GOSR1, YKT6, RHOB, STX16, BET1L 
JAK-STAT cascade 
STAT4, NMI, SOCS3, STAT5A, STAT3, STAT1, IL20, IL22RA2, SOCS2, FGFR3, CCL2, STAT2, IL29, PIGU, PIAS1, 
SOCS1, IL12A, LYN, HCLS1, STAMBP, IFNAR2, IFNAR1, IL31RA, CCR2, SOCS6, CLCF1, STAT5B, F2R, HGS, 
F2, NF2 
Response to other 
organism 
FOSL1, POLA1, CCL22, ISG20, BCL10, BCL3, IFNGR1, APOBEC3G, IFI44, TRIM22, IFNK, IRF7, TLR3, RSAD2, 
SLC11A1, CCL5, APOBEC3F, S100A12, TNF, NOS2, IL29, WFDC12, CCL8, S100A7, BNIP3L, PTPRC, CHIT1, 
IL12A, CCL11, CCL4, FGR, IFNAR2, CD1D, IL10, NOD2, PGLYRP2, HNRNPUL1, CAMP, NLRC4, STAB1, IFNA4, 
IFNAR1, TLR7, CFP, PGLYRP3, BANF1, IFNGR2, CREBZF, HBXIP, CCL19, IFNA17, IFNA7, DEFB127, DEFB118, 
IL28RA, AZU1, LALBA, LILRB1, BCL2, SPN, DUOX2, TLR6, IVNS1ABP, IFNW1, TLR8, NOD1, CCDC130, 
CXCL12, CD24, STAB2, CXCR4, SPACA3, PGLYRP4, ABCE1, DMBT1, ITLN1, PGLYRP1, TARBP2, CHIA, 
BNIP3, C19orf2, PRKRA 
T-cell activation 
CD47, IL12B, ELF4, CD3D, CD3E, CD7, FOXP3, CLEC7A, SPINK5, SLA2, CD2, JAG2, SFTPD, LAT, CRTAM, 
CD28, NCK1, LCK, SIRPG, PTPRC, NLRC3, EBI3, ZAP70, CD1D, IL7, IL18, IL27, IL2, CD4, SART1, ICOSLG, 
CD276, SIT1, LAX1, GLMN, IL4, IL21, CD24, NCK2, INS, NHEJ1, SOCS5, THY1, CADM1 
keratinocyte differ-
entiation 
TGM1, ANXA1, IVL, IL20, DSP, CSTA, SPRR1B, SPRR1A, TXNIP, SCEL, EVPL, LOR, TGM3, NME2, EREG 
GO MF_Pathways Genes 
Interleukin receptor 
activity 
IL4R, IL12RB2, IL15RA, IL10RB, IL7R, IL22RA2, IL9R, IL2RB, IL6R, IL12RB1, IL6ST, IL10RA, IL2RA, IL1R1, 
IL3RA, IL2RG, CSF2RB, IL5RA, CXCR2, IL13RA2 
Interleukin binding 
IL4R, IL12RB2, IL15RA, IL10RB, IL7R, IL22RA2, IL9R, IL2RB, IL6R, IL12RB1, IL12A, IL6ST, IL10RA, IL2RA, 
EBI3, IL18BP, IL1R1, IL3RA, IL2RG, CSF2RB, HAX1, IL5RA, CXCR2, A2M, IL13RA2 
Cytokine binding 
IL4R, PLP2, IL12RB2, IL15RA, IL10RB, IL7R, IFNGR1, IL22RA2, IL9R, TNFRSF14, TNFRSF25, ELANE, IL2RB, 
IL22RA1, IL6R, IL12RB1, TNFRSF1A, TNFRSF18, TNFRSF4, IL12A, IL6ST, IL10RA, IL2RA, EBI3, IL18BP, IL1R1, 
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TNFRSF1B, CD74, IL3RA, IFNAR2, IL2RG, IFNAR1, CSF2RB, ACVR1, IFNGR2, HAX1, IL17F, IL5RA, CXCR2, 
ACVRL1, TGFBR1, GPR17, XCR1, CNTFR, CMKLR1, A2M, CRLF1, IL13RA2 
Hematopoietin in-
terferon classd200 
domain cytokine re-
ceptor activity 
IL4R, OSMR, IL12RB2, IL15RA, IL10RB, IL7R, IFNGR1, IL22RA2, IL9R, IL2RB, IL22RA1, IL6R, IL12RB1, IL6ST, 
IL10RA, IL2RA, IL1R1, IL3RA, IFNAR2, IL2RG, IFNAR1, CSF2RB, IL31RA, IFNGR2, GHR, IL5RA, CXCR2, 
CNTFR, GFRA1, GFRA2, LIFR, IL13RA2, EPOR 
Cytokine activity 
TYMP, CCL22, CKLF, OSM, IL12B, CXCL16, SIVA1, ERAP1, IFNK, IL20, CCL17, CXCL11, IL1RN, CCL13, 
CXCL1, CCL5, CXCL10, MUC4, CCL2, CCL26, TNF, CXCL6, INHBA, CX3CL1, IL29, CSF2, CCL8, PIK3R1, 
CCL23, CCL21, IFNA13, CSF3, GDF15, IL12A, CXCL3, C5, CCL11, CCL4, CD40LG, CCL3, IFNA14, TRIP6, IL7, 
IL8, CXCL9, GH1, CSF1, IFNA4, CCL16, CCL15, IL25, AIMP1, SECTM1, YARS, CTF1, CXCL2, CCL28, IFNA8, 
CCL27, IFNG, XCL2, IL19, IL5, CXCL14, IL27, IL2, BRE, CXCL13, CCL19, IFNA5, CCL20, IFNA16, IFNA17, 
IFNA7, IFNA2, ERBB2IP, CCL18, MIF, CNTF, CCL7, TGFB2, IFNA21, IL3, CCL1, IL17F, GLMN, IL17B, IL4, 
ERBB2, IL21, CXCL12, FGF10, FIGF, INHA, NAMPT, IL17A, CCL25, CXCL5, CCL24, PF4, PRL, IL17C, VEGFA, 
SPRED1, SPRED2, CDK5, INHBB, TNFRSF11B, XCL1, BMP4, SDCBP, SCG2 
Chemokine activity 
CCL22, CKLF, CXCL16, CCL17, CXCL11, CCL13, CXCL1, CCL5, CXCL10, CCL2, CCL26, CXCL6, CX3CL1, 
CCL8, CCL23, CCL21, CXCL3, C5, CCL11, CCL4, CCL3, IL8, CXCL9, CCL16, CCL15, CXCL2, CCL28, CCL27, 
XCL2, CXCL14, CXCL13, CCL19, CCL20, CCL18, CCL7, CCL1, CXCL12, CCL25, CXCL5, CCL24, PF4, XCL1 
Chemokine receptor 
binding 
CCL22, CKLF, CXCL16, CCL17, CXCL11, CCL13, CXCL1, CCL5, CXCL10, CCL2, CCL26, CXCL6, CX3CL1, 
CCL8, CCL23, CCL21, CXCL3, C5, CCL11, CCL4, CCL3, IL8, CXCL9, CCL16, CCL15, CXCL2, CCL28, CCL27, 
XCL2, CXCL14, CXCL13, CCL19, CCL20, CCL18, CCL7, CCL1, CCR2, CXCL12, CCL25, CXCL5, CCL24, PF4, 
XCL1 
Kegg Pathways Genes 
DNA replication 
PRIM1, POLE2, POLA1, PCNA, POLD3, MCM5, LIG1, RFC4, RFC5, MCM6, RPA3, POLA2, POLE4, RPA2, POLD4, 
FEN1, MCM4, POLE3, MCM2, POLD1, RFC2, RPA1, RFC1, RNASEH2B, MCM7, PRIM2, POLE, MCM3, DNA2, 
POLD2, RFC3, RNASEH2A, RNASEH2C, SSBP1, RNASEH1, RPA4 
Mismatch repair 
PCNA, POLD3, LIG1, RFC4, MSH6, RFC5, RPA3, RPA2, POLD4, POLD1, RFC2, EXO1, MSH3, RPA1, RFC1, MLH3, 
POLD2, MLH1, MSH2, RFC3, SSBP1, RPA4, PMS2 
Cytosolic DNA 
sensing pathway 
PYCARD, NFKB1, TMEM173, POLR3GL, NFKBIA, RIPK1, TBK1, NFKBIB, DDX58, IRF7, IKBKG, CCL5, 
CXCL10, IRF3, TREX1, ADAR, IL6, IL1B, POLR3D, ZBP1, POLR3K, IFNA13, CASP1, IFNB1, AIM2, CCL4, RIPK3, 
IFNA14, IFNA1, IL18, IL33, IFNA4, POLR1D, IFNA8, IFNA5, IKBKE, POLR3F, IFNA16, IFNA17, IFNA10, IFNA7, 
IFNA6, IFNA2, POLR3C, CCL4L2, POLR3B, POLR3G, IKBKB, IFNA21, RELA, CHUK, POLR3H, POLR1C, 
POLR3A, MAVS 
Cytokine receptor 
interaction 
CCR7, IL4R, FLT3LG, OSMR, TNFRSF11A, CCL22, IL18R1, CXCR5, IL12RB2, IL15RA, IL24, CCR8, IL10RB, 
OSM, CRLF2, IL12B, NGFR, CXCL16, EGFR, IL1RAP, TNFRSF6B, TNFRSF13B, CSF2RA, IL7R, RELT, IL1A, 
TNFSF10, IFNGR1, IL11, TNFRSF12A, IL15, IFNK, IL20, CCL17, CXCL11, IL22RA2, LTB, TNFRSF10A, CCL13, 
CD70, CXCL1, CCL5, CD40, IFNE, CXCL10, IL9R, IL18RAP, CCR4, CXCR6, TNFRSF14, IL28A, CCL2, CCL26, 
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TNF, IL13, TNFRSF25, CXCL6, INHBA, FLT3, CX3CL1, IL29, CSF2, LTA, CD27, IL2RB, TNFRSF9, IL6, IL13RA1, 
IL1B, CCL8, IL22RA1, IL23R, CCL23, CCL21, IL6R, IFNA13, IL28B, IL12RB1, TNFSF9, CCR10, FAS, MET, CSF3, 
TNFRSF1A, IL20RB, PDGFA, TNFRSF18, TNFRSF4, CCR6, IL12A, IFNB1, CXCL3, TNFRSF10B, TSLP, IL6ST, 
CCR5, CCL11, CCL14, CCL4, IL10RA, CD40LG, IL2RA, CCL3, IL1R1, GH2, TNFRSF1B, CCL3L1, IL3RA, IFNAR2, 
TNFSF13B, IFNA14, IL10, IL7, IL8, VEGFC, AMH, IFNA1, CXCL9, IL18, FASLG, CX3CR1, GH1, CSF1, TGFB1, 
IL2RG, IFNA4, CCL16, CCL15, IL25, IFNAR1, CSF1R, TNFRSF17, CSF2RB, TNFRSF8, CTF1, CXCL2, ACVR1, 
BMP7, TNFSF8, EGF, CCL28, IFNA8, IFNGR2, CCL27, LEP, IFNG, CXCR3, XCL2, IL19, IL5, IL21R, CCL3L3, 
CXCL14, IL2, IL17RA, TNFSF14, TNFSF12, CXCL13, CCL19, IFNA5, CCL20, CCR1, IL9, IFNA16, IFNA17, 
IFNA10, IFNA7, IFNA6, IFNA2, LTBR, CCL4L2, KITLG, CCL18, PLEKHO2, IL28RA, PDGFB, TNFSF4, CNTF, 
TPO, TNFSF18, IL11RA, TNFRSF10C, TGFBR2, TNFRSF21, IL1R2, HGF, CCL7, TGFB2, IFNA21, IL3, CCL1, 
TNFSF15, EDAR, IL17B, GHR, CCR3, CCR2, IL20RA, FLT4, IFNW1, IL5RA, CXCR2, IL4, CLCF1, ACVRL1, FLT1, 
TGFBR1, CXCR1, IL21, KDR, CXCL12, CCR9, ACVR1B, BMPR2, TGFB3, EPO, INHBC, PPBP, XCR1, CNTFR, 
TNFRSF13C, IL17RB, MPL, PDGFRA, TNFRSF10D, IL22, AMHR2, FIGF, LEPR, CXCR4, GDF5, IL17A, ACVR2A, 
PRLR, PDGFRB, CCL25, CSF3R, KIT, CXCL5, BMPR1B, CCL24, VEGFB, INHBE, PF4, PRL, PF4V1, VEGFA, 
IL23A, TNFSF11, LIF, LIFR, IL26, INHBB, TNFRSF11B, BMP2, PDGFC, XCL1, TNFSF13, EPOR, EDA2R, EDA, 
TNFRSF19, BMPR1A, ACVR2B 
Proteasome 
PSMB9, PSMD7, PSMB2, PSMA6, PSMB8, PSMA5, PSMA7, PSME1, PSMD2, PSMA2, PSMD8, PSME2, PSMB7, 
PSMA4, PSMC1, PSMB10, PSMC4, PSMB1, PSMD11, PSMC5, PSMB6, PSMB3, PSME4, POMP, PSMA3, PSMB4, 
SHFM1, PSMD4, PSMC3, PSMC2, PSMC6, PSMA8, IFNG, PSMD14, PSMA1, PSME3, PSMF1, PSMD13, PSMD3, 
PSMB5, PSMB11, PSMD12, PSMD6, PSMD1 
Natural killer cell 
mediated cytotoxi-
city 
HLA-C, HLA-A, ULBP2, NFATC1, HLA-B, HLA-E, PTK2B, HLA-G, KIR2DS4, CD247, KLRC1, TNFSF10, IFNGR1, 
ICAM1, PPP3CC, SH2D1B, NCR3, MICB, KLRC2, TNFRSF10A, PTPN6, SOS2, RAET1E, PIK3CA, CHP2, TNF, 
HCST, RAC1, CSF2, RAC2, CD48, RAET1L, KLRC3, LAT, ULBP1, PRF1, PIK3R1, KLRD1, KLRK1, IFNA13, 
KIR2DL4, SH2D1A, NCR1, FAS, NFATC3, TYROBP, LCK, PIK3CD, KIR2DL1, KIR3DL1, MAPK3, IFNB1, 
FCER1G, TNFRSF10B, VAV2, KIR2DL3, ITGB2, SH3BP2, PIK3CB, ZAP70, FCGR3B, ITGAL, IFNAR2, LCP2, 
IFNA14, ARAF, PPP3R1, CD244, ICAM2, CASP3, SHC3, KIR3DL2, IFNA1, FASLG, FCGR3A, VAV3, IFNA4, 
MICA, HRAS, IFNAR1, MAP2K1, SOS1, PIK3CG, CHP, IFNA8, NFATC2, IFNGR2, RAET1G, IFNG, PRKCB, 
NFAT5, IFNA5, IFNA16, IFNA17, IFNA10, IFNA7, IFNA6, IFNA2, GZMB, PIK3R5, PPP3R2, SHC1, BID, VAV1, 
TNFRSF10C, NCR2, SHC2, SHC4, IFNA21, GRB2, PRKCA, KRAS, MAP2K2, ULBP3, MAPK1, NRAS, 
TNFRSF10D, SYK, PLCG2, BRAF, PPP3CA, PIK3R3, PIK3R2, PTPN11, PAK1, RAF1, PLCG1, NFATC4, PRKCG, 
FYN, RAC3, PPP3CB 
Primary immunode-
ficiency 
TAP1, TAP2, ICOS, ADA, TNFRSF13B, IL7R, UNG, BLNK, CD3D, AICDA, IKBKG, CD40, CIITA, CD3E, 
DCLRE1C, CD19, LCK, PTPRC, IGLL1, JAK3, CD40LG, RFXANK, ZAP70, CD79A, IL2RG, BTK, RFXAP, CD4, 
RAG2, CD8A, RFX5, TNFRSF13C, AIRE, RAG1, CD8B 
Antigen processing 
and preservation 
B2M, HLA-C, HLA-A, HLA-B, HLA-E, TAP1, TAP2, HLA-F, HLA-G, KIR2DS4, KLRC1, CTSB, PSME1, KLRC2, 
CIITA, PSME2, IFI30, LTA, KLRC3, KLRC4, HSPA2, KIR3DL3, HLA-DRB1, KLRD1, HLA-DQB1, IFNA13, 
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KIR2DL4, HSPA6, HLA-DPB1, TAPBP, CTSL1, KIR2DL1, KIR3DL1, HLA-DRA, KIR2DL3, HLA-DRB5, HLA-
DQA2, CD74, RFXANK, HLA-DMA, HSPA1A, IFNA14, HLA-DPA1, KIR3DL2, IFNA1, IFNA4, HSPA5, NFYB, 
HLA-DOB, IFNA8, RFXAP, CTSS, HSP90AA1, CD4, IFNA5, IFNA16, IFNA17, IFNA10, IFNA7, IFNA6, IFNA2, 
HSPA1L, HSPA1B, LGMN, HLA-DQA1, NFYC, PDIA3, CREB1, PSME3, IFNA21, CD8A, CALR, HLA-DOA, RFX5, 
HLA-DMB, HSPA8, CANX, CD8B, HSPA4, HSP90AB1, NFYA 
GO_CC Pathways Genes 
Chromosome 
STAG3, POLA1, DSN1, TINF2, PCNA, RFC4, RFC5, NPM2, SMC1A, CDT1, RPA3, SUMO3, JUN, XRCC4, ING2, 
RPA2, SMC2, RGS12, SMC4, TMPO, TIPIN, KIF22, CLIP1, SUV39H1, CENPC1, PSEN1, ZWILCH, MCM2, RFC2, 
ACD, HMGB2, TIMELESS, CENPA, CHMP1A, DMC1, PMF1, DCTN2, RAD51, SYCE2, PURA, RPA1, ERCC1, 
HELLS, OIP5, RFC1, RB1, CHEK1, BUB3, MCM7, HIST4H4, PAFAH1B1, UBE2I, ZWINT, HMGN1, FOXC1, APTX, 
MIS12, APC, ERCC4, MCM3, MAF, BIRC5, CENPE, JUND, JUNB, NOL6, HDAC8, BCL6, CENPF, NCAPD2, 
NDC80, CDCA5, TOP2A, ZW10, RAN, ZBED1, RCC1, TERF2, BUB1B, RFC3, ATRX, NSL1, TUBG1, PIF1, IN-
CENP, POLG2, H1FNT, ZNF238, CBX5, MAD2L1, H2AFY, ZNF330, TNKS, BUB1, TOP1, RPA4, ZMIZ2, TTN, 
CLASP1, SYCE1, KLHDC3, HMGB1, LIG4, SMARCA5, PURB, SUGT1, TNP1, UPF1, TERF2IP, MKI67IP, LRPPRC, 
PAM, CBX1, NUFIP1, PSEN2, SUV39H2, H2AFY2, SMARCE1, MYCN, TOP2B, DNMT3A, REPIN1 
Chromosomeperi-
centric region 
DSN1, SMC1A, SUMO3, KIF22, CLIP1, CENPC1, PSEN1, ZWILCH, CENPA, PMF1, DCTN2, HELLS, BUB3, 
PAFAH1B1, ZWINT, MIS12, APC, BIRC5, CENPE, CENPF, NDC80, ZW10, BUB1B, NSL1, INCENP, MAD2L1, 
ZNF330, BUB1, CLASP1, SUGT1, PSEN2 
Condensed Chro-
mosome 
STAG3, DSN1, SMC1A, XRCC4, SMC2, RGS12, SMC4, SUV39H1, HMGB2, CHMP1A, DMC1, PMF1, RAD51, 
SYCE2, CHEK1, UBE2I, MIS12, CENPE, NOL6, CENPF, NCAPD2, RCC1, NSL1, TUBG1, TTN, SYCE1, HMGB1, 
LIG4, SMARCA5, MKI67IP, LRPPRC, PAM 
Condensed Nuclear 
Chromosome 
STAG3, SMC1A, RGS12, SUV39H1, CHMP1A, DMC1, RAD51, SYCE2, CHEK1, UBE2I, NOL6, RCC1, TUBG1, 
TTN, SYCE1, MKI67IP, LRPPRC 
Nuclear Chromo-
some Part 
STAG3, POLA1, NPM2, RPA3, RPA2, TIPIN, ACD, TIMELESS, SYCE2, PURA, RPA1, ERCC1, MCM7, UBE2I, 
FOXC1, ERCC4, MCM3, RCC1, ATRX, PIF1, H1FNT, CBX5, H2AFY, RPA4, ZMIZ2, SYCE1, KLHDC3, PURB, 
PAM, CBX1, NUFIP1, H2AFY2, REPIN1 
Chromosomal part 
STAG3, POLA1, DSN1, TINF2, PCNA, RFC4, RFC5, NPM2, SMC1A, CDT1, RPA3, SUMO3, RPA2, SMC2, SMC4, 
TMPO, TIPIN, KIF22, CLIP1, CENPC1, PSEN1, ZWILCH, MCM2, RFC2, ACD, TIMELESS, CENPA, PMF1, DCTN2, 
SYCE2, PURA, RPA1, ERCC1, HELLS, OIP5, RFC1, RB1, BUB3, MCM7, HIST4H4, PAFAH1B1, UBE2I, ZWINT, 
HMGN1, FOXC1, APTX, MIS12, APC, ERCC4, MCM3, MAF, BIRC5, CENPE, JUND, JUNB, BCL6, CENPF, NDC80, 
CDCA5, ZW10, RAN, RCC1, TERF2, BUB1B, RFC3, ATRX, NSL1, PIF1, INCENP, H1FNT, CBX5, MAD2L1, 
H2AFY, ZNF330, TNKS, BUB1, RPA4, ZMIZ2, CLASP1, SYCE1, KLHDC3, PURB, SUGT1, TNP1, UPF1, PAM, 
CBX1, NUFIP1, PSEN2, SUV39H2, H2AFY2, MYCN, TOP2B, DNMT3A, REPIN1 
Proteasome com-
plex 
PSMD7, PSME1, PSMD2, PSMD8, PSME2, PSMC4, PSMD10, PSMD11, PSMC5, ADRM1, KIAA0368, SHFM1, 
PSMD4, PSMC3, PSMC2, PSMC6, PSMD14, PSME3, PSMD13, PSMD5, PSMD3, PSMD12, PSMD1 
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Table 3. LIHC resume table of viral infection. 
LIHC Samples Nº Reads 
Human 
Reads 
Non-Hu-
man Reads 
Viral In-
fection 
Virus 
Found 
Total Hu-
man Viral 
Reads 
Total ppm of 
Human Viral 
Reads 
Human 
Virus 
with 
ppm>10 
Sum of all 
Reads with 
ppm>10 
Sum of all 
ppm bigger 
than 10 
Bigger ppm 
found 
Virus with bigger ppm 
TCGA-DD-AAEK-01A-11R-A41C-07 70305983 2549987 72855970 Yes 1 10367 4065.510922 1 10367 4065.510922 4065.510922 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADP-01A-11R-A39D-07 120792108 5308131 126100239 Yes 2 13923 2622.95712 1 13916 2621.638388 2621.638388 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADV-01A-11R-A39D-07 175339586 6929501 182269087 Yes 6 10724 1547.586184 2 10718 1546.72032 1531.134782 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACA-01A-11R-A41C-07 151429927 6551245 157981172 Yes 2 9488 1448.274335 1 9486 1447.96905 1447.96905 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADU-01A-11R-A41C-07 118532667 4460172 122992839 Yes 5 5895 1321.697907 1 5858 1313.402263 1313.402263 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A116-11A-12R-A26B-07 164021083 5908704 169929787 Yes 1 7010 1186.385373 1 7010 1186.385373 1186.385373 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAD0-01A-11R-A41C-07 116619732 2917337 119537069 Yes 1 3387 1160.990314 1 3387 1160.990314 1160.990314 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACA-02B-11R-A41C-07 147739426 4580425 152319851 Yes 1 5263 1149.020015 1 5263 1149.020015 1149.020015 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A1EA-01A-11R-A131-07 119368196 2714982 122083178 Yes 1 3107 1144.390644 1 3107 1144.390644 1144.390644 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADL-01A-11R-A41C-07 145068722 5905214 150973936 Yes 2 6584 1114.946893 1 6582 1114.608209 1114.608209 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAE2-01A-11R-A41C-07 154007360 5528320 159535680 Yes 3 6152 1112.815467 1 6147 1111.911033 1111.911033 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACA-02A-11R-A41C-07 137698888 9739493 147438381 Yes 2 9983 1025.00202 1 9982 1024.899345 1024.899345 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACS-01A-11R-A41C-07 81221104 1966642 83187746 Yes 1 1987 1010.351655 1 1987 1010.351655 1010.351655 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADD-01A-11R-A41C-07 103924450 3328756 107253206 Yes 1 3210 964.32421 1 3210 964.32421 964.32421 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-G3-A25U-01A-11R-A16W-07 144672990 4185121 148858111 Yes 1 3716 887.907423 1 3716 887.907423 887.907423 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACN-01A-11R-A41C-07 112002050 5588980 117591030 Yes 2 4904 877.440965 1 4903 877.262041 877.262041 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACD-01A-11R-A41C-07 115179921 4355831 119535752 Yes 1 3683 845.533263 1 3683 845.533263 845.533263 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADG-01A-11R-A41C-07 126862944 4273798 131136742 Yes 1 3528 825.495262 1 3528 825.495262 825.495262 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADF-01A-11R-A41C-07 109953620 4444063 114397683 Yes 1 3243 729.73763 1 3243 729.73763 729.73763 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACV-01A-11R-A41C-07 93954755 7653309 101608064 Yes 2 5502 718.904724 1 5501 718.774062 718.774062 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACE-01A-11R-A41C-07 99542909 3144155 102687064 Yes 1 2135 679.03777 1 2135 679.03777 679.03777 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-G3-A3CH-11A-11R-A22L-07 130874869 4910062 135784931 Yes 2 3224 656.610854 1 3213 654.370556 654.370556 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A3MB-01A-11R-A213-07 172470251 5675462 178145713 Yes 3 3611 636.247763 1 3609 635.895369 635.895369 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAC9-01A-11R-A41C-07 105757426 5027831 110785257 Yes 2 3072 610.999057 1 3071 610.800164 610.800164 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAVP-01A-11R-A41C-07 71806971 1917621 73724592 Yes 1 1154 601.787319 1 1154 601.787319 601.787319 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-ED-A7XP-01A-11R-A352-07 128149090 4219283 132368373 Yes 5 2503 593.228754 1 2497 591.806712 591.806712 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADM-01A-11R-A41C-07 121165330 3054419 124219749 Yes 1 1780 582.762221 1 1780 582.762221 582.762221 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A7IK-01A-12R-A33R-07 141663929 4556810 146220739 Yes 2 2639 579.13321 1 2638 578.913758 578.913758 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-2Y-A9H4-01A-11R-A38B-07 89704718 3192920 92897638 Yes 2 1838 575.648623 1 1836 575.022237 575.022237 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
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TCGA-DD-A116-01A-11R-A131-07 129114971 4657198 133772169 Yes 2 2606 559.563927 1 2594 556.98727 556.98727 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACT-01A-11R-A41C-07 70785343 2699939 73485282 Yes 3 1494 553.345835 1 1492 552.605077 552.605077 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-ED-A8O6-01A-11R-A36F-07 136720850 6909177 143630027 Yes 1 3799 549.848412 1 3799 549.848412 549.848412 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A123-01A-11R-A131-07 126196774 6224414 132421188 Yes 1 3373 541.898402 1 3373 541.898402 541.898402 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACW-01A-11R-A41C-07 111630959 6796395 118427354 Yes 1 3490 513.507529 1 3490 513.507529 513.507529 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-UB-A7MC-01A-11R-A33R-07 174291370 7284614 181575984 Yes 4 3547 486.916672 1 3532 484.857537 484.857537 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADC-01A-11R-A41C-07 79662146 2997752 82659898 Yes 1 1449 483.362199 1 1449 483.362199 483.362199 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-QA-A7B7-01A-11R-A32O-07 179421506 5568424 184989930 Yes 3 2637 473.563076 1 2635 473.203908 473.203908 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACQ-01A-11R-A41C-07 145940758 5518663 151459421 Yes 2 2508 454.4579 1 2507 454.276697 454.276697 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-G3-A3CK-01A-11R-A213-07 182140953 6627479 188768432 Yes 3 2970 448.1342 1 2968 447.832426 447.832426 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-BW-A5NP-01A-11R-A27V-07 143882626 5297759 149180385 Yes 1 2342 442.073715 1 2342 442.073715 442.073715 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-BC-A10W-11A-11R-A131-07 139476978 5500511 144977489 Yes 3 2408 437.777508 1 2405 437.232104 437.232104 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A119-11A-11R-A131-07 139917728 5972110 145889838 Yes 3 2546 426.314987 1 2543 425.812652 425.812652 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAE3-01A-11R-A41C-07 92166571 7024566 99191137 Yes 1 2974 423.371351 1 2974 423.371351 423.371351 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAD6-01A-11R-A41C-07 72689256 4665642 77354898 Yes 1 1811 388.156657 1 1811 388.156657 388.156657 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-G3-A25Z-01A-11R-A16W-07 176263715 4673251 180936966 Yes 2 1811 387.524659 1 1810 387.310675 387.310675 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-G3-AAV1-01A-11R-A38B-07 139722555 3251606 142974161 Yes 1 1247 383.502798 1 1247 383.502798 383.502798 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-BC-A10W-01A-11R-A131-07 158686279 5629997 164316276 Yes 3 2164 384.369654 1 2160 383.659174 383.659174 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A5UD-01A-11R-A28V-07 113890691 4179505 118070196 Yes 2 1597 382.102665 1 1594 381.384877 381.384877 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-5264-01A-01R-A131-07 182762654 8180852 190943506 Yes 6 3109 380.033766 1 3066 374.77759 374.77759 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-G3-AAV0-01A-11R-A37K-07 110875134 7983570 118858704 Yes 1 2729 341.827027 1 2729 341.827027 341.827027 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A11A-01A-11R-A131-07 153811676 4723364 158535040 Yes 4 1636 346.363313 1 1605 339.800193 339.800193 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADR-01A-11R-A41C-07 105546520 7949768 113496288 Yes 3 2620 329.569367 1 2617 329.191997 329.191997 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACP-01A-11R-A41C-07 105739285 5482233 111221518 Yes 2 1804 329.062993 1 1794 327.238919 327.238919 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-5C-AAPD-01A-21R-A39D-07 107403930 4365579 111769509 Yes 2 1430 327.562506 1 1428 327.104377 327.104377 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A1EH-11A-11R-A131-07 153296943 6346057 159643000 Yes 2 2046 322.40492 1 2044 322.089764 322.089764 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAD5-01A-11R-A41C-07 138243163 6656224 144899387 Yes 2 2121 318.649132 1 2119 318.348661 318.348661 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACK-01A-11R-A41C-07 297195465 13045146 310240611 Yes 4 3933 301.491451 1 3927 301.03151 301.03151 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-RC-A7SB-01A-21R-A352-07 160585269 7531328 168116597 Yes 2 2250 298.752093 1 2249 298.619314 298.619314 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A1EL-11A-11R-A155-07 189341448 8625236 197966684 Yes 2 2567 297.615045 1 2566 297.499106 297.499106 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAVW-01A-11R-A41C-07 107402980 2252658 109655638 Yes 1 661 293.431138 1 661 293.431138 293.431138 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADK-01A-11R-A41C-07 217476210 5667329 223143539 Yes 1 1605 283.202193 1 1605 283.202193 283.202193 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
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TCGA-DD-A1EI-01A-11R-A131-07 179005382 9698836 188704218 Yes 3 2686 276.940449 1 2682 276.528029 276.528029 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A9FS-01A-11R-A37K-07 132932504 8042963 140975467 Yes 5 2264 281.488302 1 2189 272.163381 272.163381 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A9FU-01A-11R-A37K-07 149731807 10595946 160327753 Yes 7 2903 273.972707 1 2873 271.141435 271.141435 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A8HT-01A-11R-A36F-07 120177349 4112849 124290198 Yes 1 1093 265.752523 1 1093 265.752523 265.752523 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACC-01A-11R-A41C-07 101844100 2743024 104587124 Yes 4 748 272.691745 1 726 264.671399 264.671399 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A9FW-01A-11R-A37K-07 157970876 14571315 172542191 Yes 5 3846 263.943234 1 3828 262.70793 262.70793 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A5UC-01A-11R-A28V-07 95246463 2488787 97735250 Yes 2 654 262.778614 1 653 262.376812 262.376812 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-RC-A7S9-01A-11R-A33R-07 149288714 7633147 156921861 Yes 3 1896 248.390343 1 1892 247.866313 247.866313 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAVS-01A-11R-A41C-07 143619299 4731031 148350330 Yes 2 1130 238.848572 1 1129 238.637202 238.637202 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A1EI-11A-11R-A131-07 170306508 9821702 180128210 Yes 2 2282 232.342622 1 2281 232.240807 232.240807 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A1EL-01A-11R-A155-07 202763897 8184656 210948553 Yes 4 1780 217.480124 1 1768 216.013966 216.013966 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-ZS-A9CF-02A-11R-A38B-07 125447430 3326319 128773749 Yes 3 808 242.911159 2 807 242.610526 206.534611 NC_001401 » Adeno-associated virus - 2 
TCGA-CC-A7IL-01A-11R-A33R-07 170102848 6186113 176288961 Yes 2 1261 203.843673 1 1260 203.682021 203.682021 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A5UE-01A-11R-A28V-07 118614217 8007365 126621582 Yes 3 1615 201.68932 1 1609 200.94001 200.94001 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAVV-01A-11R-A41C-07 113773940 6912205 120686145 Yes 2 1363 197.187438 1 1361 196.898095 196.898095 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAVQ-01A-11R-A41C-07 143933966 3594225 147528191 Yes 3 697 193.922194 1 695 193.365746 193.365746 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAEE-01A-11R-A41C-07 146909251 8683866 155593117 Yes 4 1666 191.850035 1 1660 191.159099 191.159099 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-UB-A7ME-01A-11R-A33J-07 137082425 7847284 144929709 Yes 1 1458 185.796767 1 1458 185.796767 185.796767 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-ZS-A9CF-01A-11R-A38B-07 114291705 3040523 117332228 Yes 3 644 211.805667 2 642 211.147885 180.232151 NC_001401 » Adeno-associated virus - 2 
TCGA-CC-A7IG-01A-11R-A33J-07 134679947 6832383 141512330 Yes 3 1237 181.04957 1 1224 179.146866 179.146866 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-BW-A5NO-01A-11R-A27V-07 69371126 2174331 71545457 Yes 5 402 184.884455 1 390 179.365515 179.365515 
NC_004102 » Hepatitis C virus genotype 
1 
TCGA-G3-A3CJ-01A-11R-A213-07 140239378 4857483 145096861 Yes 3 884 181.987256 1 843 173.54667 173.54667 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-ED-A7XO-01A-11R-A352-07 100062337 11379880 111442217 Yes 1 1820 159.931388 1 1820 159.931388 159.931388 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A7II-01A-11R-A33J-07 149995731 7544334 157540065 Yes 2 1187 157.336619 1 1185 157.071519 157.071519 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAD1-01A-11R-A41C-07 103205530 3386345 106591875 Yes 1 480 141.745747 1 480 141.745747 141.745747 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A8HS-01A-11R-A36F-07 124175914 3639743 127815657 Yes 2 509 139.845039 1 496 136.273358 136.273358 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A1HT-01A-11R-A131-07 211315313 10525266 221840579 Yes 5 1357 128.927858 1 1332 126.552621 126.552621 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-A119-01A-11R-A131-07 139208308 6106845 145315153 Yes 3 747 122.321756 1 745 121.994254 121.994254 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-G3-AAV7-01A-11R-A38B-07 115166415 3241311 118407726 Yes 1 388 119.70465 1 388 119.70465 119.70465 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-K7-A5RG-01A-11R-A28V-07 121204308 5740945 126945253 Yes 3 1332 232.01755 2 1331 231.843363 118.447398 
NC_007605 » Human herpesvirus 4 com-
plete wild type genome 
TCGA-DD-AAE6-01A-11R-A41C-07 119527821 8064701 127592522 Yes 2 949 117.673302 1 948 117.549305 117.549305 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADO-01A-11R-A41C-07 133437448 4380264 137817712 Yes 1 496 113.235184 1 496 113.235184 113.235184 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
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TCGA-CC-A3MC-01A-11R-A22L-07 130149809 4923556 135073365 Yes 2 525 106.630248 1 523 106.224038 106.224038 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAD3-01A-11R-A41C-07 128928168 3631565 132559733 Yes 1 365 100.507632 1 365 100.507632 100.507632 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAE4-01A-11R-A41C-07 95963487 13501057 109464544 Yes 4 1324 98.066397 1 1316 97.47385 97.47385 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAE0-01A-11R-A41C-07 54294469 2853088 57147557 Yes 1 273 95.685797 1 273 95.685797 95.685797 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-5258-01A-01R-A131-07 167273080 7867384 175140464 Yes 1 731 92.915256 1 731 92.915256 92.915256 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-EP-A12J-11A-11R-A131-07 85325945 1934322 87260267 Yes 6 174 89.953999 1 164 84.784229 84.784229 
NC_004102 » Hepatitis C virus genotype 
1 
TCGA-RG-A7D4-01A-12R-A33R-07 112303322 5193397 117496719 Yes 6 442 85.108071 1 422 81.257027 81.257027 
NC_004102 » Hepatitis C virus genotype 
1 
TCGA-DD-A3A3-01A-11R-A22L-07 113103848 5428176 118532024 Yes 3 447 82.348104 1 445 81.979656 81.979656 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-5262-01A-01R-A131-07 115574935 5524615 121099550 Yes 3 426 77.109445 1 423 76.566421 76.566421 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAEB-01A-11R-A41C-07 94766527 17555085 112321612 Yes 3 1257 71.603185 1 1254 71.432294 71.432294 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A7IE-01A-21R-A38B-07 113936414 4980508 118916922 Yes 3 355 71.27787 1 353 70.876304 70.876304 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-5263-01A-01R-A131-07 159417127 5376674 164793801 Yes 4 422 78.487183 2 408 75.883343 63.794085 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADA-01A-11R-A41C-07 129667935 6949364 136617299 Yes 1 408 58.710409 1 408 58.710409 58.710409 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A8HU-01A-11R-A36F-07 114800545 3800558 118601103 Yes 1 214 56.307521 1 214 56.307521 56.307521 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAD2-01A-11R-A41C-07 94558874 3250259 97809133 Yes 1 176 54.149531 1 176 54.149531 54.149531 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-2Y-A9HA-01A-11R-A39D-07 166224345 5133144 171357489 Yes 8 299 58.248902 1 280 54.547466 54.547466 
NC_004102 » Hepatitis C virus genotype 
1 
TCGA-DD-AADN-01A-11R-A41C-07 74846180 19537816 94383996 Yes 5 1051 53.793116 1 1030 52.718277 52.718277 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-BC-A10Y-01A-11R-A131-07 157767649 5886385 163654034 Yes 3 435 73.899346 2 433 73.559579 46.038443 NC_001401 » Adeno-associated virus - 2 
TCGA-DD-AAED-01A-12R-A41C-07 92674598 16941737 109616335 Yes 2 732 43.206904 1 726 42.852749 42.852749 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACO-01A-11R-A41C-07 77523906 28323575 105847481 Yes 3 998 35.235666 1 994 35.09444 35.09444 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A3M9-01A-11R-A213-07 143077895 7906795 150984690 Yes 3 271 34.274317 1 268 33.894897 33.894897 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AAVU-01A-11R-A41C-07 121889622 3564414 125454036 Yes 3 120 33.666123 1 117 32.82447 32.82447 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-EP-A12J-01A-11R-A131-07 121179511 3472578 124652089 Yes 7 118 33.980517 1 108 31.100813 31.100813 
NC_004102 » Hepatitis C virus genotype 
1 
TCGA-DD-AACU-01A-11R-A41C-07 114400017 4614271 119014288 Yes 1 126 27.306589 1 126 27.306589 27.306589 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACF-01A-11R-A41C-07 127573548 6464344 134037892 Yes 2 164 25.369937 1 163 25.215242 25.215242 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACB-01A-11R-A41C-07 79164411 5337481 84501892 Yes 3 176 32.974356 1 133 24.918121 24.918121 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADY-01A-11R-A41C-07 74991128 3081874 78073002 Yes 1 68 22.064497 1 68 22.064497 22.064497 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-A7IJ-01A-11R-A33R-07 136224206 5770539 141994745 Yes 3 112 19.408932 1 104 18.02258 18.02258 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACH-01A-11R-A41C-07 162207670 5238087 167445757 Yes 2 90 17.181845 1 89 16.990936 16.990936 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-BC-A10Q-11A-11R-A131-07 137951153 7936190 145887343 Yes 1 127 16.002641 1 127 16.002641 16.002641 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AADW-01A-11R-A39D-07 162750012 7899238 170649250 Yes 3 111 14.051988 1 108 13.672205 13.672205 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-RC-A6M3-01A-11R-A32O-07 140797149 4498398 145295547 Yes 4 63 14.004985 1 58 12.893479 12.893479 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
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TCGA-DD-A3A3-11A-11R-A22L-07 102687232 3558051 106245283 Yes 1 44 12.366321 1 44 12.366321 12.366321 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-ED-A66Y-01A-11R-A311-07 127544015 3803926 131347941 Yes 2 48 12.618542 1 44 11.566997 11.566997 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CC-5259-01A-31R-A213-07 84953221 18295332 103248553 Yes 1 209 11.423679 1 209 11.423679 11.423679 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-G3-A25T-01A-11R-A16W-07 156872955 4101211 160974166 Yes 1 43 10.484708 1 43 10.484708 10.484708 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-DD-AACJ-01A-11R-A41C-07 190817423 17321852 208139275 Yes 4 208 12.007955 1 177 10.218307 10.218307 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-5R-AA1C-01A-11R-A41C-07 56201161 2440167 58641328 Yes 2 27 11.064816 1 26 10.655008 10.655008 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
 
 
Table 4. Count and ratio (number of mutations found divided by the number of sample) of somatic mutations present in 193 samples in LIHC. 
 Samples 
Infection 
(%) 
Frame Shift 
Del. 
Frame Shift Del. (ra-
tio) 
Frame Shift 
Ins. 
Frame Shift Ins. (ra-
tio) 
In Frame 
Del. 
In Frame Del. (ra-
tio) 
Inf. 45 23.32 668 14.84 234 5.20 172 3.82 
Non-Inf. 148 76.68 1206 8.15 624 4.22 402 2.72 
Total 193 100.00 1874 9.71 858 4.45 574 2.97 
 
 
 
Samples 
In Frame 
Ins. 
In Frame 
Ins. (ratio) 
Missense 
Mutation 
Missense Muta-
tion (ratio) 
Nonsense 
Mutation 
Nonsense Mu-
tation (ratio) 
Nonstop Mu-
tation 
Nonstop Mu-
tation (ratio) 
Inf. 45 45 1.00 4780 106.22 302 6.71 14 0.31 
Non-Inf. 148 131 0.89 16006 108.15 954 6.45 36 0.24 
Total 193 176 0.91 20786 107.70 1256 6.51 50 0.26 
 
 Samples RNA 
RNA 
(ratio) 
Silent 
Silent 
(ratio) 
Splice Site Splice Site (ratio) 
Translation Start 
Site 
Translation Start 
Site (ratio) 
Inf. 45 6714 149.20 1819 40.42 366 8.13 39 0.87 
Non-Inf. 148 11415 77.13 6107 41.26 1190 8.04 132 0.89 
Total 193 18129 93.93 7926 41.07 1556 8.06 171 0.89 
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Table 5. List of genes bearing somatic mutations in immune-related pathways significantly over-represented in the infected group in LIHC. 
Pathway Genes 
Phosphatidylinositol phos-
pholipase C activity 
CASR, PLCB4, PLCH1, PLCL1, PLCG1, CHRM3, PLCB2, PLCE1, PLCB3, EDNRA, PLCL2, CCR5, PLCD3, 
CCR1, BDKRB2, CHRM1, C3AR1, PLCB1, PLCD1, PLCG2, CCL5 
Inflammatory mediator reg-
ulation of TRP channels 
PRKCH, MAP2K3, MAPK9, PIK3CB, PRKCQ, CAMK2A, PRKACA, ASIC4, ADCY2, GNAS, ITPR3, PLCB4, 
TRPA1, PLA2G4C, PIK3R2, PIK3CG, MAPK10, PLA2G4A, PIK3CA, ITPR2, PLCG1, PTGER2, PRKCG, 
CYP2J2, HTR2B, PLCB2, PIK3R5, PRKACB, TRPM8, PIK3R1, PLCB3, ITPR1, ADCY8, GNAQ, PLA2G4D, 
ADCY9, F2RL1, ADCY1, PRKCB, BDKRB2, PLA2G4F, JMJD7-PLA2G4B, CALML6, PTGER4, PIK3CD, 
PPP1CA, ADCY5, ADCY6, P2RY2, PLCB1, PLA2G6, MAPK11, PPP1CC, PLA2G4E, IL1RAP, HRH1, TRPV1, 
PLCG2, NTRK1, ASIC3, ASIC5 
Leukocyte aggregation 
MAD1L1, CYP26B1, ITGAL, FYN, CD6, SLC11A1, CD44, RC3H2, ATG5, CASP8, AP3D1, PRKCQ, PRKCZ, 
BCL3, RORA, JMJD6, CDC42, STK10, TBX21, GLI2, DLG1, PAG1, PAK3, APBB1IP, PSEN1, TCF7, CYLD, 
BAX, SIRPG, LAG3, ICAM1, CD209, IL12RB1, MYH9, SLA2, BMP7, BMX, ELF4, CSK, RIPK2, CLPTM1, 
RASAL3, TGFB1, JAK3, PIK3CG, LFNG, EPHB6, GLI3, DOCK8, GATA3, PPP3CB, FOXN1, IFNG, PTPN6, 
CD83, SRF, ITK, IL4, BCL6, CD86, HHLA2, FOXP1, ZAP70, IL1RL2, IL18R1, SOS1, SLAMF1, PLA2G2D, 
MYB, SLC46A2, NR4A3, GPAM, IFNA8, TNFSF11, HSPH1, EGR1, CD80, PIK3CA, LAX1, PREX1, RUNX2, 
BCL11B, EIF2AK4, RIPK3, AP3B1, SPINK5, PTPN22, RSAD2, IL6ST, DOCK2, MAP3K7, IL6, HLX, IL36B, 
RPS6, IRF4, PDE5A, LEF1, PPP3CA, PDPK1, ERBB2, ITPKB, SOX13, HSPD1, PIK3R1, TNFRSF21, GNRH1, 
IFNA16, CDKN2A, GSN, ZEB1, SCGB1A1, PAK1, ADAM8, ADAM17, CAMK4, ZFP36L2, CD8A, CXADR, 
ADK, BATF, KIT, NCK1, CD1D, PLA2G2F, PKNOX1, AIRE, CD3G, C1ORF177, IL23R, NLRP3, SLAMF6, 
FZD5, EOMES, SPTA1, CTLA4, IL15, F2RL1, CASP3, RICTOR, SHH, ATP7A, RAG1, STAT6, NOD2, IGF2, 
NFKBID, CTNNB1, IL12A, LGALS9, PRELID1, HAS2, SOCS5, CHD7, PTGER4, PIK3CD, CTPS1, PRNP, 
RASGRP1, THEMIS, SP3, CD7, LIG4, LEP, TRAF6, PTPN2, SART1, YES1, PAWR, PTPN11, EGR3, PAK2, 
FUT7, CLEC4G, SATB1, LCK, JAG2, BTLA, IFNA10, HLA-DRB1, CD55, CD47, SRC, SPN, PDCD1LG2, 
KIF13B, CARD11, MTOR, BTNL2, HLA-G, PSMB10, LAT, HLA-DPB1, IFNA14, IFNA13, IFNA17, HLA-
DQA2, HLA-DMB, PRKDC, INS, CCL5 
Somatic diversification of 
immune receptors 
ERCC1, TBX21, MLH1, TCF7, MSH2, CD40, NBN, IL27RA, TGFB1, EXOSC3, SUPT6H, IFNG, AICDA, IL4, 
BCL6, FOXP1, MSH6, BCL11B, LEF1, HSPD1, VPRBP, ATM, DCLRE1C, BATF, PAXIP1, RNF168, RAG1, 
STAT6, EXO1, LIG4, CLCF1, PRKDC 
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 Table 6. HNSC resume table of viral infection. 
HNSC Sample Nº Reads 
Human 
Reads 
Non Hu-
man Reads 
Viral 
Infec-
tion 
Vi-
rus 
Fou
nd 
Total Hu-
man Viral 
Reads 
Total ppm of Hu-
man Viral Reads 
Human 
Virus 
with 
ppm>10 
Sum of all 
Reads with 
ppm>10 
Sum of all 
ppm bigger 
than 10 
Bigger ppm 
found 
Virus with bigger ppm 
TCGA-BA-5558-01A-01R-1514-07 178296042 4432752 182728794 Yes 2 44417 10020.186105 2 44417 
10020.18610
5 
8446.22031
6 
NC_001806 » Human herpesvirus 1 
strain 17 
TCGA-BB-7866-01A-11R-2232-07 142680545 3536686 146217231 Yes 6 9936 2809.409714 2 9909 2801.775447 
2789.89992
3 
NC_001526 » Human papillomavirus 
type 16 
TCGA-HD-A634-01A-11R-A28V-07 123216743 3988746 127205489 Yes 3 9506 2383.205148 2 9500 2381.700916 
2251.58483
4 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-7385-01A-11R-2016-07 84968417 2786891 87755308 Yes 3 5310 1905.349007 2 5309 1904.990184 
1849.01382
9 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BA-A4IH-01A-11R-A266-07 149753372 5110362 154863734 Yes 5 8142 1593.233513 1 8138 1592.450789 
1592.45078
9 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BA-5153-01A-01R-1436-07 113588728 3229575 116818303 Yes 4 4894 1515.369671 2 4890 1514.131117 
1447.86852
8 
NC_001526 » Human papillomavirus 
type 16 
TCGA-QK-A6IF-01A-11R-A31N-07 93210195 2195620 95405815 Yes 1 2884 1313.524198 1 2884 1313.524198 
1313.52419
8 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-5374-01A-01R-1436-07 132205310 2676214 134881524 Yes 3 3567 1332.853053 2 3566 1332.479391 
1295.11317
1 
NC_001526 » Human papillomavirus 
type 16 
TCGA-P3-A5QE-01A-11R-A28V-07 141754948 4883442 146638390 Yes 7 6939 1420.924012 2 6930 1419.081050 
1294.57870
1 
NC_001526 » Human papillomavirus 
type 16 
TCGA-P3-A5QF-01A-11R-A28V-07 129671800 3994934 133666734 Yes 4 5235 1310.409634 2 5231 1309.408366 
1290.63458
9 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BB-4223-01A-01R-1436-07 122395774 2941968 125337742 Yes 4 3914 1330.401963 2 3909 1328.702420 
1269.21842
8 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DQ-7596-01A-11R-2232-07 186902827 4127016 191029843 Yes 4 5356 1297.789978 2 5336 1292.943861 
1195.29461
5 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BA-A4IG-01A-11R-A266-07 137500248 4862032 142362280 Yes 5 6322 1300.279389 2 6311 1298.016961 
1191.68281
9 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-5250-01A-01R-1514-07 140959816 4054266 145014082 Yes 5 4866 1200.217252 2 4849 1196.024138 
1133.62073
4 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CV-6433-01A-11R-1686-07 130216642 3571443 133788085 Yes 3 4351 1218.275079 2 4350 1217.995080 
1132.03542
7 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-5249-01A-01R-1514-07 165138012 4483339 169621351 Yes 6 5132 1144.682568 2 5121 1142.229040 
1079.32949
1 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DQ-7590-01A-11R-2232-07 132065535 3582294 135647829 Yes 4 3708 1035.090923 2 3694 1031.182812 993.776614 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-A499-01A-11R-A24H-07 135674179 4462691 140136870 Yes 2 4269 956.597712 1 4264 955.477312 955.477312 
NC_001526 » Human papillomavirus 
type 16 
TCGA-QK-A6V9-01A-11R-A34R-07 147402470 6258677 153661147 Yes 2 6246 997.974492 2 6246 997.974492 937.258785 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BA-4077-01B-01R-1436-07 122867820 3359582 126227402 Yes 2 3160 940.593205 1 3135 933.151803 933.151803 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-5243-01A-01R-1514-07 167713985 4865922 172579907 Yes 2 4771 980.492495 2 4771 980.492495 909.796746 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-5248-01A-01R-2016-07 126888267 4113519 131001786 Yes 4 3872 941.286524 2 3840 933.507296 907.738605 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BB-4228-01A-01R-1436-07 149357498 4842695 154200193 Yes 4 4641 958.350670 2 4637 957.524684 888.554823 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BA-5559-01A-01R-1514-07 207623967 6146672 213770639 Yes 2 5027 817.840939 2 5027 817.840939 799.945076 
NC_001526 » Human papillomavirus 
type 16 
TCGA-P3-A5Q5-01A-11R-A28V-07 147803156 4521324 152324480 Yes 5 3527 780.081232 1 3511 776.542446 776.542446 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-4741-01A-01R-1436-07 184712981 7415768 192128749 Yes 7 5885 793.579304 2 5851 788.994478 767.553678 
NC_001526 » Human papillomavirus 
type 16 
TCGA-RS-A6TP-01A-12R-A34R-07 175517410 5885287 181402697 Yes 4 4512 766.657598 1 4497 764.108870 764.108870 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-7404-01A-11R-2132-07 186133140 6742338 192875478 Yes 4 5139 762.198514 1 5134 761.456931 761.456931 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DQ-7594-01A-11R-2232-07 168595744 6026470 174622214 Yes 4 4448 738.077183 1 4443 737.247510 737.247510 
NC_001526 » Human papillomavirus 
type 16 
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TCGA-HD-7754-01A-11R-2081-07 202359466 7242726 209602192 Yes 7 5404 746.127908 2 5368 741.157404 728.178865 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CV-5443-01A-01R-1514-07 107803780 5153354 112957134 Yes 2 3918 760.281556 2 3918 760.281556 727.681428 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CV-6961-01A-21R-1915-07 219188595 7056839 226245434 Yes 5 5113 724.545367 1 5076 719.302226 719.302226 
NC_001526 » Human papillomavirus 
type 16 
TCGA-T2-A6X0-01A-11R-A34R-07 183179180 5981510 189160690 Yes 1 3973 664.213551 1 3973 664.213551 664.213551 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-6472-01A-11R-1873-07 129132136 4515880 133648016 Yes 6 2993 662.772263 1 2982 660.336413 660.336413 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-A6UY-01A-12R-A34R-07 118815651 5039976 123855627 Yes 4 3571 708.535121 4 3571 708.535121 642.066550 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-6480-01A-11R-1873-07 155416151 7408274 162824425 Yes 3 4978 671.951389 2 4977 671.816405 641.579942 
NC_001526 » Human papillomavirus 
type 16 
TCGA-DQ-7593-01A-11R-2232-07 165708392 5994003 171702395 Yes 6 4154 693.026013 4 4131 689.188844 636.135818 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-6487-01A-11R-1873-07 189054842 7061599 196116441 Yes 6 4161 589.243315 2 4155 588.393649 577.064770 
NC_001526 » Human papillomavirus 
type 16 
TCGA-MZ-A6I9-01A-11R-A31N-07 134307185 7303926 141611111 Yes 3 4287 586.944610 2 4282 586.260047 569.419789 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BB-7861-01A-11R-2232-07 174434590 5014836 179449426 Yes 6 2836 565.521982 1 2762 550.765768 550.765768 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-A49C-01A-11R-A24H-07 124974532 3740336 128714868 Yes 3 1997 533.909253 1 1993 532.839830 532.839830 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-6470-01A-11R-1873-07 158273594 8076161 166349755 Yes 4 4405 545.432415 2 4396 544.318024 525.125737 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-7369-01A-11R-2132-07 172407521 3424838 175832359 Yes 1 1718 501.629566 1 1718 501.629566 501.629566 
NC_001526 » Human papillomavirus 
type 16 
TCGA-UP-A6WW-01A-12R-A34R-07 180911163 6970629 187881792 Yes 3 3417 490.199665 2 3416 490.056206 456.917159 
NC_001526 » Human papillomavirus 
type 16 
TCGA-HL-7533-01A-11R-2232-07 135132943 5936385 141069328 Yes 4 2665 448.926410 1 2653 446.904977 446.904977 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-7368-01A-11R-2132-07 198925741 4297086 203222827 Yes 3 1909 444.254549 1 1906 443.556401 443.556401 
NC_001526 » Human papillomavirus 
type 16 
TCGA-KU-A6H7-01A-11R-A31N-07 147223139 4832235 152055374 Yes 2 2158 446.584241 2 2158 446.584241 435.823175 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BA-7269-01A-11R-2016-07 179436339 5524223 184960562 Yes 3 4422 800.474564 2 4421 800.293543 405.486889 NC_009334 » Human herpesvirus 4 
TCGA-CV-5442-01A-01R-1514-07 135098526 3699540 138798066 Yes 3 1482 400.590345 1 1475 398.698217 398.698217 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CQ-A4CE-01A-11R-A266-07 147271524 4139643 151411167 Yes 4 1630 393.753761 1 1593 384.815792 384.815792 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-CV-7406-01A-11R-2081-07 178604642 3196035 181800677 Yes 2 1179 368.894584 1 1178 368.581696 368.581696 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CQ-5323-01A-01R-1686-07 105148902 2957031 108105933 Yes 3 1007 340.544282 1 984 332.766210 332.766210 
NC_001526 » Human papillomavirus 
type 16 
TCGA-H7-A76A-01A-51R-A34R-07 111590609 8668029 120258638 Yes 2 3044 351.175567 2 3044 351.175567 330.178868 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-A6V7-01A-12R-A34R-07 168327652 7820521 176148173 Yes 4 2554 326.576708 1 2550 326.065233 326.065233 
NC_001526 » Human papillomavirus 
type 16 
TCGA-P3-A6T6-01A-11R-A34R-07 76553500 10714136 87267636 Yes 3 3338 311.551020 1 3335 311.271016 311.271016 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-6473-01A-11R-1873-07 122259215 4298884 126558099 Yes 3 1240 288.446955 1 1201 279.374833 279.374833 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-6481-01A-11R-1873-07 192691897 12676274 205368171 Yes 8 3737 294.802717 2 3712 292.830527 278.236333 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-A63T-01A-11R-A28V-07 138983576 3282137 142265713 Yes 2 985 300.109350 2 985 300.109350 274.516268 
NC_001806 » Human herpesvirus 1 
strain 17 
TCGA-CN-A6V6-01A-12R-A34R-07 99608301 10868175 110476476 Yes 6 2909 267.662235 1 2893 266.190046 266.190046 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CV-5971-01A-11R-1686-07 180411398 6129940 186541338 Yes 3 1527 249.105211 1 1508 246.005671 246.005671 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CR-6482-01A-11R-1873-07 154178104 16003375 170181479 Yes 9 3708 231.701126 1 3529 220.515985 220.515985 
NC_001526 » Human papillomavirus 
type 16 
TCGA-TN-A7HL-01A-11R-A34R-07 159013405 10179024 169192429 Yes 5 2320 227.919690 2 2313 227.232002 213.674710 
NC_001526 » Human papillomavirus 
type 16 
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TCGA-BB-A6UM-01A-12R-A34R-07 150961103 6887740 157848843 Yes 4 1474 214.003433 1 1454 211.099722 211.099722 
NC_001526 » Human papillomavirus 
type 16 
TCGA-KU-A6H7-06A-21R-A31N-07 155248111 7054785 162302896 Yes 2 1130 160.174974 2 1130 160.174974 149.118648 
NC_001526 » Human papillomavirus 
type 16 
TCGA-P3-A6SW-01A-11R-A34R-07 110477818 7115906 117593724 Yes 2 752 105.678743 1 751 105.538213 105.538213 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CQ-A4CH-01A-11R-A266-07 145105130 3788177 148893307 Yes 2 357 94.240580 1 356 93.976601 93.976601 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-BB-7864-01A-11R-2232-07 168951816 3593200 172545016 Yes 5 196 54.547479 1 145 40.354002 40.354002 
NC_001593 » Human papillomavirus 
type 53 
TCGA-UF-A7J9-01A-12R-A34R-07 163504031 8265279 171769310 Yes 3 318 38.474200 1 316 38.232224 38.232224 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-CN-A6V1-01A-12R-A34R-07 122071735 8337650 130409385 Yes 3 322 38.619994 1 317 38.020305 38.020305 
NC_001526 » Human papillomavirus 
type 16 
TCGA-QK-A8ZB-01A-11R-A39I-07 228156611 7006637 235163248 Yes 1 241 34.395959 1 241 34.395959 34.395959 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-CV-7438-11A-01R-2132-07 169290651 6212166 175502817 Yes 4 205 32.999762 1 200 32.194890 32.194890 NC_009333 » Human herpesvirus 8 
TCGA-QK-A64Z-01A-11R-A30B-07 149647966 4756730 154404696 Yes 3 174 36.579752 1 142 29.852441 29.852441 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-BB-7862-01A-21R-2232-07 178399393 3925905 182325298 Yes 3 128 32.603947 1 104 26.490707 26.490707 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CV-5970-01A-11R-1686-07 145450222 8979265 154429487 Yes 5 291 32.407998 1 230 25.614569 25.614569 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-DQ-7589-01A-11R-2232-07 219008217 4034911 223043128 Yes 3 108 26.766390 1 87 21.561814 21.561814 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-A642-01A-12R-A30B-07 139134715 4008903 143143618 Yes 2 87 21.701698 1 86 21.452253 21.452253 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-H7-A6C5-11A-11R-A30B-07 129937690 5482433 135420123 Yes 3 120 21.888093 1 105 19.152081 19.152081 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CV-5436-01A-01R-1514-07 134988322 4884792 139873114 Yes 2 101 20.676418 1 95 19.448116 19.448116 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-F7-A61S-01A-11R-A28V-07 96279012 6341880 102620892 Yes 3 220 34.690029 2 218 34.374665 17.345014 NC_009334 » Human herpesvirus 4 
TCGA-D6-6826-01A-11R-1915-07 219244422 20802869 240047291 Yes 2 352 16.920743 1 339 16.295829 16.295829 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-BA-A4IF-01A-11R-A266-07 134538615 3548393 138087008 Yes 3 72 20.290875 1 58 16.345427 16.345427 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-A49B-01A-31R-A24H-07 135288392 4003670 139292062 Yes 4 66 16.484876 1 61 15.236021 15.236021 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BA-6870-01A-11R-1873-07 219307265 9732023 229039288 Yes 2 163 16.748830 1 151 15.515787 15.515787 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-HD-A633-01A-11R-A28V-07 165013079 4791625 169804704 Yes 4 72 15.026217 1 68 14.191428 14.191428 
NC_001526 » Human papillomavirus 
type 16 
TCGA-CN-A641-01A-11R-A30B-07 168368761 4322442 172691203 Yes 3 59 13.649691 1 56 12.955639 12.955639 
NC_003977 » Hepatitis B virus (strain 
ayw) genome 
TCGA-CV-7091-11A-01R-2016-07 115894814 2685963 118580777 Yes 2 32 11.913790 1 31 11.541484 11.541484 
NC_001806 » Human herpesvirus 1 
strain 17 
TCGA-CQ-5332-01A-01R-1686-07 122274030 2393307 124667337 Yes 1 28 11.699293 1 28 11.699293 11.699293 
NC_006273 » Human herpesvirus 5 
strain Merlin 
TCGA-CN-A49A-01A-11R-A24H-07 150104592 4436461 154541053 Yes 2 50 11.270245 1 49 11.044840 11.044840 
NC_001526 » Human papillomavirus 
type 16 
TCGA-BA-A4II-01A-11R-A266-07 141864878 4660809 146525687 Yes 5 135 28.964927 2 107 22.957387 11.585971 
NC_007605 » Human herpesvirus 4 
complete wild type genome 
TCGA-CN-4735-01A-01R-1436-07 171643158 3614630 175257788 Yes 3 40 11.066139 1 38 10.512833 10.512833 NC_001716 » Human herpesvirus 7 
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Table 7. List of genes in significant pathways related to immune response and viral integration in host DNA in HNSC samples obtained through GSEA. 
HNSC 
GO_BP Pathways Genes 
Chromosome Organiza-
tion and Biogenesis 
STAG3, NUSAP1, SMC4, CHAF1B, CHAF1A, RBBP4, MSH2, EZH2, SUV39H2, CENPH, MSH3, HDAC6, 
ZWINT, RBM14, ESPL1, SMARCC2, HELLS, DDX11, PDS5B, HIRIP3, TOP2A, ARID1A, NSD1, EHMT1, 
PBRM1, RPS6KA5, CDC23, RFC1, NASP, SMC1A, SMARCC1, SIRT1, SATB1, TSSK6, DFFB, TERT, INO80, 
HDAC2, CREBBP, NDC80, REC8, BPTF, NAP1L4, ACTL6A, ACIN1, SYCP1, MTA2, HUWE1, MIS12, 
CENPE, NCAPH, PIF1, TAF6L, WHSC1L1, SYCP3, NPM2, KIF25, HDAC5, LATS1, HDAC3, HDAC1, 
SMARCA5, SAFB, NBN, NAP1L1, SET, PAPD7, HDAC8, KDM4A, TLK2, SUPT16H, SMARCE1, MRE11A, 
SIRT5, SUPT4H1, RSF1, PPARGC1A, HDAC11, H1FNT, HMGB1, CDCA5, SMG6, AIFM2, POT1, TEP1, 
PTGES3, MAP3K12, ERCC4, SMARCD1, SIRT4, RAD50, HDAC4, PRMT8, TERF2, HDAC10, HMGA1, DKC1, 
NAP1L3, CARM1, VCX, KAT2A, TINF2, SIRT2, HDAC7, ASF1A, KAT5, ACD, TERF2IP, TNP1, PRMT7, 
TLK1, UBE2N, PHB, ERCC1, HMGA2, PAM, BNIP3, ZW10, NAP1L2, CHMP1A 
DNA dependent DNA 
replication 
RPA2, CDK2, MCM3, HMGB2, MSH6, PRIM1, MSH2, POLA1, MSH3, MLH1, TP73, TSPYL2, RPA1, RFC4, 
RFC3, RFC1, RAD17, PMS1, EXO1, GMNN, CDT1, CCDC88A, MUTYH, TIPIN, ATR, PRIM2, POLG2, CDC6, 
PURA, CDC45, MSH5, PRKCG, REV3L, RPAIN, NBN, POLB, ABL1, RAD51, TFAM, RAD9A, WRNIP1, GLI2, 
GLI1, ENPP7, NF2, RPA4, S100A11, PMS2, GTPBP4, CDK2AP1, EREG 
DNA replication 
MCM2, RPA2, MCM5, CDK2, MCM3, HMGB2, MSH6, PRIM1, MSH2, POLA1, MSH3, MLH1, POLE, TP73, 
TSPYL2, RPA1, RFC4, REV1, POLE2, MCM7, RFC3, NT5M, RFC1, RAD17, NASP, POLD1, PMS1, EXO1, 
REPIN1, GMNN, CDT1, RNASEH2A, CCDC88A, POLE3, MUTYH, DBF4, TIPIN, ATR, DUT, SPHAR, PRIM2, 
NOL8, CDKN2D, POLG2, CDC6, PURA, CDC45, MSH5, KCTD13, PRKCG, REV3L, RPAIN, NBN, NAP1L1, 
POLB, SET, NUP98, ABL1, RAD51, RPA3, MCM3AP, ACHE, MRE11A, TFAM, KIN, RAD9A, WRNIP1, GLI2, 
KRT7, POT1, UPF1, GLI1, ENPP7, NF2, RAD50, TERF2, RPA4, IGF1, DKC1, PTMS, TINF2, EGF, TERF2IP, 
POLD2, S100A11, PMS2, TYMP, GTPBP4, CDK2AP1, IGHMBP2, POLD4, EREG, NAE1, TBRG1, RBMS1 
DNA replication initiation MCM3, POLA1, RAD17, CDT1, TIPIN, CDC6, PURA, CDC45, NBN, RAD9A, WRNIP1, RPA4 
GO_CC Pathways Genes 
T-cell receptor signalling 
MAP3K14, PIK3R3, NCK1, CD40LG, RAF1, PIK3CB, CD28, LCK, CD8B, CD3E, LAT, ZAP70, DLG1, ITK, 
IKBKB, CD3G, PTPRC, GRAP2, PDCD1, IL2, SOS1, CD247, PIK3CG, GSK3B, PAK3, CD4, CD3D, PTPN6, 
CD8A, LCP2, NFATC3, TEC, MAP3K8, MAP2K7, VAV1, MAPK13, PIK3R1, PIK3R5, NFATC2, GRB2, 
NFATC1, PAK2, VAV3, PDK1, NFKB1, CHP, PPP3R1, AKT3, PIK3CA, IFNG, IL4, PAK4, PPP3CC, RASGRP1, 
KRAS, ICOS, CTLA4, CDK4, NFKBIE, MAPK9, FYN, MALT1, NRAS, PAK6, CBLC, RHOA, CHP2, MAPK1, 
PRKCQ, PIK3R2, SOS2, NCK2, AKT2, IL5, NFKBIB, FOS, PAK7, MAPK14, CBLB, PLCG1, BCL10, CBL, 
CARD11, CHUK, MAPK11, MAP2K1, MAP2K2, JUN, PPP3R2, IKBKG, NFAT5, PPP3CA, PAK1, NFKBIA, 
PPP3CB, CDC42, IL10, MAP3K7, PIK3CD, VAV2, NFATC4, TNF, MAPK3, MAPK12, RELA, CSF2, HRAS, 
AKT1 
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B-cell receptor signaling 
SYK, PIK3R3, CR2, RAF1, PIK3CB, PRKCB, INPP5D, BTK, IKBKB, CD22, SOS1, CD19, CD79A, PIK3CG, 
GSK3B, PTPN6, NFATC3, CD79B, RASGRP3, LYN, BLNK, VAV1, PIK3AP1, PIK3R1, PIK3R5, NFATC2, 
GRB2, NFATC1, CD72, VAV3, NFKB1, CHP, PPP3R1, AKT3, PIK3CA, FCGR2B, PPP3CC, KRAS, PLCG2, 
NFKBIE, MALT1, NRAS, RAC2, CHP2, RAC1, MAPK1, LILRB3, PIK3R2, SOS2, DAPP1, AKT2, NFKBIB, 
FOS, BCL10, CARD11, CHUK, RAC3, MAP2K1, MAP2K2, JUN, PPP3R2, IKBKG, NFAT5, PPP3CA, NFKBIA, 
PPP3CB, PIK3CD, VAV2, IFITM1, NFATC4, MAPK3, RELA, HRAS, AKT1, CD81 
Chromosomal part 
TIMELESS, TMPO, MCM2, STAG3, RPA2, MCM3, RFC5, SMC4, SMC2, SUV39H2, NSL1, POLA1, CBX5, 
PCNA, ZWINT, CENPF, TNKS, HELLS, DNMT3A, RPA1, RFC4, OIP5, ZWILCH, MCM7, BUB1B, RFC3, 
RFC1, CENPC1, SMC1A, DSN1, ZMIZ2, TOP2B, SYCE2, APC, RCC1, REPIN1, CDT1, HIST4H4, NDC80, 
RFC2, TIPIN, BCL6, MYCN, ATRX, PMF1, MIS12, CENPE, HMGN1, CENPA, PURA, PIF1, NPM2, ZNF330, 
H2AFY, MAD2L1, KIF22, BUB3, BUB1, SYCE1, CBX1, RB1, INCENP, CLASP1, JUNB, RPA3, KLHDC3, 
H2AFY2, H1FNT, CDCA5, SUMO3, UPF1, ERCC4, TERF2, RPA4, APTX, CLIP1, JUND, UBE2I, FOXC1, 
BIRC5, DCTN2, TINF2, PURB, PAFAH1B1, MAF, ACD, TNP1, PSEN1, NUFIP1, ERCC1, PAM, ZW10, RAN, 
PSEN2, SUGT1 
Chromosome 
TIMELESS, TMPO, MCM2, STAG3, RPA2, MCM3, RFC5, SMC4, HMGB2, SMC2, SUV39H2, NSL1, POLA1, 
CBX5, PCNA, ZWINT, CENPF, TNKS, HELLS, DNMT3A, TOP2A, RPA1, RFC4, DMC1, OIP5, ZWILCH, 
MCM7, BUB1B, ZNF238, RFC3, SUV39H1, RFC1, CENPC1, SMC1A, DSN1, ZMIZ2, TOP2B, SYCE2, APC, 
RCC1, REPIN1, CDT1, HIST4H4, NDC80, RFC2, TIPIN, BCL6, MYCN, ATRX, PMF1, MIS12, CENPE, 
HMGN1, POLG2, CENPA, PURA, PIF1, ING2, ZBED1, NPM2, ZNF330, H2AFY, MAD2L1, KIF22, XRCC4, 
BUB3, BUB1, SYCE1, CBX1, SMARCA5, RB1, TUBG1, INCENP, CLASP1, JUNB, TTN, HDAC8, RAD51, 
RPA3, NCAPD2, SMARCE1, KLHDC3, H2AFY2, H1FNT, HMGB1, CHEK1, CDCA5, SUMO3, UPF1, ERCC4, 
TERF2, RPA4, RGS12, APTX, CLIP1, JUND, UBE2I, LRPPRC, FOXC1, BIRC5, JUN, DCTN2, TINF2, PURB, 
PAFAH1B1, MAF, ACD, TERF2IP, TNP1, PSEN1, TOP1, NOL6, NUFIP1, ERCC1, PAM, ZW10, LIG4, RAN, 
PSEN2, CHMP1A, SUGT1, MKI67IP 
Nuclear chromosome 
TIMELESS, STAG3, RPA2, MCM3, HMGB2, SMC2, POLA1, CBX5, RPA1, DMC1, MCM7, ZNF238, 
SUV39H1, SMC1A, ZMIZ2, SYCE2, RCC1, REPIN1, TIPIN, ATRX, PURA, PIF1, ZBED1, NPM2, H2AFY, 
SYCE1, CBX1, TUBG1, TTN, HDAC8, RAD51, RPA3, SMARCE1, KLHDC3, H2AFY2, H1FNT, CHEK1, 
ERCC4, RPA4, RGS12, UBE2I, LRPPRC, FOXC1, JUN, PURB, ACD, TERF2IP, NOL6, NUFIP1, ERCC1, PAM, 
CHMP1A, MKI67IP 
Nuclear chromosome part 
TIMELESS, STAG3, RPA2, MCM3, POLA1, CBX5, RPA1, MCM7, ZMIZ2, SYCE2, RCC1, REPIN1, TIPIN, 
ATRX, PURA, PIF1, NPM2, H2AFY, SYCE1, CBX1, RPA3, KLHDC3, H2AFY2, H1FNT, ERCC4, RPA4, 
UBE2I, FOXC1, PURB, ACD, NUFIP1, ERCC1, PAM 
Condensed chromosome 
STAG3, SMC4, HMGB2, SMC2, NSL1, CENPF, DMC1, SUV39H1, SMC1A, DSN1, SYCE2, RCC1, PMF1, 
MIS12, CENPE, XRCC4, SYCE1, SMARCA5, TUBG1, TTN, RAD51, NCAPD2, HMGB1, CHEK1, RGS12, 
UBE2I, LRPPRC, NOL6, PAM, LIG4, CHMP1A, MKI67IP 
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Chromosomepericentric 
region 
NSL1, ZWINT, CENPF, HELLS, ZWILCH, BUB1B, CENPC1, SMC1A, DSN1, APC, NDC80, PMF1, MIS12, 
CENPE, CENPA, ZNF330, MAD2L1, KIF22, BUB3, BUB1, INCENP, CLASP1, SUMO3, CLIP1, BIRC5, 
DCTN2, PAFAH1B1, PSEN1, ZW10, PSEN2, SUGT1 
Immunological synapse SYK, TRAT1, LAT, ZAP70, CD247, CD79A, GZMB, GZMA, BCL10, CARD11, MYH9 
Kegg Pathways Genes 
primary immunodefi-
ciency 
UNG, DCLRE1C, CD40LG, TNFRSF13C, RFX5, LCK, CD8B, TNFRSF13B, CD3E, ZAP70, AICDA, BTK, 
IL2RG, CIITA, PTPRC, JAK3, CD19, CD79A, CD4, CD3D, CD8A, BLNK, IGLL1, AIRE, RFXAP, ICOS, CD40, 
RFXANK, TAP1, IKBKG, IL7R, TAP2, RAG2, RAG1, ADA 
Intestinal immune net-
work for IGA production 
MAP3K14, CD40LG, TNFRSF13C, CD28, TNFRSF13B, AICDA, CXCR4, TNFRSF17, IL2, HLA-DMB, HLA-
DOA, IL15, ITGB7, ICOSLG, TNFSF13, ITGA4, HLA-DQA2, HLA-DPB1, HLA-DRA, HLA-DPA1, HLA-
DQA1, IL4, CCL25, CCR9, HLA-DMA, CCL28, ICOS, HLA-DOB, HLA-DQB1, HLA-DRB5, CD40, HLA-
DRB1, CXCL12, CCR10, CD80, IL15RA, TNFSF13B, IL5, MADCAM1, CD86, PIGR, IL10, IL6, CCL27, 
TGFB1, LTBR 
DNA replication 
MCM2, RPA2, MCM5, MCM6, MCM3, RFC5, LIG1, PRIM1, POLA1, PCNA, POLE, DNA2, RPA1, RFC4, 
POLE2, MCM7, RFC3, RFC1, POLD1, POLD3, RNASEH2A, MCM4, POLE3, POLA2, RFC2, FEN1, PRIM2, 
RNASEH2B, RPA3, RPA4, RNASEH2C, POLE4, RNASEH1, POLD2, SSBP1, POLD4 
mismatch repair 
RPA2, RFC5, LIG1, MSH6, MSH2, MSH3, PCNA, MLH1, RPA1, RFC4, RFC3, RFC1, POLD1, POLD3, EXO1, 
RFC2, RPA3, MLH3, RPA4, POLD2, PMS2, SSBP1, POLD4 
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Table 8. List of genes bearing somatic mutations in immune-related pathways significantly over-represented in the infected group in HNSC. 
Pathway Genes 
Lymphocyte activation 
CD38, ITGAL, BTK, FYN, BTN3A1, POU2F2, HDAC9, RC3H2, KLF6, PRKCZ, GAL, RORA, JMJD6, DLG1, 
MLH1, PAG1, IL4R, APBB1IP, ITCH, TCF7, MEF2C, CYLD, IGBP1, ICAM1, TYRO3, MSH2, BLNK, IL12RB1, 
LGALS1, MYH9, EP300, CD40, NFATC2, CHRNA4, ATP11C, BMX, ELF4, PYCARD, IL21R, RELB, JAK3, 
PIK3CG, LFNG, EPHB6, AHR, GLI3, DOCK8, GATA3, PPP3CB, MAP3K8, CCL2, PRKAR1A, SUPT6H, 
WHSC1, ZBTB16, PTPN6, AICDA, TREML2, DUSP22, BCL6, SOS1, LEPR, CD46, STK11, MYB, GPAM, 
HELLS, IFNA8, HSPH1, EGR1, KIAA0922, CD80, CCR2, PIK3CA, LAX1, NCKAP1L, PREX1, IRF1, PCID2, 
EIF2AK4, RIPK3, EPO, LILRB2, FLOT2, AP3B1, NOTCH2, DOCK2, HAVCR2, DTX1, MAP3K7, LCP1, RAC1, 
MARCH7, IL10, CD27, ERBB2, AKT1, HSPD1, PIK3R1, CDKN2A, GSN, ATM, ITGB1, BANK1, MERTK, 
EPHB1, BATF, PAXIP1, BRAF, NCK1, RLTPR, PKNOX1, ITGB2, PGLYRP2, IL23R, NCSTN, AZI2, ICOS, RIC-
TOR, RAG1, CLEC4E, B2M, AP1G1, AXL, MLST8, NLRC3, FADD, INPP5D, APLF, SOCS5, CHD7, PIK3CD, 
MALT1, EXO1, RAG2, PTPN2, TBC1D10C, FZD8, PAK2, PRF1, SATB1, JAG2, IFNE, ZFP36L1, IRS2, NHEJ1, 
BLOC1S3, NCR1, SEMA4A, DLL1, MAFB, HLA-DOA, PSMB10, LAT, FNIP1, HLA-DMB, PRKDC 
Fc gamma R-mediated 
phagocytosis 
PIK3CB, PLD1, AMPH, DNM2, PTPRC, MAPK1, PIK3CG, LIMK1, PIP5K1B, RPS6KB1, PLA2G4A, AKT3, 
PIK3CA, PLD2, RAF1, WASF3, DOCK2, RAC1, PIK3R5, VAV1, AKT1, FCGR2A, PIP5K1A, PIK3R1, GSN, 
FCGR1A, ASAP2, ASAP1, PRKCA, WASF2, VAV2, INPPL1, PLA2G4F, INPP5D, MAP2K1, PIK3CD, CFL1, 
MARCKSL1, RPS6KB2, LIMK2, PIP5K1C, PLA2G4E, LAT 
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Table 9. Count and ratio (number of mutations found divided by the number of sample) of somatic mutations present in 279 samples in HNSC. 
 Samples Infection (%) 
Frame Shift 
Del. 
Frame Shift 
Del. (ratio) 
Frame Shift 
Ins. 
Frame Shift 
Ins. (ratio) 
In Frame 
Del. 
In Frame 
Del. (ratio) 
Inf. 39 13.98 131.00 3.36 55.00 1.41 38.00 0.97 
Non-Inf. 240 86.02 1039.00 4.33 474.00 1.98 245.00 1.02 
Total 279 100.00 1170.00 4.19 529.00 1.90 283.00 1.01 
 
 Samples In Frame Ins. 
In Frame Ins. 
(ratio) 
Missense Muta-
tion 
Missense Muta-
tion (ratio) 
Nonsense Muta-
tion 
Nonsense Muta-
tion (ratio) 
Inf. 39.00 4.00 0.10 4540.00 116.41 362.00 9.28 
Non-Inf. 240.00 37.00 0.15 28720.00 119.67 2324.00 9.68 
Total 279.00 41.00 0.15 33260.00 119.21 2686.00 9.63 
 
 Samples 
Nonstop Mu-
tation 
Nonstop Muta-
tion (ratio) 
Silent Silent (ratio) Splice Site Splice Site (ratio) 
Inf. 39.00 9.00 0.23 1742.00 44.67 77.00 1.97 
Non-Inf. 240.00 35.00 0.15 11180.00 46.58 787.00 3.28 
Total 279.00 44.00 0.16 12922.00 46.32 864.00 3.10 
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Table 10. Function of coding genes in HPV16 virus 
Gene Function  
E6 
Oncoprotein. It has long been recognized as a potent oncogene and is intimately associated with the events that result in the 
malignant conversion of virally infected cells. 
E7 Plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. 
E1 
The Papillomaviriuses are icosahedral dsDNA viruses that encode 7 early proteins, E1 to E7, and 2 late structural proteins L1 
and L2. Host infection by members of the papillomaviruses gives rise to warts and cancer in some instances. The E1 helicase 
protein is an ATP-dependent DNA helicase that facilitates the inititiation of viral DNA replication through its interactions with 
the viral E2 protein. The E1-E2 complex binds to the viral origin of replication where E1 acts to unwind the DNA and E2 acts 
as a transcriptional activator. 
E2 Regulatory protein. 
E4 
Although located in the early part of the viral genome, the E4 proteins are primarily expressed during the late stages of infection, 
at or around the time that genome amplification is initiated. E4 proteins have been shown to inhibit cell proliferation in G2, and 
to participate in efficient genome amplification. 
E5 Oncoprotein. Contributes to cell transformation. Produces polyploid cells by endoreplication. 
L2 Minor capsid protein. 
L1 
Major capsid L1 protein; Two structural proteins are involved in papillomavirus capsid formation, a major (L1) and a minor 
(L2) protein; L1 forms the pentameric assembly unit of the viral shell while L2 mediates several facets of viral entry including 
endosomal escape after uncoating. 
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Table 11. Expression of HPV16 genes when infecting CESC and HNSC, obtained through HTSeq. Number of reads aligned in each coding sequences in HPV16. Number of reads 
with no feature represents the number of reads that could not align completely with any feature. Ambiguous reads are the ones which have been allocated in more than one fea-
ture. Too low aQual represent the reads with alignment quality below 10 (by default). Not aligned reads are reads without alignment in the SAM file. Finally, reads in alignment 
not unique are the ones which have more than one alignment.  
   E6 E7 E1 E2 E4 E5 L2 L1 
Total aligned 
reads 
No 
feature 
Ambiguous 
Too low 
aQual 
Not 
aligned 
Alignment 
not unique 
C
E
S
C
 
TCGA-ZJ-AAXD-
01A-21R-A42T-07 
Counts 1534 1548 772 0 1825 592 43 107 3339 11598 3395 155 1420079 0 
Percentage 45.94% 46.36% 23.12% 0.00% 54.66% 17.73% 1.29% 3.20% 100.00% – – – – – 
TCGA-VS-A9V5-
01A-11R-A42T-07 
Counts 4951 6445 9099 0 5311 2336 626 1264 18636 44924 9472 313 2341402 0 
Percentage 26.57% 34.58% 48.82% 0.00% 28.50% 12.53% 3.36% 6.78% 100.00% – – – – – 
TCGA-VS-A9UD-
01A-11R-A42T-07 
Counts 299 500 772 0 2983 2509 124 5188 11576 16657 2752 355 1724084 0 
Percentage 2.58% 4.32% 6.67% 0.00% 25.77% 21.67% 1.07% 44.82% 100.00% – – – – – 
TCGA-Q1-A6DT-
01A-11R-A32P-07 
Counts 1339 1763 5669 0 18515 7511 519 1182 33396 72376 25492 1065 3182368 0 
Percentage 4.01% 5.28% 16.98% 0.00% 55.44% 22.49% 1.55% 3.54% 100.00% – – – – – 
TCGA-EA-A97N-
01A-11R-A38B-07 
Counts 2092 3326 1793 0 2384 865 45 83 5170 17082 4692 447 2571472 0 
Percentage 40.46% 64.33% 34.68% 0.00% 46.11% 16.73% 0.87% 1.61% 100.00% – – – – – 
H
N
S
C
 
TCGA-QK-A6IF-
01A-11R-A31N-07 
Counts 1278 1589 2595 0 154 0 0 4 2753 5096 670 0 1941273 0 
Percentage 46.42% 57.72% 94.26% 0.00% 5.59% 0.00% 0.00% 0.15% 100.00% – – – – – 
TCGA-HD-A634-
01A-11R-A28V-07 
Counts 2573 3120 1842 0 6343 4237 23945 1927 38294 54039 9376 0 3522307 0 
Percentage 6.72% 8.15% 4.81% 0.00% 16.56% 11.06% 62.53% 5.03% 100.00% – – – – – 
TCGA-CR-7385-
01A-11R-2016-07 
Counts 3010 3700 4068 0 2068 763 111 73 7083 17919 4501 0 2596620 0 
Percentage 42.50% 52.24% 57.43% 0.00% 29.20% 10.77% 1.57% 1.03% 100.00% – – – – – 
TCGA-BB-7866-
01A-11R-2232-07 
Counts 7206 7736 7571 0 1725 2526 2726 6715 21263 42832 5666 0 3174764 0 
Percentage 33.89% 36.38% 35.61% 0.00% 8.11% 11.88% 12.82% 31.58% 100.00% – – – – – 
TCGA-BA-A4IH-
01A-11R-A266-07 
Counts 5482 4476 4507 0 5341 1772 395 5174 17189 35755 8216 0 4690191 0 
Percentage 31.89% 26.04% 26.22% 0.00% 31.07% 10.31% 2.30% 30.10% 100.00% – – – – – 
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Table 12. Product of coding sequences in HBV virus 
Coding sequences Product  Function 
CDS0 Polymerase  
CDS1 Large envelope protein  
CDS2 Middle envelope protein  
CDS3 Small envelope protein  
CDS4 X protein Promotes cell cycle progression and inhibits tumor suppressor protein 
CDS5 Pre-capsid protein  
CDS6 Capsid protein  
 
 
Table 13. Expression of HBV genes when infecting LIHC samples, obtained through HTSeq. Number of reads aligned in each coding sequences inHPV16. Number of reads with 
no feature represents the number of reads that could not align completely with any feature. Ambiguous reads are the ones which have been allocated in more than one feature. Too 
low aQual represent the reads with alignment quality below 10 (by default). Not aligned reads are reads without alignment in the SAM file. Finally, reads in alignment not unique 
are the ones which have one more than one alignment. 
   cds0 cds1 cds2 cds3 cds4 cds5 cds6 
Total aligned 
reads 
No fea-
ture 
Ambiguous 
Too low 
aQual 
Not aligned 
Alignment not 
unique 
L
IH
C
 
TCGA-2Y-
A9H4 
Count 1 0 0 4765 8908 38 0 13712 19985 129 0 2965024 0 
Percentage 0.01% 0% 0% 34.75% 64.96% 0.28% 0% 100.00% – – – – – 
TCGA-CC-
A7IK 
Count 371 0 0 4324 4272 363 0 9330 15724 1975 0 4236928 0 
Percentage 3.98% 0% 0% 46.35% 45.79% 3.89% 0% 100.00% – – – – – 
TCGA-
DD-AAEK 
Count 52 0 0 44031 25638 313 0 70034 123797 722 0 2273311 0 
Percentage 0.07% 0% 0% 62.87% 36.61% 0.45% 0% 100.00% – – – – – 
TCGA-ED-
A7XP 
Count 21 0 0 16861 21371 56 0 38309 60247 337 0 3854298 0 
Percentage 0.05% 0% 0% 44.01% 55.79% 0.15% 0% 100.00% – – – – – 
TCGA-G3-
A25U 
Count 14 0 0 29449 22914 0 0 52377 92052 26 0 3572354 0 
Percentage  0.03% 0% 0% 56.23% 43.75% 0% 0% 100.00% – – – – – 
 
 
